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SUMMARY
This thesis reports the results on a variety of immunological 
studies on a cohort of the haemophiliac population attending the 
Haemophilia Centre at Glasgow Royal Infirmary.
The studies were carried out, looking for any abnormality which 
could be associated e ither with factor consumption or HIV infection.
A small percentage (around 8%) of the haemophiliac population
show evidence of HIV infection as detected by the presence of
antibodies to the virus. Skin testing showed an impaired cell mediated 
immunity in vivo which was related to the amount of concentrate used 
in therapy.
Various in v itro  tests were carried out, the patients being 
grouped according to HIV antibody status or factor usage.
Lymphopenia was not present in any patient group and reduced T 
cell subset ratios were observed only in the HIV+. This was due to a 
decrease in absolute numbers of T  ^ c e lls . The in v itro  response to 
mitogens and antigen was reduced but only in the HIV+ group.
Assays were developed to measure Interleukin-2 and
immunoglobulin production in v it ro . HIV+ but not HIV" patients 
produced s ign ificantly  less IL-2 than controls. Serum IgG, IgM and
IgA were raised in a ll treated patient groups, especially those HIV+ . 
In v itro  studies show that while HIV" patients have normal production 
of immunoglobulins spontaneously, HIV+ patients show increased levels. 
Neither group can be stimulated to produce levels as high as controls. 
82-Microglobulin levels were raised in a ll haemophiliacs, with HIV+ 
being higher than HIV".
F ina lly , the e ffec t of addition of concentrate or disrupted HIV 
on various in v itro  studies was examined. In general, addition of 
these inhibited the response of normals.
1C H A P T E R  O N E
HAEMOPHILIA -  A REVIEW
31.1 THE HISTORY OF HAEMOPHILIA
1.1.1 The Early References
Genetically determined bleeding disorders are probably as old 
as time but they were not reported by the Egyptian, Roman and Greek 
Physicians. Written reference to what may have been human haemophilia 
can be traced back to the 2nd Century A.D.. Babylonian Talmud Rabbi 
Judah the Patriarch made a ru lin g  which exempted a woman's th i rd  male 
ch ild  from being circumcised i f  the two previous brothers had died 
from excessive bleeding a f te r  circumcision (Sussman, 1967). The 
Rabbi's decree recognised the fa m il ia l  and sex-linked nature of the 
bleeding defect (Rosner, 1969). In the 10th century males of a 
certa in  v i l la g e  who bled to death from t r i v i a l  wounds were described 
by Khalaf ibn Abbas known as Albucasis. Thereafter, down the years 
there are other scattered references in the s c ie n t i f ic  l i t e ra tu re  to 
the deaths o f males who bled to death a f te r  surgery or from t r i v i a l  
wounds. In the older l i t e ra tu re ,  various names have been used to 
describe the disorder e.g. haemorrhaphilia, haematophi 1ia ,  haemorrhoea 
The word haemophilia is  derived from two Greek words "haima" - blood 
and "p h i le in "  - to love and i t s  f i r s t  use is a ttr ib u te d  to Schonlein 
(Virchow, 1854) although the f i r s t  w r it te n  pub lica t ion  using the word 
"haemophilia" was in 1828 with the publication  o f a thesis e n t i t le d  
"Die Hamophilie" by D r.Friedrich  Hopff (1828), a student o f Schonlein. 
Several years elapsed before the medical profession used th is  term 
only in the spec if ic  way tha t i t  is  today. I t  is  now rea lised tha t a 
va r ie ty  of d e f ic ie n t factors may produce the same c l in ic a l  p ic tu re . 
The commonest disease is haemophilia A or c lass ic  haemophilia and is 
due to d e f ic ie n t a c t iv i t y  of antihaemophilic fac to r  (AHF or Factor 
V I I I ) .  This accounts fo r  90% of bleeding defects. In th e ir
monumental review of 1912, Bulloch and Fildes (1912) c i te  references 
back to 1519 as they carry out a s c ie n t i f ic  analysis of inheritance 
on a l l  published work to tha t time.
The f i r s t  probable case of haemophilia in America was recorded
in the anonymous Obituary of Izac Zoll which appeared in the Salem
(Mass) Gazette of March 22nd, 1791 (Anon,1962). The Obituary describes
his death from:
"a s l ig h t  cut in one o f his fe e t,  w ith an axe. From the 
time of his receiving the wound t i l l  he expired, no method 
could be devised to stop the bleeding"
The Obituary goes on to describe the deceased’ s f iv e  brothers 
who had a l l  died of exsanguination fo l low ing  minor trauma, e.g 
scratch with a comb, prick  w ith a thorn or needle. I t  is  of great 
in te re s t tha t the boy's fa the r, Henry Z o l l ,  was twice married and 
only the children of his f i r s t  w ife were affected by the bleeding 
tendency.
1.1.2 Inheritance and Distribution of Haemophilia
The f i r s t  s ig n i f ic a n t  observations on the inheritance of 
haemophilia are a ttr ib u te d  to John C. Otto. In 1803 he reported 
(Otto, 1803) the cases o f fam ilies  in New England and Maryland with 
bleeding disorders. He coined the word "bleeders" and noted tha t only 
males in a fam ily  were bleeders but females, while exempt, could 
transmit the disease to th e ir  sons. Hay (1813) made what is  probably 
the most important con tr ibu tion  on our knowledge of inheritance when 
he reported on an Ipswich, Massachusetts fam ily  who have subsequently 
been followed down to modern times (McKusick, 1962).
Hay made the observation:
"Children o f bleeders are never subject to th is  d ispos it ion  
but th e ir  grandsons by th e i r  daughters"
The f i r s t  European notices o f the disease are case reports by 
the Editor of Sammlung auserlesener Abhandlungen (1805) and Consbruch 
(1810) followed by careful c l in ic a l  and post-mortem observations by 
Blagden (1817) and Wilson (1819). I t  is of in te re s t tha t in 1816 
Meckel (Meckel, 1816) postulated a coagulation defect in haemophiliac 
blood but his suggestion was ignored fo r  e ighty years. In 1820 Nasse 
(1820) published a co lle c t io n  of a l l  cases o f tha t time and put 
forward his formulation on the inheritance of haemophilia in what has 
become known as Nasse's Law which stated tha t haemophilia occurs only 
in males and is  transmitted by unaffected females to th e ir  sons.
The f i r s t  report of haemophilia in the Scottish l i t e ra tu re  is 
probably that of Theodore Davis, a surgeon from Nail sea in B r is to l .  He 
deta iled (Davis, 1826) a fam ily  w ith two bleeder sons, both o f whom 
died of haemorrhage although several daughters were unaffected. None 
o f the maternal uncles had reached adulthood and the maternal aunts, 
though healthy, had transmitted the disease to th e ir  sons, but not to 
th e i r  daughters. One o f the sons who died was noted to have swollen 
jo in ts  and severe rheumatic pain and th is  is  probably one of the 
e a r l ie s t  descriptions of j o in t  involvement in haemophilia. This 
report was followed by one from Alexander Murray (1826), a surgeon 
from A lfo rd . He described the Coutt's fam ily  from Cobbleseat in the 
Parish of Keig in Aberdeenshire. Four sons were affected by 
recurrent oral and nasal haemorrhage, bru is ing and excessive 
bleeding from t r i v i a l  cuts resu lt ing  in the deaths of three o f them.
Probably the most famous o f haemophiliacs are the several 
o ffsp r ing  of Queen V ic to r ia .  Without previous fam ily  h is to ry  and 
a f te r  four normal ch ild ren , Queen V ic to r ia  in 1853 gave b ir th  to a 
haemophiliac son, Leopold, Duke of Albany (Rosner, 1969). He was 
severely affected by haemophilia, su ffe r ing  recurrent l i f e  threatening
bleeds and developing arthropathy before dying at the age o f 30 of 
cerebral haemorrhage a fte r  a f a l l  (Anon. 1884). His only daughter was 
a c a r r ie r  who transmitted the disease to her son, who also died of 
cerebral haemorrhage. Two of V ic to r ia 's  daughters, A lice and Beatrice, 
proved to be ca rr ie rs  when they produced both haemophiliac sons and 
ca rr ie r  daughters. Through the marriage of V ic to r ia 's  affected 
grandchildren the disease was transmitted to various Royal Houses of 
Europe including Prussia, Russia, and Spain. The dramatic social and 
p o l i t ic a l  consequences of- the dissemination o f th is  rare disease 
through the Royal European Households has been o f great in te re s t  to 
h is to r ians . The desperate attempts to t re a t  V ic to r ia 's  great-grandson, 
the Tsarovich, were close ly intertw ined with the f a l l  o f the Tsars and 
the Russian Revolution. This Royal connection also heightened public  
in te re s t but probably more importantly tha t of the medical profession. 
Large numbers o f cases were soon reported and numerous s c ie n t i f ic  
studies were commenced.
In 1855 Grandidier (1855) co llected a l l  cases published up to 
that time and found that there were 452 males and 32 females. 
However, these female cases contained ones which were probably not 
due to haemophilia, e.g. umbilical haemorrhage.
Legg provided his a u th o r i ta t ive  account in 1872 (Legg, 1872) in 
"Treatise on Haemophilia" and did as much as anyone to influence the 
use of the term "haemophi1ic "  fo r  only a h e r id i ta ry  and congenital 
bleeding disorder in males, often w ith swelling o f the jo in ts .  
However, i t  was not u n t i l  1890 tha t the involvement o f jo in ts ,  
probably the most ch a rac te r is t ic  symptom of haemophilia, was 
described in de ta il  by K'onig (1890). H is to r ic a l ly ,  the disease ranks 
second only to red-green colour blindness in the chronology of 
recognition o f sex-linked abnormalities. There are f iv e  mating
combinations in sex-linked recessive inheritance. Otto (1803) 
described c a r r ie r  female x normal male and Hay (1813) normal female x 
bleeder male. Brinkhous and Graham (1950) showed tha t mating 
bleeder dogs with c a r r ie r  bitches produced haemophilic dogs in the 
expected proportions. Thus with the a v a i la b i l i t y  of bleeder females 
i t  was possible to tes t the remaining two combinations, i .e .  bleeder 
female x normal male and bleeder female x bleeder male and resu lts  
were exactly as predicted by Mendalian genetics. (Brinkhous, Graham, 
Penick e t a l , 1951). So, some 150 years a f te r  the descrip tion by Otto 
the pattern of sex-linked inheritance was f u l l y  confirmed. As 
haemophilia is  sex-linked recessive an affected boy w i l l  acquire the 
disease from his c a r r ie r  mother. The sons of a haemophiliac do not 
in h e r i t  his X-chromosome and are unaffected but a l l  the 
haemophiliac's daughters w i l l  be ca rr ie rs  since they do in h e r i t  the 
affected X-chromosome. In the very rare instance o f marriage between 
a haemophiliac male and a c a r r ie r  female, the daughters have an equal 
chance of being haemophilic by in h e r i t in g  the abnormal a l le le  from 
each parent. At least four such authentic cases have been reported 
(Merskey 1951).
Classical haemophilia a ffec ts  about 1 in 10,000 of the B r i t is h  
population although only 1 in 40,000 is severely a ffected. A s im ila r  
f igu re  is  found in Europe and the United States. The disease has now 
been described in every rac ia l group (Prentice and Ratnoff, 1967) but 
is  uncommon in some groups, e.g. the American Negro (Lewis, Didisheim, 
Ferguson et a l,  1963) and East African Negroes (Forbes, Mackay and 
Khan, 1966). The severity  o f the bleeding tendency re la tes c lose ly the 
plasma concentration of Factor V I I I  or Factor IX coagulant a c t iv i t y  
(Nilsson, Blomback and Ramgren, 1961) and the c l in ic a l  c la s s i f ic a t io n  
of the severity  is as fo l lo w s :-
Less than 1% - severe
1-4% - moderate 
5-30% - mild
1.1.3 The Coagulation System and the Defect in Haemophilia
The end stage of the coagulation process is  the production of 
an insoluble f i b r in  c lo t .  Modern understanding o f blood coagulation 
has been based on the hypotheses independently formulated by Ratnoff 
(Davie and Ratnoff, 1964) and Macfarlane (1964) tha t the system 
functions as a cascade or w a te r fa l l ,  each enzyme releasing the active 
fac to r from i t s  in e r t  precursor in sequence.
The coagulation sequence functions as three in te rac t in g  parts. 
In t r in s ic  a c t iv i t y  is generated by exposure to a fore ign surface 
leading to ac tiva tion  o f Factor X on the p la te le t  surface by a complex 
of Factor IXa, Factor V I I I  and calcium. Factor X is  also activated 
through the e x t r in s ic  system by Factor VII in the presence of t issue 
thromboplastin. In the presence of Factor V and calcium, Factor Xa 
acts on prothrombin to form thrombin, which cleaves fib r inogen to form 
f ib r in .  The cascade is  shown in Figure 1.1.
In the 19th Century there was s t i l l  no understanding as to the 
cause o f the defect. Some w r ite rs  thought bleeding was due to a 
vascular abnormality. Wright (1893) discovered tha t the c lo t t in g  
time of the patients blood was prolonged and Addis (1911) observed 
tha t the addition of normal blood could correct the c lo t t in g  defect of 
haemophiliac blood. In the f i r s t  few years o f th is  century the 
diagnosis of haemophilia depended on c l in ic a l  and fam ily  h is to ry  plus 
the find ing  of a prolongation of whole blood c lo t t in g  time (L is ton, 
1893 ; Wright, 1893).
The f i r s t  major biochemical advance occurred in 1935 when
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Figure 1.1: The Coagulation Cascade
Bendien and Van Creveld (1935) then Patek and Taylor (1937) found 
that p la te le t  free plasma, p rec ip ita ted  with water at pH of 5.3 - 5.8, 
yielded a substance which was capable of correcting  the c lo t t in g  
abnormality. With other colleagues, Taylor (Lewis, Tagnon, Davidson 
e t a l , 1946) la te r  ca lled th is  f ra c t io n  "anti-haemophiliac g lobu lin " 
which we now know as Factor V I I I .  Pavlovsky (1947) made the
important f ind ing  tha t blood from one haemophiliac could correct the 
c lo t t in g  defect in another. This started the idea tha t there could be 
more than one disorder c o l le c t iv e ly  known as haemophilia. In vivo and 
in v i t r o  observation by Schulman and Smith (1952) and Ko lle r (1954) as 
well as the development of tests of thromboplastin generation (Biggs 
and Douglas, 1953) confirmed tha t there were two separate groups of 
patients. Biggs (1952) and colleagues in Oxford and Aggeler (1952) in 
San Francisco, and Schulman and Smith (1952) in New York a l l
described a condition c l in i c a l l y  and g ene t ica l ly  s im ila r  to
haemophilia but one which could be corrected by infusion of 
haemophiliac plasma. This new disease, f i r s t  described by the Oxford 
group in the 1952 Christmas e d it ion  of the B r i t is h  Medical Journal, 
is  associated with lack of a fac to r  found in serum called Christmas
fac to r (named a f te r  the f i r s t  pa tien t)  or Factor IX and is now also
known as haemophilia B.
As knowledge increased new tests were devised which led to
bleeding disorders other than the haemophilias being described, e.g. 
Factor V defic iency (Owren, 1947).
Ratnoff and colleagues (Zimmerman, Ratnoff and Powell, 1971) 
described immunological experiments where they prepared rabb it
anti serum to human Factor V I I I .  When they tested the serum on normal 
plasma they obtained a single p re c ip i t in  l in e  and demonstrated the 
neutra lisa tion  of Factor V II I  a c t iv i t y  by the antiserum. However,
10
when they tested the anti serum against haemophiliac's plasma they 
s t i l l  found a single p re c ip i t in  l in e  ind ica ting  presence of the 
Factor V I I I  prote in antigen. This work has been widely confirmed, 
and so haemophilia had to be redefined as a sex-linked, recessive
coagulation disorder in which the b io log ica l a c t iv i t y  o f Factor V II I  
( V111C) is reduced because the Factor V II I  molecule, although present 
in normal amounts a n t ige n ica l ly ,  is fu n c t io n a l ly  impaired. The 
formation of defective molecules of Factor V I I I  is  probably due to 
the presence o f an abnormal recessive a l le le  a t the gene locus on 
the X-chromosome c o n tro l l in g  synthesis of th is  fa c to r .  Therefore,
molecules possessing th is  one abnormal X-chromosome w i l l  produce a 
p rote in , an t ige n ica l ly  s im ila r  and in an equal amount to normal 
Factor V I I I  but w ith d e f ic ie n t  a c t i v i t y  (Zimmerman e t a l , 1971). The 
loc i fo r  Christmas fac to r  and Factor V I I I  are apparently fa r  apart on 
the X-chromosome. I t  is  thought tha t in Christmas disease there are
two va r ie t ie s ,  one in which there seems to be a complete absence of
protein and another much ra rer type in which the plasma contains 
Factor IX which is an t ige n ica l ly  ind is tingu ishab le  from normal 
Christmas fa c to r  (Hougie and Twomey, 1967) but has d i f fe re n t  a c t iv i t y .  
Cases have been recorded where both c lass ic  haemophilia and Christmas 
disease apparently co -ex is t (Soulier and Larrieu, 1953).
1.1.4 Treatment of Haemophilia
A h is to ry  on the treatment of haemophilia can be divided in to  
two eas ily  id e n t i f ia b le  sections: "ea r ly "  and "modern" therapies.
In 1901 the United States Surgeon General's catalogue included 
fo r  the f i r s t  time a section on treatment o f haemophilia. The l i s t  
included such forms of treatment as inha lation of oxygen, 
administration of lime and even the use o f g e la t in .  In 1926 the
next published l i s t  was even la rger w ith remedies such as in je c t io n  
of calcium lac ta te  or sodium c i t r a te  and even splenectomy. To th is  
period belongs the Timperely treatment w ith a bromide ex trac t o f egg 
white (Timperely, Nash and Clark, 1936) which some haemophiliacs have 
believed had helped them. Most o f these treatments could have been 
based on l i t t l e  more than guesswork.Their ineffectiveness is  te s t i f ie d  
to by the extensive morbid ity  and early  m o r ta l i ty  recorded in de ta il  
by Carol Birch (1937) in her c lass ic  monograph which d if fe re d  l i t t l e  
from the natural h is to ry  o f the disease in the 19th Century 
(Grandidier, 1855) (Kerr, 1963). Probably the f i r s t  treatment to 
be used on sound experimental re s u lt  was the top ical app lica tion  of 
coagulant snake venom a f te r  work by Macfarlane (Macfarlane and 
Barnett 1934).
In 1840 was published one o f,  i f  not the most, h is to r ic  and 
important papers on the treatment of haemophilia. Lane (1840) in 
Lancet describes the successful transfusion o f blood. An 11 year old 
boy had bled fo r  s ix  days a f te r  a minor operation to co rrec t a squint. 
He was given a d ire c t  transfusion o f blood a f te r  which the bleeding 
stopped and the boy recovered. Also in th is  paper Lane c ites  the 
work of Wardrop who in 1835 described the cases o f several people who
had an inordinate d ispos it ion  to bleed from s l ig h t  in ju r ie s .
He (Wardrop) a tt r ib u te d  th is  disease to a defic iency in the
coagulation power of the blood. This f i r s t  case o f successful 
transfusion came some e igh t years a f te r  being suggested by Schonlein 
(1832). The use of whole blood therapy was not rediscovered fo r
almost s ix ty  years (Ward 1905). Feissly (1924) and Payne and Steen 
(1929) then showed tha t the use of plasma was superior to whole blood 
and th is  treatment became standard practice  fo r  t h i r t y  years.
The key to modern treatment was suggested in 1938 by Macfarlane
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when he concluded:
" i t  is  probable, therefore, tha t there is  in normal 
blood a fa c to r ,  at present un iden tif ied  that is 
essential fo r  the rapid ac t iva t ion  o f prothrombin 
and tha t th is  fa c to r  is  at fa u l t  in haemophilia."
This missing fac to r is now known as Factor V I I I  in haemophilia A
and Factor IX in haemophilia B. Macfarlane had appreciated tha t by
means of transfusion i t  was possible to t re a t  a bleeding episode by
temporarily replacing a missing essential component (Biggs, 1967).
Following the work of Cohn, human preparations o f Factor V II I  
were developed in the 1950's in B r i ta in  (Kekwick and Wolf, 1957) in 
France (Sou lie r, Gobbi and Larrieu, 1957 ) and Sweden (Blomback, 
Blomback and Nilsson, 1958). At th is  time concentrates were also 
being produced from animal blood (Macfarlane, 1954).
Antihaemophiliac g lobu lin  (AHG) was being used to t re a t  l i f e  
threatening bleeds and to cover major surgery (Biggs, 1967) but the 
concept of preventative treatment fo r  a bleed at an early  stage, 
to stop c r ipp l in g  damage to jo in ts  and to maintain as normal a l i f e  
fo r  the haemophiliac, was as yet unformulated. This, however, was to 
change in 1965 when Professor Judith Pool reported (Pool and Shannon, 
1965) tha t on slowly thawing frozen plasma much o f the Factor V I I I  
a c t iv i t y  remained with the fibrinogen sludge which was slow to 
redissolve. This was ca lled c ryop rec ip ita te  and could be spun down 
and so re-frozen fo r  storage, and the supernatant plasma could be 
re-associated with the ce l ls  from the blood donation from which i t  
was derived thus recons t itu t ing  the p in t  o f blood fo r  other use. With 
increasing a v a i la b i l i t y  of freeze-dried concentrates i t  became 
possible to s ta r t  home-treatment whereby patients could tre a t 
themselves promptly by intravenous in jec t ions  o f Factor V II I
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concentrates which they keep at home.
By 1980 most Haemophilia Centres in B r i ta in  had introduced home 
treatment. Forty -four percent o f a l l  haemophiliacs and 60% of those 
severely affected were being treated th is  way (Rizza and Spooner,1983). 
The increased a v a i la b i l i t y  o f 1yophi1ised concentrate was such tha t 
by 1980 only 14% of Factor V I I I  was given in form the cryop rec ip ita te  
(Rizza and Spooner, 1983).
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1.2 TRANSFUSION ASSOCIATED HEPATITIS
As already mentioned one of the most severe problems a ffec t ing  
haemophiliacs is  in te rna l bleeding, p a r t ic u la r ly  in to  muscles and 
jo in ts ,  especia lly  the knee and elbow. Bleeding episodes l ik e  these 
can leave the pa t ien t p a in fu l ly  cripp led and immobile.
However, the treatment of haemophilia, i .e .  the use of blood 
derived products has also led to problems fo r  the patients . In 1943 
Beeson reported seven cases of jaundice which a l l  occurred a f te r  the 
transfusion of whole blood or plasma, and he therefore suggested that 
they were somehow transfusion associated (Beeson, 1943). Serum 
hepa t it is  was f i r s t  described by Lurman in 1855 fo llow ing  an outbreak 
of jaundice in a Bremen shipyard where workers were vaccinated with 
human lymph against smallpox. One hundred and ninety-one out of 
1,289 people became jaundiced while 500 other workers vaccinated with 
a d i f fe re n t  l o t  of lymph remained free from disease. There have been 
many other reports in the l i te ra tu re  of outbreaks of jaundice a f te r  
transfusion of blood or blood products (Propert, 1938)(Spur!ing, Shone 
and Vaughan, 1946). A major advance in the study of v i ra l  hepa tit is  
occurred in 1967 w ith the discovery by Blumberg o f the Austra lia  
antigen (Blumberg, Gerstley, Hungerford e t a l , 1967) which lead to the 
development of tests fo r  he pa t it is  B v irus  antigens (HbsAg) and 
antibodies (HbsAb). The high r isk  of he pa t it is  B associated with 
intravenous use of c ryop rec ip ita te , Factor V I I I  or Factor IX 
concentrate became well documented amongst haemophiliacs (Barber, 
Peterson, Schulmar e t a l ,  1973) (Hoofnagle, Aronson and Roberts, 1975) 
(Gerety and Barker, 1976). Since 1972 i t  has been a legal requirement 
in the U.S.A. to te s t  a l l  blood donors fo r  HbsAg. However, the 
overall incidence o f h e pa t it is  in rec ip iants  did not decline, although
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the proportion defined as h e p a t it is  B dropped from 2.2% to 0.5% (Seeff
1981). I t  has been shown tha t 89% of post transfusion h epa t it is  in
the United States was caused by an unknown v irus  other than hepa t it is
type A or B and th is  is known as Non-A, Non-B he pa t it is  (A l te r ,
Purcell and Holland, 1975). In a re trospective  study, Craske and
colleagues (1978) showed tha t non-B h e p a t it is  developed in 52 out of
417 patients receiving commercial Factor V I I I  preparations.
Persistent e levations in l i v e r  enzymes have been observed in
haemophiliacs (Mannucci, Capitanio, Del Ninno e ta l , 1975). Following
these find ings a study of l i v e r  biopsies in selected haemophiliac
populations found presence of chronic active h e p a t i t is ,  chronic
pers is ten t he pa t it is  or c i r rh o s is  (Mannucci, Ronchi, Rota e t a l ,
1978) (Spero, Lewis, Van Thiel e t a l , 1979). These find ings along
e t al_,_
with a more recent study by HayA(1985) which concludes:
" I t  is  an tic ipa ted  tha t l i v e r  disease in 
haemophiliacs w i l l  become an increasing 
c l in ic a l  problem in the fu tu re"
a l l  support the suggestions made in The B r i t is h  Medical Journal in
1981 tha t:
" in  some cases ea r ly  death from l iv e r  disease 
might prove to be the price paid by haemophiliacs 
fo r  the improved q u a l i ty  o f l i f e  afforded by the easy 
a v a i la b i l i t y  o f c lo t t in g - fa c to r  concentrates"
(B.M.J. E d i to r ia l ,  1981).
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1.3 ACQUIRED IMMUNE DEFICIENCY SYNDROME
1.3.1 The New Threat
A rt ic le s ,  le t te rs  and comments on the Acquired Immune 
Deficiency Syndrome (AIDS) have ra re ly  been absent from e ithe r  
medical journals (Gracie, Froebel, Madhok e t a l , 1985) (Gracie, Lowe 
and Forbes, 1985) or the popular press since the f i r s t  c l in ic a l
descriptions o f the disease in June, 1981. These f i r s t  reports
recorded by the Centre fo r  Disease Control (CDC) (G o tt le ib ,
Groopman, Schanker e t al,1981) deta iled  cases o f f iv e  young
homosexuals from Los Angeles who died of Pneumocystis c a r in i i
pneumonia. This was soon followed by reports (Hymes, Cheung and
Greene e t a l , 1981) of the deaths o f a fu r th e r  26 homosexuals who had
developed a rap id ly  progressive form of Kaposi's sarcoma. I t  was
soon apparent tha t these cases represented the f i r s t  reports o f a new
epidemic, one which medicine had not seen before, and one which was
to have dramatic consequences, s c ie n t i f i c a l ly ,  medically and
so c ia l ly .  Dysfunction o f the p a t ie n t 's  ce l l  mediated immune system 
was soon recognised as the ch a ra c te r is t ic  feature o f the disease. 
Early cases occurred in homosexuals (G ott le ib  e t a l , 1981) and
intravenous drug abusers (Gold, Thomas and Garrett, 1982). These 
reports were soon followed by other cases which c le a r ly  f e l l  in to  
well defined groups, namely haemophiliacs (MMWR 1982) (Poon, Landay, 
Prasthofer e t a l , 1983) receiv ing c lo t t in g  fac to r  concentrates and
recip ients of blood transfusions (Curran, Lawrence, Ja ffe  e t a l ,
1984).
The occurrence o f a unique c l in ic a l  syndrome d isplaying such a 
d e f in i te  pattern of occurrence strong ly  suggested tha t the cause was a 
transmissible in fec tious  agent. Human Immunodeficiency Virus (HIV)
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f i r s t  iso la ted by Montagnier in Paris (Barre-S inoussi, Chermann, Rey 
et a l , 1983) called lymphadenopathy associated v irus (LAV) and sho rt ly  
afterwards by Gallo and co-workers (Popovic, Sarngadharan, Read e t a l ,
1984) in the United States and termed human T ce ll  lymphotropic v irus 
type I I I ,  is  now known to be the v irus  responsible fo r  a va r ie ty  of 
c l in ic a l  syndromes ranging from a glandular fe v e r - l ik e  i l ln e s s  to the 
f u l l  blown c l in ic a l  p ic tu re  o f AIDS with opportun is t ic  in fe c t ion s , 
tumours and nervous system involvement. Most o f the early  cases o f 
AIDS could be accounted fo r  by the above mentioned high r is k  groups 
with only ra re ly  a case being reported in an ind iv idua l who 
apparently had no r is k  fac tors  (Chamberland, Castro, and Haverkos e t 
a l,  1984).
The occurrence o f the disease in blood transfusion rec ip ien ts  
and haemophiliacs was soon rea lised to be caused by a transmissable 
agent in contaminated blood products. S im ila r ly ,  intravenous drug
abusers were at r isk  because they shared needles, syringes and other 
equipment contaminated w ith  blood. But how was the disease spread in 
homosexuals? I t  is known tha t some homosexuals are more promiscuous 
than heterosexuals having many more sexual partners ( " fa s t  lane"). 
Also, anal intercourse and the use o f sexual "toys" lead to tears o f 
the anal mucosa w ith the p o s s ib i l i t y  o f semen infected w ith HIV
entering the receptive pa rtner 's  blood (Shearer 1983). This has been 
confirmed by anti-sperm antibodies which have been found in the serum 
of some homosexuals (receptive partners) (M a v lig it ,  Talpaz, Hsia e t a l ,
1984) and sperm has been shown to contain HIV (Ho, Schooley and Rota,
1984).
The o r ig in a l strategy set up in the United States, fo r
containment and control of the AIDS epidemic was based on the
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suggestion that AIDS occurred only w ith in  the defined high r is k  groups 
and i t  would remain as such. On the whole, to date, th is  has held 
true with only about 5% of reported cases f a l l in g  outwith these r is k  
groups. Sexual contact is believed to be the only r is k  fa c to r  fo r  64% 
of reported cases in the United States (MMWR,1985). Of th is  f ig u re , 
about 2% is due to heterosexual spread with a male to female ra t io  of 
5.5:1. Most o f these were due to male to female transmission although 
transmission in the opposite d ire c t io n  has occurred. I t  has been 
suggested (Sande, 1986) tha t the d if fe rence between the two sexes in 
the rate of transmission is due to the fa c t  tha t there are more male
i . v .  drug abusers and bisexuals capable o f transm itt ing  the disease 
to females than there are infected women capable o f transm itt ing  to 
men. HIV has now been iso la ted  from cerv ica l secretions o f people at 
r isk  from AIDS (Vogt, W itt ,  Craven e t a l , 1986) and HIV ca rr ie rs  
(Wofsky, Cohen, Haver e t a l , 1986) and th is  could prove to be ye t 
another body f l u id  capable of transm itt ing  the disease. I f  th is  is 
so then female p ro s t i tu te s  could pose the biggest th rea t in the 
transmission from female to male and studies from the United States 
c i te  contact w ith p ro s t i tu te s  as a high r is k  fa c to r  (Van de Perre, 
Clumeck, Carael e t a l , 1985). This leaves a small percentage of cases 
which do not f i t  any o f the recognised high r is k  groups (MMWR, 1985) 
(Sande, 1986).
Only re la t iv e ly  recently  has AIDS been serious ly  considered as 
a threat to the heterosexual population (Gracie, Lowe and Forbes, 1986) 
The incidence o f heterosexual transmission seen in the USA and Europe 
at the moment, is somewhat d i f fe re n t  from tha t being experienced in 
certa in  parts o f A fr ica  where there is  evidence of widespread 
heterosexual transmission. In early  1985 at the In te rna tiona l 
Congress on AIDS in A tlan ta , USA, data from central A fr ica  (Clumeck
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et a l , 1985) suggested that heterosexual transmission was o f great 
importance in the development of AIDS. The f i r s t  in d ire c t  piece of 
evidence was the sex ra t io  of AIDS victims in Zaire, being 1:1.1 (male 
to female) (P io t, Quinn, Taelman e t a l ,  1984). This strongly 
suggested tha t homosexual contact was not the most important fac to r  
in the spread of the disease in A fr ica . In add it ion , there is  l i t t l e  
epidemiological evidence of homosexuality. This near balanced sex 
ra t io  would suggest that transmission could be e ith e r  male to 
female or vice versa otherwise there would soon be .an imbalance of 
the ra t io .  Recent studies from c i t ie s  in Zaire (Mann, Francis, Quinn 
e t a l , 1986), Zambia (Melbye, N jelesani, Bayley e t a l , 1986) Kenya 
(Kreiss, Koech, Plummer et a l , 1986) and Rwanda (Clumeck, Van de Perre, 
Carael e t a l , 1985) confirm tha t the human immunodeficiency v irus  is 
spread mainly through heterosexual tranmsission and tha t the highest 
prevalences o f antibodies to HIV are found in the most sexually 
active groups.
As o f A pril 1987 there have been 45,608 cases o f AIDS worldwide 
with an overall f a t a l i t y  of around 50%. This f igu re  may r ise  as the 
time o f diagnosis to f u l l  blown syndrome can vary from a few months to 
a few years. A higher percentage o f deaths have occurred amongst the 
e a r l ie r  recorded cases. The growth o f numbers has been la rge ly  
exponential. The number of diagnosed cases in the United Kingdom as of 
A p r i l ,  1987 was 734 w ith  405 deaths. The marked increase in numbers in 
early 1987, 173 new cases alone by March 31st, h igh l igh ts  the growing 
threat o f th is  disease to socie ty. This concern is  re f lec ted  by both 
the increased media a tten tion  the subject now receives and also the 
increased p u b l ic i ty  and education programmes cu rren t ly  being set up 
here in the United Kingdom. The evidence from epidemiological 
studies to date indicates tha t about 10% to 30% of those infected
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with HIV w i l l  develop AIDS and another 26% w i l l  develop AIDS-related 
symptoms. The apparently long in te rva l during which the in fec t ion  
may incubate adds to the d i f f i c u l t y  o f p red ic ting  the course of the 
disease.
Table 1.1 gives a breakdown of recorded cases in to  the 
recognised r is k  groups fo r  the United Kingdom up to the end of 
March, 1987.
- 1.3.2 Haemophilia and Transfusion Associated AIDS
I t  has long been known tha t the use o f blood transfusion and 
blood products provide an e f f i c ie n t  vehic le fo r  transmission of 
in fectious organisms. The l i s t  o f in fec tious  agents transmitted by 
blood has gradually expanded and now many post-transfus ion v i r a l ,  
bacteria l and p a ra s it ic  diseases are well described (Sou lie r, 1984)
The f i r s t  case of AIDS associated w ith  c e l lu la r  blood products 
transfusion was of a 20-month old in fa n t  who developed severe c e l lu la r  
immunodeficiency and m u lt ip le  opportun is t ic  in fec tions  a f te r  receiving 
several blood componant transfusions (Amman, Cowan, Wara e t a l , 1983). 
Subsequently, the inves t iga tion  o f three adults who developed 
Pneumocystis can in i i  pneumonia strengthened the hypothesis tha t a 
p o te n t ia l ly  transm ittab le  agent was producing AIDS in transfusion 
recip ients (Curran, Lawrence, Jaffe  e t a l , 1984). The f i r s t
haemophilia pa tien t w ith AIDS was reported to CDC in January, 1982 
(CDC, 1982) and workers soon suspected tha t non-heat treated Factor 
V II I  preparations were the po ten tia l vehicle fo r  HIV transmission. 
As of March 31st, 1987 there had been 31 cases of AIDS amongst the 
haemophiliac population in B r i ta in  w ith 23 f a t a l i t i e s .
The r isk  of HIV in fe c t ion  in haemophilia has been shown to be 
related to the amount o f concentrate used (Melbye, Froebel, Madhok et
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a l , 1984; Ludlam, Tucker, Steel e t a l , 1985). The amount used w i l l  be 
d ire c t ly  re lated to the number o f exposures to d i f fe re n t  donors and 
therefore increased r isk  of HIV in fe c t io n .
An "average" severe B r i t is h  haemophiliac w i l l  probably use
40,000 I.U. of Factor V I I I  concentrate per year. To maintain th is
supply approximately 160 l i t r e s  of plasma are required each year fo r  
each pa tien t. As the production method fo r  the concentrate involves 
pooling donated plasma, 160 l i t r e s  could, there fo re , be a re s u lt  of 
donations by many people, perhaps in to  the thousands. The r is k  of 
receiving blood products from an in fected donor is  n a tu ra l ly
increased i f  the production o f the product involves the use of
m u lt ip le  donations from d i f fe re n t  donors.
In v i r t u a l l y  a l l  European studies, seroconversion has been 
s ig n i f ic a n t ly  associated with the use o f commercial concentrate 
most of which is  imported from U.S.A. (Melbye e t a l , 1984). Cross
sectional studies of HIV antibody prevalence shows presence of
antibody in almost a l l  populations studied. Retrospective studies on 
antibody prevalence has shown antibodies to HIV in haemophiliac serum 
from 1979 (Evatt, Stein, Francis e t a l , 1983), th is  is  in keeping 
with both the f i r s t  death from AIDS occurring in mid 1982 (Davis,
Horsburgh, Hasiba e t a l , 1983) and what is  now known of the time
course o f the disease. Since then the numbers of HIV antibody
pos it ive  patients has increased s ig n i f ic a n t ly ,  p a r t ic u la r ly  between 
1981-83 with fewer conversions between 1984-85 (Eyster, Goedert, 
Sarngadharan e t a l , 1985). The pattern in Europe has lagged the 
American epidemic by 1-2 years, the f i r s t  seroconversions occurring 
in 1980-81 (G urtle r, Wernicke, Eberle e t a l , 1984).
Much speculation i n i t i a l l y  surrounded the c l in ic a l  s ign if icance 
o f the presence of HIV antibody. Suggestions included innoculation
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with iso la ted v i ra l  p ro te ins, innoculation w ith  whole v irus and the 
passive trans fe r of antibody from fac to r concentrate despite the 
in a b i l i t y  to detect the presence o f antibody in implicated batches. 
HIV has now been isola ted from seropositive haemophiliacs (A l la in ,  
Laurian, Paul e t a l , 1986) (Vilmer, Barre-S inoussi, Rouzioux e t a l ,
1984) implying that the presence o f antibody indicates innoculation 
with whole v irus .
As in other r is k  groups HIV in fe c t ion  in haemophilia has been 
associated with a glandular fever l ik e  i l ln e s s ,  characterised by 
fever, macular rash, generalised lymphadenopathy and splenomegaly 
(Tucker, Ludlam, Craig e t a l,  1985). The most frequent in fec tious  
agents in haemophiliac cases of AIDS have been Pneumocystis c a r in i i  
pneumonia, Toxoplasmosis j candid iasis, Myobacterium avium and 
Cryptococcus m eningit is . There is  no evidence to suggest tha t the 
spectrum of opportun is tic  in fec tions  reported in haemophiliac cases 
d i f fe rs  from other r is k  groups. Kaposi's sarcoma, the most frequently  
occurring neoplasm in AIDS patients has been in frequen tly  reported 
amongst haemophiliac cases although i t  has been documented in one 
patien t with Factor V defic iency (Velez-Garcia, Robles-Cardona, and 
Fradera (1985).
1.3.3 Reducing the Risk
What has been done to c u r ta i l  the AIDS problem in the use of 
blood and blood products?
Blood donor screening has now been introduced. A ll  blood donations 
are tested fo r  antibodies to HIV with any pos it ive  samples being 
discarded from the donor pool. However, the p o s s ib i l i t y  o f a donor 
being infected but not seropositive w i l l  mean tha t there is  s t i l l  a 
r is k  o f infected blood being used. Heat-treated c lo t t in g  fac to r
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concentrates were developed several years ago w ith the u n fu l f i l le d  
goal of decreasing h ep a t it is  in f e c t i v i t y  of the fa c to r  concentrates. 
These products have been commercially ava ilab le , but were not widely 
used u n t i l  studies showed tha t HIV is heat sens it ive  (Spire, Dormont, 
Barre-Sinoussi e t a l , 1985). A ll fac to r  concentrate now being used 
is heat treated. However, many patients were treated with non heat 
treated material and because o f the long incubation period o f AIDS, 
cases w i l l  continue to occur. The gene fo r  Factor V I I I  has been 
cloned (Wood, Capon, Simonsen e t a l , 1984). However, there are no 
d e f in i te  predictions as to when bio-engineered fa c to r  products w i l l  be 
widely ava ilab le . Most investiga to rs  ind ica te  tha t several years 
delay is  probable.
1.3.4 The Causative Agent
An in fec tious agent, in p a r t ic u la r  a v irus  was strongly 
suspected in the aetio logy o f the acquired immune defic iency syndrome 
from the onset o f the epidemic (Curran, Morgan, Hardy e t a l , 1985).
Retroviruses in p a r t ic u la r  were considered to be prime candidates 
because an animal re tro v iru s ,  fe l in e  leukaemia v irus ,  was known to
cause a disease s im ila r  to AIDS in cats (Hardy, Hess, McEwan e t a l ,
1976). In addit ion , the mode o f transmission, the spread of the
disease and the se lective  T ce l l  depletion was reminiscent of the
patterns previously seen with the then known T ce ll  t rop ic  human 
re trov irus  (Wong-Staal, Shaw, Hahn e t a l , 1985). I t  has now been well 
established that the Human Immunodeficiency Virus (HIV) is  the causal 
agent of AIDS.
The e a r l ie s t  report o f a re tro v iru s  as the possible cause of 
AIDS was from Barre-Sinoussi and colleagues (1983). They described 
C-type re tro v iru s  p a r t ic le s  iso la ted  from T lymphocytes from a pa tien t
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with generalised lymphadenopathy. The subsequent a v a i la b i l i t y  of 
permanent T ce ll l ines allowed recovery of high t i t r e s  of v irus 
(Popovic, Sarngadharan, Read e t a l , 1984). Virus iso la t io n  could be 
achieved from over 80% of pre-AIDS and 30-50% of AIDS patients 
(Gallo, Salahuddin, Popovic e t a l , 1984;) (Salahuddin, Markham,
Popovic e t a l , 1985). This in turn allowed the production o f te s t
reagents fo r  epidemiological surveys. The high prevalence of HIV 
antibody in patients with overt disease and in the aforementioned 
high r is k  groups, w ith subsequent v irus iso la t io n  established the 
f in a l  l in k  between HIV in fe c t ion  and AIDS. Retrospective studies 
confirm th is  and show tha t 15 to 50% of HIV infected persons in high
r isk  groups have developed AIDS or AIDS-related symptoms a f te r  a
period o f 3 to 4 years (Goedert, B i f fe r ,  Weiss e t a l , 1986 ). HIV as 
mentioned is a re tro v iru s . Therefore, i t  carr ies i t s  genetic 
information in the form of RNA. On in fe c t in g  a ta rge t ce ll  the v irus 
makes use of the unique enzyme Reverse Transcriptase (RT) to convert 
i t s  own RNA in to  DNA (p ro -v i ra l)  which is  then integrated in to  the DNA 
of the host cel 1.
The genomes of re p l ica t io n  competent re trov iruses are s im ila r  
s im ila r  in organisation, most posessing three genes:-
1. gag : coding fo r  the group sp e c if ic  antigen proteins
which are found in the core.
2 . pol : coding fo r  reverse transcrip tase .
3. env : coding fo r  v i ra l  envelope prote ins.
They are arranged gag-pol-env in the d ire c t io n  from 5' to 3' end of 
the genomic RNA. In the v i r io n  RNA of HIV these genes are flanked
by parts of long terminal repeat sequences (LTR) (S tarc ich, Ratner,
Josephs e t a l , 1985) and are interspersed by sequences with open 
reading frames (ORF) called sor, 31o r f  and t a t . Both sor and 3 'o r f  
are expressed during re p lica t ion  and antibody to th e ir  products have
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been found (Kan, Frachin i, Wong-Staal e t a l , 1986) but the functional 
property of these proteins is s t i l l  unknown. Between sor and 31o r f  
is ta t  which codes fo r  a prote in w ith trans-activated  tra nsc r ip t io n  
a c t iv i t y  directed by the HIV LTR (Sodroski, Patarka, Rosen e t a l ,
1985) (Seigel, Ratner, Josephs e t a l , 1986). Transactivation genes 
and mechanisms have also been observed in HTLV I and I I  (Sodroski, 
Rosen and Haseltine, 1984) and in visna v irus (Hess, Clements and 
Narayam, 1985) and may play a crucia l ro le  in determining the 
b io log ica l a c tv i ty  of these viruses (Sodroski e t a l , 1984, Wong-Staal 
and Gallo, 1985). A representative diagram of the structure  of HIV 
is  shown in Figure 1.2.
1.3.5 Retrovirus Replication and the Origin of HIV
The rep lica t ion  of re trov iruses is unique and w i l l  be b r ie f ly
described with spec if ic  relevance to HIV. The f i r s t  stage is  the
adsorption of the virus to a spec if ic  receptor on a susceptible c e l l .  
There is  strong evidence tha t fo r  HIV part o f the T helper ce ll  
antigen termed CD4 is involved in the process (Dalg le ish, Beverly, 
Clapham e t a l , 1984). Binding o f the v irus is  mediated by i t s  own 
envelope g lycoprote in, gpllO (McDougal, Kennedy, Sligh e t a l , 1986).
A fte r adsorption comes penetration (endocytosis) and uncoating o f the 
v ira l  genome (possibly in lysosomes).
Reverse transcriptase then converts the v i ra l  RNA in to  a
double-stranded DNA molecule which can be incorporated in to  the DNA 
of the host c e l ls .  The p ro -v ira l DNA thus becomes a part of the
genetic material of the ce l ls  which, upon a c t iva t ion , programmes the 
fu r th e r  manufacture o f v i ra l  components and th e i r  assembly in to  the 
whole v irus . The new viruses leave the ce ll  by budding out through 
the ce ll  membrane and are capable o f in fec t ing  other ce l ls  w ith the
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HTLV’I I I  V IR IO N , or virus particle, is a sphere, that is roughly 1,000 angstrom units 
(one ten-thousandth of a millimeter) across. The particle is covered by a membrane, made 
up of two layers of lipid (fatty) material, th at is derived from the outer membrane of the 
host cell. Studding the membrane are glycoproteins (proteins with sugar chains a t­
tached). Each glycoprotein has two components: gp41 spans the membrane and £pl20 
extends beyond it. The membrane-and-protein envelope covers a core made up of proteins 
designated p24  and p l8 .  The viral RNA is carried in the core, along with several copies 
of the enzyme reverse transcriptase, which catalyzes the assembly of the viral DNA.
Figure 1.2: Representative Structure of HIV.
(from Gallo, 1987).
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same host. Therefore, in fe c t ion  once acquired, probably pers is ts  fo r  
l i f e  and infected subjects remain in fec tious  to others (Curran, 
e t a l,  1985).
The or ig ins  o f HIV are not ye t c lear. I t  has been suggested 
that the v irus might be man-made by laboratories in the U.S.A. or 
Soviet Union, in an attempt to engineer b io log ica l warfare (Medvedev, 
1986 j Seale, 1986). A l te rn a t iv e ly ,  there is  more support fo r  the 
theory tha t HIV f i r s t  occurred in remote po lu la t ions in A fr ica  and 
subsequently spread via population movement (P inch ing,1986). Research 
has been la rge ly  d irected a t the p o s s ib i l i t y  tha t HIV in humans may 
have orig inated from the animal kingdom.
Sequences o f HIV have been compared to other HTLV viruses and 
with other re troviruses (Wong-Staal & G a llo ,1985). HIV has been shown 
to have close homology w ith  a simian v irus ca lled  STLV-III MAC 
which causes immunodeficiency in the Asian macaque monkey. A ttention 
has a d d it io n a l ly  focused on the African green monkey. A v irus re la ted 
to HTLV-III has been iso la ted  from healthy animals o f th is  species. 
Antibodies to th is  v irus known as STLV-III AGM have been found to 
cross react with HTLV-III.
Recent observations have indicated the presence o f at leas t one 
other re tro v iru s , gene t ica l ly  closer to the simian v irus in human 
populations in West A fr ica . Barin and colleagues (1985) have reported 
tha t antibodies to the AIDS v irus  found in a number of healthy 
subjects were more c lose ly  re la ted  to STLV-III ASM than to reference 
s tra ins of HTLV-III. Whether or not th is  v irus which has been ca lled 
HTLV-IV (Kanki, Barin, M'Boup e t a l , 1986) or LAV-2 (Montagnier, 1986) 
causes disease in humans is not ye t c lear.
The HIV genome has also been shown to have close homology to 
that o f equine in fec tious  anaemia v irus (Stephens, Casey and Rice,
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1986) and to members o f the Lentiv irus  subfamily such as visna (Gonda, 
Wong-Staal, Gallo et a l , 1985). A considerable degree o f genomic
d iv e rs i ty ,  especia lly  in the envelope gene, has been found among 
d i f fe re n t  HIV iso la tes (Wong-Staal e t a l , 1985) (S tarc ich , Hahn, Shaw 
et a l,  1986).
The o r ig ins  of HIV are thus shrouded in uncerta in ty but 
evidence s t i l l  favours the theory tha t i t  somehow orig inated  in 
A fr ica .
1.4 IMMUNOLOGY OF AIDS
Before discussing the immune defects found in AIDS i t  is 
necessary to f i r s t  o f a l l  give a b r ie f  overview of the workings o f the 
in ta c t  immune system.
1.4.1 Organisation of the Immune System
The sole function of the immune system is  to d is t ingu ish  s e l f  
from non-self and, i f  necessary, to mount a response against tha t 
which is  fore ign to elim inate i t  from the body. The i n i t i a l  
d iscrim ination is made by a d is t in c t  set o f thymus derived T ce l ls  
known as T helper/inducer (Th) c e l ls .  The ce ll  does th is  when antigen 
tha t has been processed by an antigen presenting ce l l  such as a 
macrophage is presented to i t  in the context of s e l f  components known 
as Class I I  structures coded fo r  by the Major H is tocom pa tib i l i ty  
Complex (MHC). This is  probably done by a single receptor on the 
T helper ce l l  surface which recognises the antigen in conjunction 
with the Class I I  s tructures. T helper ce l ls  also express a 55 -
k i loda lton  ce ll  surface molecule known as CD4. The use o f anti-CD4 
monoclonal antibodies is a convenient way o f enumerating th is  ce ll  
type (Reinherz, Kung, Goldstein e t  a l , 1979). The precise function 
of CD4 is not yet known but i t  is thought to be part o f the T ce ll  
receptor involved in secondary or associative recognition o f class 
I I  s tructures.
As a consequence o f T helper ce l l  recogn ition, they then switch 
on various arms of the immune response as appropriate. They may 
induce an tigen-spec if ic  B ce lls  to p ro l i fe ra te  and d i f fe re n t ia te  in to  
plasma ce lls  secreting antigen spec if ic  antibody. They can also 
induce T cy to tox ic  (Tc) which recognise antigens on c e l ls  surfaces in
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conjunction w ith Class I MHC products and lyse c e l ls .  The
cytotoxic/suppressor ce ll populations express the CD8 (T8 ) molecule 
(Reinharz and Schlossman,1981). The immune system can function e ith e r  
through d ire c t ce ll to ce ll contact or by the release o f lymphokines 
such as In te r leuk in  2 ( IL -2 ) ,  gamma in te rfe ron  (y-IFN), B ce ll  growth
fac to r (BCGF) e tc . ,  which are a l l  produced by the CD4 T helper c e l ls .
These lymphokines have potent e ffec ts  on other ce l ls  in the immune
system such as natural k i l l e r  (NK) ce l ls  and macrophages.
1.4.2 Infections and Immune Defects
Before the advent of AIDS, i t  was known tha t ce rta in  types of 
in fec t ion  could be associated w ith sp ec if ic  immune defects. V ira l ,  
fungal and protozoal in fec tions  tend to occur in patients with a 
T ce ll defect whereas bacteria l in fec tions  are more o f a problem fo r  
people with B ce ll dysfunction (Rosen, Cooper and Wedgewood, 1984). 
Some in fec tions  l ik e  Pneumocystis c a r in i i  pneumonia are opportun is tic  
occurring only in patients with immune dysfunction, whereas other 
such as Herpes can occur in both normal and immunodeficient patien ts .
1.4.3 HIV Infection in AIDS
From the immunologic standpoint, the AIDS phenomenon is best 
viewed as an HIV in fec t ion  a ffec t ing  T c e l ls .  AIDS is  characterised 
by progressive lymphopenia predominantly o f T he lper/ inducer ce lls  
which renders the pa tien t immunologically compromised and thus 
susceptible to a va r ie ty  of opportun is tic  in fec tions  and malignancies.
A prime determinant o f s u s c e p t ib i l i ty  to HIV in fe c t ion  is  the presence 
of the CD4 molecule on the ce ll surface which acts as a receptor fo r  
the v irus and which binds the gpllO envelope glycoprote in o f the v irus . 
Certain CD4 monoclonal antibodies can block v i ra l  binding and
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in fec tion  (Dalgleish e t a l , 1984). S im ila r ly ,  v irus infected ce lls  
bind and fuse with uninfected CD4+T c e lls  (but not CD4 T c e lls )  
resu lt ing  in syncytia formation tha t can be inh ib ited  by anti-CD4 
monoclonal antibodies (L ifson, Reyes, McGrath e t a l , 1986). D irect 
demonstration of a bimolecular complex of the CD4 molecule and v ira l  
gpllO has been obtained in radioimmunoprecipitation experiments 
(McDougal e t a l , 1986). Also when human ce ll  l ines which do not 
express CD4 and cannot be infected by HIV are rendered CD4-positive by 
transfection with the human CD4 gene then v irus can bind to and 
rep lica te  w ith in  these c e l ls  (Maddon, Dalgleish, McDougall e t a l , 1986).
While in fe c t io n  and depletion of CD4+ T c e lls  is  l i k e ly  the
major con tr ibu to r to q uan t ita t ive  v i ra l  re p l ica t io n  and pathogenesis 
o f immunodeficiency in the host, in fe c t ion  o f other ce ll  types has 
been demonstrated. Monocytes have been shown to express low leve ls of 
CD4 (Wood, Warner & Warnke,1983) and HIV p a r t ic le s  have been found in 
certa in monocyte derived ce ll types (Gyorkey, Melnich, Sinkovics e t a l ,
1985). Montagnier (1984) described HIV re p lica t io n  in B ce ll  l ines 
which have subsequently been shown to be CD4+ (Dalgleish and Clapham,
1985). Neuropsychiatric symptoms may be a prominent c l in ic a l  feature 
of HIV in fe c t io n , and HIV has been iso la ted  from brain tissue (Shaw, 
Harper, Hahn e t a l , 1985).
1.4.4 Immunological Abnormalities in AIDS
The f i r s t  abnormality to be associated with AIDS was the
reversal of the normal T helper to T suppressor (T^/Tg) ra t io  found in 
the blood (G ott le ib  e t a l,1981). I t  is now known tha t the inverted 
ra t ios  are due to a marked decrease in the absolute number of
helper/inducer T ce l ls  combined with a variab le  number (increased, 
decreased or normal) of suppressor/cytotoxic T ce lls  (Schroff,
G ottle ib , Prince e t a l , 1983). The decrease in ce l ls  is a more 
spec if ic  marker fo r  severe immunodeficiency as defined by the CDC 
surveillance d e f in i t io n  o f AIDS (Fauci, Macher, Longo e t a l , 1984).
ce ll depletion is consistent w ith resu lts  o f in v i t r o  tests fo r  
T ce ll function. When tested as iso la ted  T ce l ls  w ith normal B ce l ls  
in a pokeweed mitogen driven assay fo r  immunoglobulin production 
T helper ce ll function has been reported to be normal or depressed 
depending on severity  of T ce ll  depletion in the patients selected 
(Lane, Masur, Edgar e t a l , 1983). I t  is  ra re ly  t o ta l l y  abrogated 
except in AIDS patients w ith severe T ce ll  depletion. On the other 
hand, p ro l i fe ra t iv e  responses to soluble antigen and autologous mixed 
lymphocyte response are more cons is ten t ly  depressed or even
abrogated, and, these may be the e a r l ie s t  q u a l i ta t iv e  defects in the
immune system of the HIV infected pa tien t. Responses to T ce ll  
mitogens tend to be depressed when assayed on unseparated lymphocyte 
cu ltu res, but are generally normal in ce ll  separation studies where 
the d i f fe re n t  subpopulations are reconstitu ted in normal numbers 
(Lane e t a l , 1983). Response to soluble antigen however is  abnormal in 
reconst itu t ion  experiments and Lane (1985) has suggested an in t r in s ic  
defect in the capacity o f surv iv ing T c e l ls  to recognise soluble
antigen. Antigen-specif ic  p ro l i fe ra t iv e  responses are an in v i t r o
corre la te of Delayed Type H ypersens it iv ity  (DTH), and skin tes ting  
shows impairment in HIV-infected pa tien ts . Total anergy is  most l i k e ly  
to occur in those with severest T ce l l  depletion (Lane and Fauci, 1985) 
The T^ helper ce ll  is  akin to the conductor o f an orchestra.
Without him the rest do not know what to do and depend on him fo r  
ins truc t ions . I t  is well known tha t the T^ ce ll  is  central to the 
immune response and contro ls many of the other functions. This is 
shown in Figure 1.3.
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Figure 1.3: Central Role of the T^ Helper Cell.
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The numbers of Tg ce l ls  can be normal, elevated or depressed. 
These ce lls  comprise the T suppressor and T cyto toxic subsets. There 
is some evidence that asymptomatic HIV-infected subjects have higher 
levels o f Tg ce lls  than normal contro ls . This e levation is due to a 
subset of Tg ce l ls  associated w ith cyto tox ic  precursor and e f fe c to r  
function (Clement, Dagg and Landay, 1984). HIV-infected subjects 
mount poor cyto tox ic  e f fe c to r  responses in v i t r o  but presumably have 
re la t iv e ly  normal precursors. The s p e c i f ic i ty  and function of the 
increased number of Tg ce l ls  id e n t i f ie d  as cyto tox ic  c e l ls  and th e ir  
relevance to c l in ic a l  course or prognosis remains to be determined. A 
poor immune system could re s u lt  from e ith e r  a loss o f helper function 
or an excess of suppressor function . Much work has, therefore, 
focused on the second p o s s ib i l i t y  in  patients w ith AIDS. In v i t r o  
work (Lane e t a l,  1983) (Lane and Fauci, 1985) has shown tha t in fa c t  
there is  no evidence o f excess suppressor a c t iv i t y .  Although there 
does not seem to be excessive suppressor a c t iv i t y  by c e l ls ,  
several workers have described suppressor fac to rs . Laurence e t al 
(1983) have described the spontaneous production in v i t r o  o f such a 
suppressor fac to r dependent on T ce ll  - monocyte in te rac t ions . Other 
workers (Cunningham-Rundles, Michel is  and Masur, 1983), (Siegel, 
Djeu, Stocks e t a l , 1984) have described factors in the sera o f AIDS 
patients w ith suppressive or immunomodulating a c t iv i t y .  Pahwa (1985) 
suggested tha t re trov irus  products such as the gpllO envelope 
glycoproteins themselves could be immunosuppressive.
Another population of c e l ls  studied have been Natural K i l le r  
(NK) c e l ls .  These c e lls  reside la rg e ly ,  but not exc lus ive ly , w ith in  a 
population of lymphocytes known as large granular lymphocytes. Much 
l ik e  the resu lts  o f MHC-restricted and allogeneic cy to tox ic  c e l ls ,  NK
ce ll function is normal in asymptomatic HIV-infected ind iv idua ls  but 
declines in severe immunodeficiency and c l in ic a l  complications 
(Lopez, F itgera ld  and Siegel, 1983). Pol i (1985) suggested tha t the
functional defect is in the k i l l i n g  process i t s e l f .  Another two
ch a rac te r is t ic  f ind ings in AIDS patients are hypergammaglobulinaemia 
and elevated levels of immune complexes (Fauci, e t a l , 1984)
(McDougal, Hubbard, Nicholson e t a l , 1985). Despite th is  polyclonal 
immunoglobulin e levation, AIDS patients mount a poor an tigen-spec if ic  
antibody response a f te r  in -v ivo  immunisation. Primary responses are
affected to a greater degree than secondary responses (Lane e t a l,
1983). Patients can show a high t i t r e  o f antibody against HIV which 
drops only w ith end stage disease (Sarngadharan, Popovic, Bruch et 
a l , 1984). Much of the work on B ce ll function has been done by
Lane, Fauci and co-workers . B ce l ls  from AIDS patients produce a 
poor immunoglobulin response in v i t r o  to pokeweed mitogen stim ula tion  
(Lane e t a l , 1983). This is not due e n t i re ly  to a defect in 
immunoregulatory T ce l ls  because p u r i f ie d  B ce lls  from patients are 
poorly responsive when mixed with normal T c e l ls ,  nor can they be 
stimulated by T ce ll independent stimulus such as Staphylococci (Lane 
et a l , 1983). There seems to be a high degree o f spontaneous
polyclonal B ce ll  s tim ula tion rendering the HIV infected patients 
poorly responsive to normal early ac tiva tion  signals. The reason fo r  
th is  B ce ll  ac tiva tion  is  s t i l l  a matter o f speculation. One 
suggestion is tha t the abnormality of T ce ll control allows in fec tions 
or reac tiva t ion  o f other v i ra l  in fec t ions , e.g. Epstein Barr Virus, 
which are B ce ll  ac tiva to rs . Another p o s s ib i l i t y  is tha t HIV-infected 
T ce lls  elaborate B ce ll s tim ula ting  fac tors .
Blood monocytes and tissue macrophages form one of the f i r s t  
l ine5of defence against in fec t ion  by migrating towards s i te  o f entry,
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phagocytosing foreign m ateria l, and in most cases degrading and
inac t iva ting  the foreign micro-organisms. Many o f the monocyte 
functions have been examined in AIDS patien ts . Numbers o f monocytes 
are usually normal but those from AIDS patients may d isplay defective 
chemotaxis (Pinching, McManus, J e f f r ie s  e t a l , 1983). H2O2 and
superoxide production are generally normal (Murray, Rubin, Masur e t a l ,
1984) but resu lts  on phagocytosis and in t ra c e l lu la r  k i l l i n g  have been 
reported both as normal (Murray e t a l , 1984) and abnormal (Pinching et 
a l , 1983). Other abnormal responses have been reported fo r  monocyte- 
mediated, antibody-dependent, c e l lu la r  c y to to x ic i ty  and Fc-mediated 
clearance o f IgG-coated autologous erythrocytes (Bender, Auger, Quinn 
e t a l , 1986).
Another o f the important functions o f monocytes is  to process 
and present antigen in the context of Class I I  MHC structures to 
T c e l ls .  Monocytes recovered from AIDS patients express Class I I  MHC
structures of a lower density than tha t from normals. I t  has not been
determined whether monocyte defects re s u lt  from d ire c t  in fe c t ion  with 
HIV or as a re su lt  of immunoregularity T ce ll  abnormalities. As
mentioned e a r l ie r  recent papers (Gyorkey e t a l , 1985) have shown
d irec t in fec tion  of monocytes which express the CD4 antigen which 
could re su lt  in v i ra l  persistence as monocytes are long l ived  compared 
to T c e l ls  and thus could pose problems in therapeutic s tra teg ies fo r  
e lim ination o f HIV. As well as a ffec t ing  c e l ls  o f the immune system, 
HIV in fec t ion  has resulted in abnormalities in lymphokines and other 
soluble serum substances. The production o f IL -2 , the T ce ll  derived 
T ce ll growth fa c to r ,  is generally regarded to be d e f ic ie n t in 
response to mitogen (Hauser, Bino, Rosenberg e t a l , 1984) though some 
workers have suggested normal production (Lane, Depper, Greene e t a l ,
1985). This defic iency is  proportionate to the amount o f T ce ll
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depletion as remaining T ce lls  respond normally to the addition of 
exogenous IL-2 (Gluckman, Kaltzmann, C ava il le -Col1 e t a l , 1985).
There is  decreased production o f gamma in te r fe ron , a T ce ll  derived 
protein with potent a n t iv ira l  and immunopotentiating e ffe c ts . Again, 
th is  is due to quan t ita t ive  depletion o f T ce l ls  rather than a 
q u a l i ta t ive  defect in production or responsiveness (Murray e t a l ,
1985). Levels of a unique form of alpha in te rfe ron  tha t is acid 
la b i le  are higher in AIDS patients especia lly  those w ith more severe 
immunodeficiency (Eyster, Goedert, Poon e t a l , 1983). I ts  ro le  is 
unknown but could be produced by the po lyc lona lly  activated B ce lls
(Boumpas, Harris , Hooks e t a l , 1984). Elevated levels o f immune
complexes are also found in AIDS patients (G o tt le ib , Groopman, 
Weinsten e t a l , 1983).
Beta-2 microglobulin (82M) is a low molecular weight
glycoprotein associated with Class I MHC structures found on the 
surface of a l l  nucleated c e l ls .  Neoptrin is  a c e l lu la r  purine
metabolite. Serum levels of both of these substances corre la te  with 
ce ll destruction and turnover and an increased level o f both are found 
in AIDS patients (Grieco, Reddy, Kothari e t a l , 1984) (Wachter, Fuchs, 
Hausen e t a l , 1984) and increased leve ls o f B2M have been reported in 
haemophiliacs pos it ive  fo r  antibody to HIV (Madhok, Gracie, Lowe et a l,
1986).
1.4.5 The Haemophiliac Problem
The intensive use of potent c lo t t in g  fac to r  concentrates 
obtained from large plasma pools in the treatment o f haemophiliacs has 
markedly improved the l i f e  expectancy of these patients ( Ikka la , 
Helske, M ylly la  e t a l , 1982). However, the possible existence of 
undesirable s ide-e ffec ts  such as excessive antigenic load and
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transmission of v ira l  diseases has become a matter of great concern. 
As already mentioned, h e pa t it is  is well recognised as being closely 
associated with the use o f fa c to r  concentrates. Also, more recently , 
haemophiliacs have been well recognised as a r isk  group fo r  contracting 
AIDS through the use o f fa c to r  concentrate contaminated with HIV. 
This has prompted many laboratories to study c a re fu l ly  the immune 
system of the haemophiliac. Previous work from many labora tories , 
including our own, have reported immunologic abnormalities in 
haemophiliacs who are apparently asymptomatic showing no signs o f HIV 
in fec t ion . These abnormalities have included inverted T lymphocyte 
subset ra t io ,  elevated serum immunoglobulin leve ls , decreased lympho- 
p ro l i te ra t iv e  responses to T ce ll  mitogens and diminished NK a c t iv i t y  
(Stein, Evatt, McDougal e t a l , 1985). I t  should be noted tha t many of 
these studies were carried out before the serological k i ts  were 
available fo r  measuring anti HIV antibodies. Therefore, many o f the 
patients, although asymptomatic c l in i c a l l y ,  could in theory have been 
infected with HIV.
Since the advent of the antibody screening tests  fo r  HIV i t  has 
been possible to group the patients according to HIV status and 
therefore fo llow  th e ir  immunological status w ith a c learer 
understanding of underlying in fe c t io n . Broadly speaking the 
immunological defects seen in HIV antibody pos it ive  haemophiliacs are 
s im ila r  to those seen in the HIV pos it ive  patients belonging to the 
other a t r is k  groups (Stein e t a l , 1985).
1.4.6 TREATMENT OF AIDS
There have been endless numbers o f publications on several 
treatment regimes fo r  the various opportun is tic  in fec tions and tumours, 
as well as other problems encountered by a pa tien t su ffe r ing  from AIDS.
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However, the u ltimate goal is  a cure fo r  AIDS, ( i . e .  against HIV) and 
also a way of preventing in fe c t ion , e.g. by vaccination. Work towards 
producing a vaccine is  cu rren t ly  intense and i t  is  hoped to soon have 
a prototype vaccine which should be available  fo r  human t r ia ls  w ith in  
the next 12 months. There seems to be many problems involved in 
try ing  to produce a vaccine. HIV iso la tes from d i f fe re n t  sources 
although often quite s im ila r ,  can show d is t in c t  d ifferences in the 
genome. I f  these differences occur in areas of the genome encoding, 
fo r  example the envelope pro te ins, then d i f fe re n t  HIV iso la tes  w i l l  
express d i f fe re n t  envelope prote ins. This could mean tha t antibodies 
produced in response to vaccination w i l l  recognise the s tra in  of 
virus in the vaccine but not other genetic variants which could 
in fe c t  the ind iv idua l.
For a vaccine to be e ffe c t iv e  i t  must safe ly evoke two 
d if fe re n t  types of immunologic response. The B ce lls  must be 
stimulated to produce neu tra l is ing  antibodies which bind to the 
envelope proteins of the v irus and prevent i t  from entering c e l ls .  
Also the c e l lu la r  immune system invo lv ing the T ce l ls  must be 
activated and must be capable o f attacking and destroying ce l ls  
already infected with v irus . Although people infected with HIV do 
make antibodies to i t ,  the amount o f e f fe c t iv e  neu tra l is ing  antibody 
is d is tu rb in g ly  low, and c e l lu la r  immunity is  severely impaired by the 
death o f the T^ c e l ls .  A successful vaccine must boost both responses 
greatly .
A vaccine is not a cure fo r  people already in fected. Various 
l ines of research have been followed in looking fo r  treatment or a 
cure. Much work is  looking at an a n t i - v i r a l  approach. These may 
include in h ib i t io n  of binding of the v irus w ith i t s  receptor on 
target ce ll  membrane. This could be achieved by the use of
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monoclonal antibodies directed against e ith e r  v i ra l  proteins 
(especia lly  envelope glycoproteins) or the antigen ( v i r a l )  receptor 
on the lymphocyte. Another important a n t i - v i r a l  approach is  to use 
drug therapy. Many of the drugs being tested, e.g. AZT, have 
anti-reverse transcriptase a c t iv i t y .  Therefore, the virus cannot 
rep lica te . However, these drug therapies, although sometimes 
e f fe c t ive  in ha lt ing  progression o f the disease, cannot remove the 
virus from the body and i f  therapy is stopped then de te r io ra tion  
associated with v i ra l  in fec tion  usually recurs. Other drug therapy 
angles have t r ie d  to augment the bodies immune response. Isoprinosine 
is a drug w ith both a n t i - v i ra l  and immunopotentiating properties.
Early c l in ic a l  studies proved hopeful as did some in v i t r o  studies. 
Some studies showed enhanced natural k i l l e r  a c t iv i t y ,  y  - in te r fe ron  
and IL-2 production, and an increase in pos it ive  c e l ls .  However, on 
the whole, resu lts  do not suggest tha t th is  agent w i l l  be of 
s ig n i f ic a n t  use in the treatment o f AIDS.
Possibly the most ambitious approach has been tha t of 
immunorestorative therapy. These have included bone marrow 
transplants (Lane and Fauci, 1985), white ce ll  transfusion (Lane, 
Masur, Longo e t a l , 1984) and thymic transp lan ta tions, but they have 
met w ith l i t t l e  or no success. Attempts have been made to augment any 
remaining immune response by in jec t ions  o f the missing lymphokines, 
e.g. IL-2 and y - in te rfe ron  but although the in v i t r o  studies were 
promising, the c l in ic a l  t r i a ls  have not been encouraging. Recent 
observations have suggested tha t HIV infected c e l ls  activated by IL-2 
show enhanced expression of v irus which is undesirable (Zagury, 
Bernard, Leonard e t a l , 1986).
I t  is evident from early c l in ic a l  t r i a l s  tha t any o f the 
cu rren t ly  available a n t i - v i ra l  or immunorestorative approaches alone
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w i l l  not be curative fo r  patients w ith HIV in fec t ion  and immune 
defic iency. However, as an e f fe c t ive  vaccine, the u ltimate goal, is 
as yet some time o f f ,  a combination o f a n t i - v i r a l  and immunorestorative 
therapy is possibly the best approach cu rren t ly  ava ilab le . A n t i - v i ra l  
agents should preferably be v i ru c id a l ,  or, i f  they are v i r u s ta t ic ,  
they should be eas ily  administered and should have no or minimal side 
e ffec ts  so tha t they could be given fo r  prolonged periods o f time. A 
r e a l is t ic  approach would be to develop an e f fe c t ive  pharmacologic 
immunopotentiator and administer i t  along w ith a safe and e f fe c t iv e  
a n t iv ira l  drug.
1.5 SCOPE OF STUDY
The i n i t i a l  purpose of th is  study was as a more comprehensive 
and larger follow-up study to the p i l o t  study already carr ied out in 
our department on a small cohort of the haemophiliac population.
I wished to examine more c lose ly  the immunological status of 
our haemophiliacs. This meant se tt ing  up new assays to measure 
various immunological parameters. I also wanted to f in d  out i f  the 
patients immune system was altered so le ly  as a re s u lt  of HIV in fec t ion  
or i f  there was some underlying immunological defect associated with 
the use of fac to r concentrate in the absence o f HIV in fe c t io n . Each 
of the various immunological parameters examined w i l l  be dealt w ith 
separately in th is  thesis and w i l l  be discussed in re la t io n  to any 
other f ind ings where re levant.
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1 .6  AIMS OF THE STUDY
The aims of the study are as fo l lo w s :-
1. To determine the degree o f HIV in fe c t ion  in our 
group of patients.
2. To estab lish  the e f fe c t  o f HIV in fec t ion  on the 
immunological status of the patients.
3. To examine the immune status in the absence of 
HIV in fe c t ion .
4. To investigate  the e f fe c t  o f Factor V I I I  concentrate
and HIV antigen on various in v i t r o  immunological assays.
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C H A P T E R  T WO
HIV STATUS OF THE HAEMOPHILIAC POPULATION
2.1 INTRODUCTION
Early in the AIDS epidemic i t  was rea lised that from 
epidemiological data tha t the cause was an in fec tious  agent which is 
ho r izon ta l ly  transmitted by intimate contact or exposure to 
contaminated blood or certa in  blood products (Chamberland e t a l ,
1984) (Curran et a l , 1984). The causative agent which we now know to
be a re trov irus  belonging to the fam ily  o f human T lymphotrophic 
viruses (HTLV) was given the name HTLV-III by Gallo and colleagues 
(1984). As described e a r l ie r  other workers described the iso la t io n  
of retroviruses which they gave d i f fe re n t  names to and the standard 
term HIV is now being used to describe the v irus , causative of AIDS.
I t  was necessary to develop some means of detecting whether or
not a pa tien t was infected by HIV. The ideal way would be to t ry  and
look fo r  l iv e  v irus from an in d iv id u a l 's  blood sample. I t  has proved 
d i f f i c u l t  to develop such assays, which would be both read ily
available , and also re la t iv e ly  easy and safe to carry out. The other 
p o s s ib i l i ty  was to develop a te s t  which would detect evidence of 
in fec tion  by HIV. In developing such a te s t  i t  would be necessary to 
have an assay system which was reproducible, easy to perform, safe, 
spec if ic  and, perhaps more important fo r  the company who developed 
and produced the assay, an assay system which would have financ ia l 
rewards. Nearly a l l  assay systems developed made use of the fa c t
that an infected person w i l l  have in his bloodstream c ircu la t in g  
antibodies to HIV. Therefore, an assay has to be able to detect 
antibodies to HIV from serum or plasma samples. There are many such 
k i ts  now available on the market which are varia t ions on th is  fac t .  
Some are radioimmunoassays and others are enzyme immunoassays
(ELISA). The k i t  used to detect antibodies to HIV in our patients
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was the ELISA developed by Abbott Laboratories (Wokingham, Berkshire, 
U.K.). I f  a sample is found to be pos it ive  i t  must be re-tested by 
the same or another s im ila r  assay and i f  again found to be pos it ive  
i t  is confirmed by a more sensit ive  technique such as Western 
B lo tt ing .
2.2 MATERIALS AND METHODS
2.2.1 Serum Samples
Serum was separated from c lo t ted  blood by cen tr i fuga t ion  at 650g 
and stored at -20°C u n t i l  assayed.
2.2.2 Biological Principles of the Assay
The Abbott ELISA is manufactured from HIV v irus propagated in 
the T lymphocyte ce ll l in e  H9/HTLV I I I  . B r ie f ly  iso la ted v irus is 
disrupted and inactiva ted with detergent and sonication p r io r  to 
coating of p la s t ic  beads. Coated beads are then incubated with the 
sample being tested. Also included are appropriate pos it ive  and 
negative contro ls , i . e .  samples known to be pos it ive  or negative fo r  
antibodies to HIV. Any antibody to HIV in the serum sample w i l l  bind 
to the HIV which is  coating the beads. The second step, a f te r  washing 
to aspirate unbound sample, is  to incubate the bead with a goat 
antibody to human IgG conjugated with horseradish peroxidase. This 
antibody w i l l  in turn bind to any human IgG which is  bound to the HIV 
on the surface o f the bead. A fte r  a fu r th e r  incubation the beads are 
again wahsed to remove any unbound m ateria l. Next, O-Phenylenediamine 
(OPD) so lution containing hydrogen peroxide is added to the bead. 
This substrate so lu tion reacts w ith the horseradish peroxidase bound 
to the bead complex and a yellow colour develops which is  proportional 
to the amount of anti-HIV antibody o r ig in a l ly  present in the serum and 
now bound to the bead. The colour change can be read on a 
spectrophotometer and inc lus ion of appropriate contro ls allows 
determination o f a pos it ive  or negative re su lt .
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2.2.3 Problems Associated with such an Assay
There are many problems associated with assays of th is  type. 
Although very s tra ightforward to carry out there is  s t i l l  an element 
of r isk  fo r  the person who has to handle the specimen. Care is 
required. The biggest problem w ith such assays is the p o s s ib i l i t y  of 
fa lse posit ive  and fa lse negative resu lts .  A re su lt  which comes back 
pos it ive  is ,  o f course, re-checked and i f  necessary re-checked again. 
The implications to the pa tien t of a pos it ive  re su lt  are obvious, 
therefore i t  is  not desirable to have " fa lse  pos it ive "  resu lts  which 
could produce unnecessary problems, psychological or otherwise, to 
the patien t. However, perhaps more important is  the desire to avoid 
fa lse negative resu lts . This would come about i f  an assay was not 
sensitive enough to pick up anti-HIV antibodies in the serum, or, i f  
there are technical problems with an assay run. I t  is  important to 
have an assay which is  re l ia b le ,  easy to carry out and one which 
contains the appropriate contro ls , e.g. "po s it ive  contro ls" which 
w i l l  t e l l  you tha t the assay i t s e l f  is  working. The consequences of 
a fa lse negative re su lt  are also obvious, fo r  example, in the 
screening o f blood fo r  the use o f in transfusions or the manufacture 
of blood products such as Factor V I I I .
I t  should be remembered tha t a negative re s u lt  does not 
guarantee that a sample is free from HIV. In some cases i t  may be 
possible to have been exposed to HIV and not produced antibodies to 
i t .  This could occur i f ,  fo r  example, blood was taken fo r  tes ting  
soon a f te r  exposure to HIV and before the body has had time to produce 
antibodies to i t .  Therefore, although the k i ts  fo r  screening antibody 
are a l l  tha t is  read ily  ava ilable  at the moment, the ideal assay 
would be to look fo r  v irus in the blood sample.
As already mentioned a pos it ive  sample is  re-checked, and i f
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s t i l l  found to be po s it ive , is confirmed by a more sensit ive  procedure 
such as Western B lo tt in g .
2.2.4 Western Blotting
Very b r ie f ly ,  Western B lo tt ing  technique involves running 
disrupted HIV on polyacrylamide gel e lectrophoresis. The prote in 
bands corresponding to the various HIV proteins can then be b lo tted 
onto N it ro -c e l1ulose s tr ip s .  These are then overlayed with te s t  sera 
and any antibody to the v i ra l  proteins w i l l  bind to the N it ro -c e l1ulose 
s tr ip s .  Bound antibody can then be detected by fu r th e r  incubation 
steps. This technique is  more sp e c if ic  than others and i t  is  possible 
to detect antibodies against the various HIV prote ins. Disease state 
has been associated with a p a r t ic u la r  serological p ro f i le ,  and a 
reduced incidence of detectable antibodies to the major HIV core 
pro te in , p24, in patients w ith AIDS compared with tha t in other people 
infected with HIV has been reported (Kalyanaraman, Cabradillo , 
Getchell e t a l , 1984) (Schupbach, H a lla r, Vogt e t a l , 1985). Loss of 
in te n s ity  of bands and to ta l loss of antibodies to p24 may therefore 
herald the onset o f AIDS (Lange, Coutinho, Krone e t a l , 1986) and in 
recent studies AIDS seemed to be strongly associated with the 
expression of HIV antigen in the serum as detected by a new te s t 
(Goudsmit, de Wolf, Paul e t a l , 1986).
2 .3 RESULTS
At regular c l in ic  appointments blood was taken fo r  HIV status 
determination. Most of our haemophiliac population (around 250) have 
now been tested fo r  antibodies to HIV. Twenty-one of the patients 
have been found to be seropositive fo r  antibodies to HIV by ELISA. 
These resu lts  have a l l  been confirmed by Western B lo t t in g . Therefore, 
approximately 8.4% of our haemophiliac population show evidence of 
exposure to HIV or HIV antigens.
2 .4 DISCUSSION
As stated 8.4% of our haemophiliacs have been shown to be HIV+ 
( i .e .  have antibodies to HIV). Many workers believe that i f  a pa tien t 
is shown to have antibodies to HIV then i t  w i l l  be possible to iso la te  
in fectious v irus from tha t ind iv idu a l.  I t  was o r ig in a l ly  suggested 
that perhaps haemophiliacs were HIV+ because of carry over of 
immunoglobulins to HIV in the Factor V II I  concentrate. However, th is  
does not seem to be the case as anti-HIV antibodies have not been 
detected in these preparations. Another p o s s ib i l i t y  is  tha t 
haemophiliacs have been exposed to disrupted v i ra l  antigens, in the 
concentrates, rather than to l iv e  v irus . I f  th is  were the case then
the concentrate would be acting in the same was as a vaccine does
with the pa tien t producing antibodies to a harmless form of the v irus
which would in turn confer immunity against in fe c t ion  with the l iv e
v irus . This seems very u n like ly  as there have now been many cases of 
AIDS amongst haemophiliacs whose only exposure to l iv e  HIV must have
been through the use of Factor V II I  preparations. HIV has now been
isolated from HIV antibody pos it ive  haemophiliacs (A l la in  e t a l , 1986). 
As in fec tion  with the v irus resu lts  in i t s  DNA being inserted in to  the 
c e l ls '  genes, then i t  has to be assumed tha t the v irus can l i e  dormant 
and i t  could be possible to reactivate the v irus . Therefore, anyone
who is HIV+ should be treated as p o te n t ia l ly  in fec t ious . Very
recently we have managed to assay our HIV+ haemophiliacs fo r  HIV 
antigen and four of them have proved to be pos it ive . I t  w i l l  be 
necessary to monitor these pa tien ts ' c l in ic a l  condition very c a re fu l ly  
as i t  has now been conclusively shown that they are infected with l iv e  
v irus. In fa c t ,  one o f these patients has now lo s t  antibodies to the 
p24 protein on Western B lo tt ing .
The percentage of patients we have who are HIV+ is much lower 
than has been reported by many other groups (Jones, Hamilton, Bird et 
a l , 1985). This is probably due to the fa c t  tha t here in Scotland we 
are se lf  s u f f ic ie n t  in the production of Factor V II I  concentrate from 
local blood donations. To date, th is  donor pool has been la rge ly  free 
from in fec tion  with HIV, thus allowing the production of re la t iv e ly  
safe concentrates. However, there has been a report in the l i te ra tu re  
of at least one batch of "home produced" concentrate which was 
contaminated resu lt ing  in several seroconversions (Ludlam e t a l , 1985). 
In contrast, are the commercially available concentrates, mostly from 
the USA, which are produced from paid blood donors. As a re s u lt ,  many 
of the high r isk  groups, e.g. intravenous drug abusers w i l l  donate 
blood to receive money which w i l l  in turn be used to obtain more 
drugs. A ll of our haemophiliacs who have seroconverted have at some 
time received commercially available  concentrates and the one patien t 
who died of AIDS received heavy prophylactic treatment with these 
commercial products while l iv in g  in England.
In summary, therefore, a small percentage o f our patients 
(8.4%) have been exposed to HIV. The m a jo r ity  o f them seroconverted 
around 1981-82 which is in keeping with the lag phase seen in 
European countries compared to the USA experience. With th is  
information available i t  w i l l  be possible to monitor various aspects 
of the immune system of haemophiliacs (as described in the fo llow ing 
chapters) to look fo r  any defects which may be a ttr ib u ta b le  through 
in fec t ion  w ith HIV, the causative agent o f AIDS.
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C H A P T E R  T H R E E
SKIN TESTING
3.1 INTRODUCTION
Abnormalities in vivo in AIDS have been observed. Skin te s t 
anergy to common reca ll antigens that usually reveal delayed-type 
hypersens it iv ity  (DTH) is generally found (G ott le ib  e t a l , 1981)
(Siegel, 1984). Anergy suggests that some part of the response from
antigen recognition through to recruitment o f inflammatory ce l ls  
causing the reaction is defective. Primary immunisation to e l i c i t  DTH 
commonly employs sk in -se ns it is ing  haptens such as 2 ,4 -D in itroch lo ro - 
benzene (DNCB). The DNCB skin te s t is considered to be the best
single tes t to evaluate both the a ffe ren t and e ffe re n t arms of the 
ce ll  mediated immune response in vivo as i t  measures a person's 
a b i l i t y  to respond to a new antigen, as DNCB is ra re ly  encountered 
(Aisenberg, 1962). DNCB binds to skin proteins or perhaps d ire c t ly  to 
antigen presenting, la-bearing ce l ls  (Langerhans c e lls )  in the skin
leading to clonal se lection and expansion o f antigen reactive T c e l ls .  
The development of contact dermatit is  on re-challenge suggests in ta c t  
c e l lu la r  immunity.
In th is  study we have measured the patients response to DNCB 
and have t r ie d  to compare th e ir  tes t score with HIV antibody status 
and Factor V I I I  concentrate consumption.
3 .2 MATERIALS AND METHODS
3.2.1 Patients
We studied 29 patients w ith c l in i c a l l y  severe haemophilia 
(Factor V II I  or IX concentration <50 U/L). Twelve o f these patients 
were known to be HIV antibody pos it ive . A ll patients were examined 
fo r  features of disease re lated to HIV. The mean annual consumption 
of fac to r concentrate was calculated from case records. The presence 
of transaminasaemia and previous exposure to h epa t it is  B v irus , 
assessed by antigen and antibody tes ting  (Abbott, Wokingham, U.K.) 
was also noted.
3.2.2 Serological Tests
Blood was withdrawn to te s t fo r  antibodies to HIV and routine 
screening fo r  viruses including CMV, Herpes, and EBV.
3.2.3 Lymphocyte Subsets
At the time of re-challenge with DNCB, blood was withdrawn fo r  
enumeration of T ce ll  subsets as by method described in Chapter 4.
3.2.4 Dinitrochlorobenzene (DNCB) Test
The p r inc ip le  of th is  tes t is to sensit ise  the pa tien t w ith an 
antigen he has not encountered before and then re-challenge and 
measure the response. I f  the pa tien t has an in ta c t  ce ll  mediated 
response then he should recognise the DNCB as foreign and a varying 
degree of reaction w i l l  be seen at exposure s ight. However, on 
re-challenge patients w ith in ta c t  ce ll mediated response w i l l  
recognise the DNCB as something met previously ( i . e .  immunological 
memory) and th e ir  response w i l l  co rre la te  to the degree of intactness
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of the immune system and w i l l  give a measure in vivo o f ce ll  mediated 
immuni ty .
A modification of the DNCB tes t described by Watson and 
colleagues (1979) was used. DNCB was dissolved in acetone to a f in a l  
concentration of 20 mg/ml. 0.1 ml was applied to an area on the 
dominant forearm measuring 2.5 cm in diameter, where the acetone 
evaporated leaving DNCB on the skin. A fte r  14 days the pa tien t was 
re-challenged on the opposite forearm. Varying doses o f DNCB (30, 15, 
7.5, 3.7 and 1.8 pg) dried onto 1 cm diameter f e l t  pads (Al te s t
patches, Astra Chemicals, Watford, U.K.) were applied to the skin. 
The p a t ie n t 's  response was then measured 48 hours la te r .
The c r i t e r ia  fo r  scoring was as fo l lo w s :-
Score
0 : No reaction or erythema only
1 : Erythema and induration confined to s i te  o f te s t  patch
2 : Erythema and induration spreading beyond te s t  patch
3 : As fo r  2 plus b l is te r in g .
The minimum score obtainable was 0 and could range to a maximum of 15 
(3 score x 5 te s t patches).
In a previous study from our area (Watson e t a l , 1979) using 
the same method o f tes ting , the median score in a group o f 15 normal 
subjects was 9 [range 4-14]. Obtaining a normal population is
d i f f i c u l t  as i t  is  undesirable to sensit ise  people to DNCB i f  they may
meet i t  again, e.g. laboratory personnel. Therefore, as the previous 
study used the same methodology and the normals were sex and age 
matched to our population, i t  was decided to use the previous re su lt  
as a control population fo r  our study.
3.3 RESULTS
3.3.1 Clinical
The DNCB response is  shown in Figure 3.1. Two patients had 
appreciable cervical lymphadenopathy but no other features of HIV 
related disease. One pa tien t had pe rs is ten t mild thrombocytopenia, 
the lowest recorded count being 96 x 109/L . No other pa tien t had 
c l in ic a l  features re lated to HIV.
3.3.2 DNCB Testing
The DNCB response is  shown in Figure 3.1. The bar value in 
th is  and a l l  subsequent scatter p lo ts throughout the Thesis represents 
the median value. The median score in normal subjects was 9 (range 
4-14). All the patients had a score below 9. The median score in 
a l l  patients was 3 (range 0-8) which was s ig n i f ic a n t ly  less than 
normals (p<0.001). In the HIV+ patients the median score was 1 
(range 0-8) which was also s ig n i f ic a n t ly  less than normals (p<0.001). 
The seronegative patients had a median score o f 4 (range 0-8). This 
too was s ig n i f ic a n t ly  d i f fe re n t  from the normals (p<0.001) but no 
d i f fe re n t  compared to the HIV+ patien ts . Among the 3 patients w ith 
c l in ic a l  features of disease re lated to HIV, the score was 0 in the 
patien t with thrombocytopenia and 0 and 4 in the patients w ith 
lymphadenopathy.
3.3.3 Serological
Twelve of the patients had antibody to HIV as tested by ELISA 
(Abbott). No patient had c i rc u la t in g  IgM to any other v irus tested. 
Previous exposure to h e p a t it is  B v irus and the presence o f trans- 
aminasaemia was s im ila r  in both patients pos it ive  and negative fo r  HIV.
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3.3.4 Lymphocyte Subsets
Table 3.1 gives the resu lts  of T lymphocyte subsets. The median 
number of T helper c e l ls  in the HIV antibody pos it ive  patients 
was 0.76 [range 0.45-1.05] x 109/L. This was not s ig n i f ic a n t ly  
d i f fe re n t  from the number in the patients negative fo r  antibody to 
HIV, (median 0.8 [range 0.3-1.67] x 109/L . The score on DNCB testing  
inpatients pos it ive  fo r  HIV antibody showed an inverse co rre la t ion
Pte-or)
with the T suppressor ce ll  count (r=0.45 but no co rre la t io n  w ith the 
T helper ce ll  count (r=0.04/^-°r).In HIV negative patients the DNCB
Pio-os)
score showed a d ire c t  co rre la t ion  (r=0.49A with the T helper ce ll
p y o - o s )
count but no co rre la t ion  (r=0.15/, w ith the T suppressor ce ll  count. 
The difference in the median number o f T helper c e l ls  in patients 
negative fo r  the antibody between those w ith DNCB scores in the 
normal range and those with scores below the normal range was 
s ig n i f ic a n t  (p<0.05).
3.3.5 Consumption of Clotting Factor
The median annual consumption of c lo t t in g  fa c to r  over four 
years in a l l  patients was 49,068 un its  [range 5,104-190,925]. The 
median consumption in seropositive patients was 97,250 [range 5,104 -
190,925] and in seronegative patients 32,375 [range 9925-92,500]. This 
difference was s ig n i f ic a n t  (p<0.05). An inverse co rre la t io n  was 
noted between increasing usage of c lo t t in g  fa c to r  and decreasing 
score on DNCB testing  as shown in Figure 3.2. ( r= -0 .3 , p<0.05). In 
seronegative patients w ith a score less than normal (<4) the median 
consumption of c lo t t in g  fac to r was 59,685 un its  [range 21,175-92,500]. 
th is  was s ig n i f ic a n t ly  more than in seronegative patients w ith a DNCB 
response in the normal range (median 22,899 un its  [range 9,925-91,925] 
p<0.02. An inverse corre la t ion  was noted in a l l  seronegative patients
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between c lo t t in g  fac to r  usage and DNCB score (r= -0.41, p<0.05), but 
the co rre la to r in seropositive patients was not s ig n i f ic a n t  (r=0.08). 
There was no s ig n i f ic a n t  d if fe rence, however, between the corre la t ions  
in the seropositive and seronegative groups.
3.3.6 Hepatic Dysfunction
There was no s ig n i f ic a n t  association between DNCB and the 
presence o f transaminasaemia or exposure to h e p a t it is  B v iru s .
3.4 DISCUSSION
As the response to DNCB evaluates both the a ffe ren t and 
e ffe ren t arms of the immune response, i t  gives a measure of the 
pa tien t 's  current ce ll mediated immune sta te . The resu lts  show tha t 
a l l  patients w ith severe haemophilia treated with Factor V I I I  
concentrate had a response below the median normal value, and in 19 of 
the 29 patients studied, the response was on or below the lower l im i t  
of the normal range ( tha t is £4). In add it ion , the response was 
impaired in patients seronegative fo r  antibody to HIV. The 
publication of th is  study (Madhok, Gracie, Lowe et a l , 1986) was the 
f i r s t  such report to show a depressed ce ll  mediated response in vivo 
in haemophiliacs in the absence of apparent in fe c t io n  with HIV as
determined by the absence of antibodies to HIV.
In patients negative fo r  antibody to HIV the response to DNCB 
was inversely re la ted to consumption o f c lo t t in g  fa c to r .  In p a r t ic u la r ,  
patients who had a subnormal response had used s ig n i f ic a n t ly  more 
fac tor concentrate than those patients w ith  a response which f e l l  
w ith in  the normal range. This asso ic ia tion  o f consumption of c lo t t in g  
fac tor with reduced ce ll  mediated immunity may be due to one o f,  or a 
combination o f, a va r ie ty  of reasons; ( i )  transmission of v ira l  
in fe c t ion , ( i i )  a d ire c t  chemical e f fe c t  o f concentrate, or ( i i i )  an 
ind ire c t e f fe c t  mediated via the immune system.
Concomitant serological studies ruled out the p o s s ib i l i t y  o f an 
incidental v ira l  in fe c t io n . In fec t ion  w ith HIV in the absence of
antibody was considered u n l ik e ly ,  as none o f our seronegative patients 
had HIV related disease features. In our pa tien t population HIV
seroconversion occurred during 1980-84, espec ia lly  1981-82 (Madhok et 
a l, 1985) and in a previous report our group have shown tha t
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seroconversion was associated with use of imported American 
concentrates (Mel bye e t a l , 1984). No seroconversions have been 
recorded in these patients since 1984, when a l l  the patients began to 
receive only lo c a l ly  prepared fac to r concentrate from an area with a 
low prevalence o f disease re lated to HIV. In add it ion , iso la tes of 
v irus from seronegative patients are exceptional (Salahuddin, Groopman, 
Markham et a l , 1984). This study, therefore, suggests tha t the
depression in ce ll  mediated immunity is probably due to e ith e r  a 
d ire c t  e f fe c t  or an immunological consequence o f in fus ion of fac to r 
concentrate.
In a previous study o f our patients Forwell e t al (1984) have 
reported high c i rc u la t in g  levels of FcY receptor antibody. This 
anti lymphocytic antibody develops a f te r  repeated blood transfusions or 
use o f blood products. The FcY receptor is an important immuno- 
regulatory prote in  (Unkeless, F le i t  and Mellman, 1981) and blocking of 
th is  receptor w ith antibody or immune complexes can stimulate a 
non-specific T suppressor ce ll  response (Moretta, Mingari, Moretta et 
a l,  1979) which could then a dd it io n a l ly  in h ib i t  macrophage ac tiva tion  
or T helper functions. Excessive a c t iv i t y  o f T suppressor ce l ls  may 
therefore account fo r  the abnormalities seen in our seronegative 
patients on DNCB tes ting .
In the twelve seropositive patien ts , the DNCB score was 
s ig n i f ic a n t ly  below normal (p<0.001), and nine of the patients had a 
score below the normal range. The score did not d i f f e r  s ig n i f ic a n t ly ,  
however, from th a t found fo r  the seronegative pa tien ts . There was no 
co rre la t ion  in the seropositive patients between the score and the 
consumption o f c lo t t in g  fa c to r .  Both o f these negative find ings may 
have been due to the small numbers in th is  group.
In conclusion, therefore, the resu lts  suggest tha t a decrease 
in ce ll mediated immunity in the severe haemophiliacs is re lated to 
the amount of Facor V II I  used in therapy. Whether th is  abnormality 
is related to r isk  of in fec tion  with HIV, or to i t s  sequelae, or 
both, is as yet unknown. Though no s ig n i f ic a n t  d if fe rence in DNCB 
score was observed between the HIV seropositive and seronegative 
groups, in fec t ion  w ith HIV was f a i r l y  recent. Future studies of DNCB 
response in the HIV seropositive pa tien ts , who have been infected fo r  
a longer period, may show lower responses, as HIV induced 
immunosuppression may take many years to become f i rm ly  established.
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C H A P T E R  F O U R
T CELL SUBSETS
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4 .1  INTRODUCTION
Since th e ir  discovery, monoclonal antibodies have been used 
extensively in many areas o f medical and s c ie n t i f ic  research (Kohler 
and Mil s te in , 1975). One of the most common uses has been to raise 
monoclonal antibodies to the various ce ll  subpopulations of the 
immune system. As these monoclonal antibodies are spe c if ic  fo r  only 
one antigenic moiety, i t  has been possible to produce antibodies 
spec if ic  to such populations as B c e l ls ,  T helper c e l ls ,  T cy to to x ic /
suppressor c e l ls ,  moncytes etc. In c l in ic a l  research in recent
years i t  has been very popular to enumerate the various ce ll  
populations, espec ia lly  the T helper ce l ls  or T cytotoxic/suppressor 
ce lls  in various c l in ic a l  conditions or disease states. The most 
popular way to express the resu lts  is as a ra t io  o f the number of T 
helper ce lls  to the number of T cytotoxic/suppressor c e l ls .  This 
ra t io  has been expressed d i f fe re n t ly  but the most common forms are 
Tf/Tc/s or the T^/Tg ra t io .  The la t t e r  got i t s  name from the 
commercially ava ilable  monoclonal antibodies which recognise the 
d i f fe re n t  ce ll  types, OK-T^ fo r  T helper ce l ls  and OK-Tg fo r  
T cytotoxic/suppressor ce l ls .
In the normal population, free from i l ln e s s ,  the T helper ce l ls
and the T cytotoxic/suppressor ce l ls  cons titu te  about 64 and 36 per
cent respective ly , o f the to ta l T ce lls  g iv ing a T^/Tc^s ra t io  of
approximately 1.7. However, th is  f igu re  can change quite  dramatica lly
even in a seemingly normal population. In disease states, however,
the ra t io  is often abnormal. Even in something quite t r i v i a l  l ik e  a
common v ira l  in fe c t io n  such as influenza, the ra t io  can be reduced.
This is due to an imbalance caused by an increase in the T0o
population re la t iv e  to the T^ population. There are many references
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in the l i te ra tu re  of such imbalances caused by ra t io  can be v i ra l  
in fec tions, e.g. cytomegalovirus (Carney, Ia cov ie l lo  and Hirsch, 
1983).
I t  is thought tha t by measuring th is  ra t io  i t  is  possible to 
f ind  out i f  fo r  instance the immune system is in ta c t  or even 
activated in f ig h t in g  an in fe c t io n .
In AIDS, the T ce ll subset ra t io  was one o f the f i r s t  
immunological tests examined. A profound defic iency in immune 
function underlies the ongoing epidemic o f AIDS. A reversed T^/Tc^s 
ce ll ra t io  (from about 1.7 in normal to about 0.5 or less in AIDS 
patients) is one o f the ch a ra c te r is t ic  f ind ings when studying the 
patients immune status (G ott ie ib  e t a l , 1981).
In f u l l  blown AIDS, th is  decrease or reversal o f the normal 
ra t io  is  due to the lyphopenia, or more sp e c if ic ,  the marked reduction 
in absolute numbers o f T helper c e l ls .  As previously mentioned the
decrease in T helper ce l l  count is  due to the tropism o f HIV fo r  T^+
cel 1 s.
Altered ra tios  have also been reported to be a common 
occurrence in haemophiliac subjects treated with lyoph il ised  Factor 
V I I I  concentrates (Ludlam, Carr Veitch e t a l , 1983) and th is  has been 
found even in the apparent absence of HIV in fe c t ion  by Ludlam and 
colleagues (Carr, Veitch, Edmond e t a l , 1984). Although in AIDS 
patients the reduction in ra t io  is  due p r im a r i ly  to a reduction in 
numbers in haemophiliacs, the cause has sometimes been found to be a 
combination of reduced and increased Tg numbers, a po in t which 
w i l l  be discussed la te r .
In the AIDS free haemophiliacs th is  abnormality could be due to
the continued infusion of excessive amounts o f fore ign prote in in the
form of the Factor V II I  concentrates.
The subset ra t io  therefore, although not d iagnostic o f AIDS on
i ts  own, can be used to examine immune a lte ra t io ns  in patients at r isk
from AIDS. Perhaps of more use in HIV pos it ive  patients is the
enumeration o f absolute number of T^+ c e l ls .
This study has examined the T ce ll  subset ra t io s  in our 
haemophiliac population. The absolute numbers o f T^ ce l ls  have also 
been enumerated in an attempt to corre la te  d ifferences with the 
previously mentioned parameters.
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4 .2 MATERIALS AND METHODS
4.2.1 Cell Preparation
Heparinised blood was obtained by venepuncture and peripheral 
blood mononuclear ce lls  were isolated by a modification of the method 
by Boyum (1968). B r ie f ly ,  blood was d ilu ted  1:1 w ith Minimum 
Essential Medium (MEM) and layered on to lymphoprep gradients 
(Nycomed, Birmingham, U.K.). A fte r cen tr i fuga t ion  at 400 g fo r  30 
minutes, the in terface containing the peripheral blood mononuclear 
c e l ls  (lymphocytes and monocytes) were removed and washed twice in 
MEM by cen tr ifuga t ion  and then resuspended fo r  counting.
4.2.2 Staining with Monoclonal Antibodies
The method used was in d ire c t  s ta in ing using a monoclonal 
antibody and a FITC-conjugated secondary antibody to the monoclonal. 
Monoclonal antibodies used were purchased from commercial suppliers. 
In th is  study, we used the fo llow ing  monoclonal antibodies as shown:-
*Monoclonals were purchased from Becton Dickinson (Lab. Impex, 
Richmond, U.K.)
Cells to be stained were counted and adjusted to 5x l0G/ml in Hanks/10% 
FCS. 0.2 ml a liquo t ( lx lO 6 ce l ls )  were used fo r  each monoclonal being 
tested. Monoclonal antibody was added to appropriate tube as per 
Manufacturer's recommended use.
S p e c if ic i ty  
T Total 
T Helper
Mab Equivalent
Leu 4* 
Leu 3a
rwT
T cytotoxic/suppressor Leu 2a
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Leu 4 - 20^1
Leu 3a - 20pl Per 0.2 ml (106 c e l ls )
Leu 2a - 20pl
Cells were incubated on ice fo r 45 minutes. A fte r  incubation ce lls  
were washed twice in Dulbecco's PBS/10% FCS by cen tr i fuga t ion  at 400 g 
fo r  10 minutes at 4°C.
For the second incubation a commercially obtained FITC-conjugated 
Goat anti-Mouse Immunoglobulin from Becton Dickinson was added to each 
tube. 200 jjI at 1:250 d i lu t io n  was used. The tubes were then once 
again incubated on ice fo r  30 minutes a f te r  which they were washed as
previously described. A fte r the f in a l  wash the ce l ls  were f ixed by
addition of 1 ml of 1% Paraformaldehyde f ix a t iv e  so lu t ion  and stored 
at 4°C u n t i l  enumeration. As a negative control fo r  non-specific 
sta in ing by the secondary antibody, one tube received 5pl of mouse IgG
instead o f the monoclonal antibody and then the secondary antibody as
described.
The percentage pos it ive  ce l ls  s ta in ing  fo r  each monoclonal were 
enumerated on a Becton Dickinson Flourescein Activated Cell Sorter 
(FACS).
A ll  blood samples were taken from patients who were c l in i c a l l y  
w e ll ,  showing no obvious signs of in fe c t ion  or i l ln e ss  (other than HIV 
in fec t ion  where applicab le).
Factor V II I  concentrate consumption was assessed from the 
pa tien ts ' case notes and records and mean consumption of fac to r 
concentrate fo r  previous years calculated. Patients who had used 
more than 20,000 un its  o f concentrate annually fo r  the previous three 
years were considered to be "heavy users".
4 .3 RESULTS
There is  no s ig n i f ic a n t  d ifference in the absolute number of 
lymphocytes when comparing haemophiliacs with an age and sex-matched 
control population, the medians and ranges being 1.8 (0.8-5.51) and 
2.05 (1.4-5) x 109/L ce lls  respective ly . Also, there is  no d iffe rence 
when comparing the various groups of haemophiliacs e ithe r  
with themselves or w ith the contro ls . The HIV+ haemophiliacs had a 
had a median lymphocyte count of 1.84 (range 1.02-3.7) x 109/L , the 
"heavy users" 1.63 (range 0.8-3.68) x 109/L and the " l i g h t  users" a 
median of 1.75 (range 0.93-5.51) x 109/L. The use o f monoclonal 
antibody s ta in ing allowed enumeration of absolute numbers o f T c e l ls ,  
T helper ce lls  and T suppressor ce lls  by m u lt ip ly ing  the percentage 
pos it ive  s ta in ing ce l ls  by the to ta l lymphocyte count obtained from 
routine haematology d i f fe re n t ia l  white ce ll counts. The resu lts  are 
shown in Table 4.1.
The only s ig n i f ic a n t  differences were in the T^ (T helper) 
numbers. When a l l  treated haemophiliacs were taken together and 
compared to contro ls there was a s ig n i f ic a n t  d if ference (p<0.05). 
The HIV+ T^ numbers also d if fe red  s ig n i f ic a n t ly  from contro ls , 
(p<0.001), from HIV negative haemophiliacs (p<0.05) and from HIV 
negative heavy users (p<0.05). No differences were seen in Tg ( to ta l 
T c e l l )  or Tg (cytotoxic/suppressor T c e l l )  when comparing any group 
combinations. There was, however, perhaps a trend tha t a few HIV+ 
haemophiliacs had increased Tg numbers. Although not s ig n i f ic a n t ,  
th is  would be in keeping with some other workers' f ind ings tha t,  on 
occasion, haemophiliacs, especia lly  those who are HIV+, can have 
increased Tg numbers.
A number o f the seropositive haemophiliacs were studied
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previously, i . e .  from mid-1984 to early  1985. Data was available  fo r  
absolute ce ll counts, on to ta l lymphocytes and T ce ll  subsets. The 
cohort studied e a r l ie r  d if fe re d  only in the absolute numbers of 
T helper ce l ls  when compared to the HIV+ patients in th is  study (p<0.05). 
The medians and ranges being 0.69 (0.4-1.74) x 109cel 1 /L fo r  the 
1984-85 cohort compared to 0.53 (0.3-0.81) x 109 c e l ls /L  fo r  th is
present study. Eight of the patients in th is  study had been examined
e a r l ie r  and therefore i t  was possible to do a comparison on absolute 
numbers in 1984-85 compared to 1986-87. However as Table 4.2 shows
there were no s ig n i f ic a n t  d ifferences in e ith e r  to ta l lymphocyte
count or in any of the T ce ll  subset counts fo r  these e igh t pa tien ts .
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4 .4  DISCUSSION
Lymphopenia has been described as one of the major laboratory 
f indings amongst AIDS patients. Carr e t al (1984) have also reported 
lymphopenia in a cohort of th e ir  haemophilia A populaton. This study 
has not found lymphopenia e ith e r  in the haemophiliac population as a 
whole or in those who are HIV antibody pos it ive . Many workers have 
reported inverted T ce ll  subset ra t ios  (T^/Tg) in both AIDS patients 
and also in the haemophiliac population (Moffat e t a l , 1985). This
study too has found abnormalities in the subset ra t io s .  However, 
th is  d ifference is only s ig n i f ic a n t  in the group o f patients who are 
HIV+. The major con tr ibu ting  fac to r to th is  abnormality is  a marked 
decrease in T^ numbers (p<0.01: vs co n tro l) .  Some workers (Stein e t 
a l , 1985) have shown an increase in Tg numbers as a cause fo r
inverted ra t io s ,  while others (Carr et a l , 1984) have found normal T 
suppressor (Tg) numbers in th e ir  studies. This study showed no
s ig n i f ic a n t  d ifference in Tg numbers although there may be a s l ig h t  
trend fo r  HIV+ haemophiliacs to have higher numbers. I f  the cause
fo r inversion of the ra t io  is studied fo r  each ind iv idua l then the 
vast m a jo r ity  are due to a decrease in absolute numbers o f T^.
As mentioned, many reports have suggested that inverted ra t ios  in 
haemophiliacs are caused by an absolute increase in Tg numbers. An 
inversion of th is  type is often referred to as "immune augmentation" 
and is  known to occur as a response to a va r ie ty  o f s t im u l i ,  especia lly  
viruses. Haemophiliacs are subjected to repeated antigenic s timulation 
from the plasma proteins and viruses found in c lo t t in g  fac to r 
concentrate (Gjerset, Martin, Counts et a l , 1984). I t  is of in te re s t 
that most o f the reports o f increased Tg numbers come from the United 
States and countries heavily dependent on th e ir  commercially produced
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fac to r concentrates, whereas reports from Scotland (Carr e t a l , 1984)
and th is  work where the patients are treated with "home produced"
concentrate do not f ind  th is  increased Tg e f fe c t .  Perhaps there is
something d i f fe re n t  in the manufacturing process resu lt ing  in 
d i f fe re n t  protein constituents in the concentrate or perhaps the
commercial concentrate has more contaminating viruses which could
cause th is  "immune augmentation" e f fe c t .  As mentioned in Chapter 2, 
the commercial concentrate is made from paid donations ra ther than
volunteer donation as is the case in Scotland. I t  is  well known that 
th is  encourages undesirable groups to donate, e.g. drug addicts who
need money to pay fo r  th e ir  drug requirements. Homosexuals have also 
been shown to represent a substantial percentage o f a l l  donors and,
o f course, i t  has been shown tha t such groups very often have a high
rate of v ira l  and other in fec tions which could carry over in to  blood 
donations and therefore in to  blood products.
The amount of fac to r concentrate consumption does not seem to 
be an important fac to r as there was no differences between "heavy" 
and " l i g h t  users". A ll of the HIV+ patients are heavy users of 
concentrate. As th e ir  T^ numbers d if fe red  s ig n i f ic a n t ly  from HIV
"heavy users" (p<0.05), then the inference is  tha t the abnormality is  
not due simply to the use of concentrate but rather to exposure to HIV.
These find ings are in keeping w ith what is  known about HIV, i .e .  
tha t i t  is  se le c t ive ly  trop ic  fo r  the T^ subpopulation o f T c e l ls .  The 
resu lts  from the comparison of the e igh t HIV+ patients in 1984-85 to 
1986-87 are in te res t ing . I t  may have been expected tha t there would 
have been a decrease over time o f absolute number o f lymphocytes and 
more s p e c if ic a l ly  of T^ ce l ls  in the HIV+ population as has been shown 
to be the case in AIDS patients. Perhaps i t  is simply tha t the time 
span between the two samples is  too short to see any s ig n i f ic a n t
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decrease in ce ll  numbers, or perhaps the T helper c e l l  count w i l l  only 
drop as c l in ic a l  signs of in fec tion  develop. Whatever the reason, 
from a prognostic point o f view i t  is obviously good to have a steady 
T helper ce ll count with no apparent drop in ce ll  numbers. The fa c t
tha t there was a s ig n i f ic a n t  d ifference in numbers in an unmatched
population of HIV+ patients at the two d i f fe re n t  time points may 
suggest that as the length of the time of in fec t ion  increases there is 
a trend in the population towards a decrease in numbers. However, 
i t  would ce r ta in ly  be of more value to fo llow  the same cohort over 
time thus allowing comparisons on ce ll  numbers w ith in  ind iv idua ls  
which would be tte r r e f le c t  what w i l l  be happening in the HIV+
population as time progresses.
The implications o f having a decrease in T^ numbers is ,  of
course, very worrying from an immunological standpoint. As described 
e a r l ie r ,  the T^ ce ll  is  probably the most important ce ll  in the
immune response having such an immunoregulatory ro le .
In summary, there is  a decrease in absolute numbers o f T^ ce lls  
only in the HIV+ population. Therefore, abnormalities seem to be 
associated with HIV infecton and not s p e c i f ic a l ly  w ith amount of
Factor V I I I  usage. The more concentrate a pa tien t uses, however, the 
greater the r is k  of receiving a batch contaminated with HIV. In a 
recent study, Gupta (1987) has shown tha t double monoclonal antibody 
s ta in ing allows subdivision o f the T^ population in to  inducers of help 
and inducers of suppression. Both supopulations are equally depleted
in early  HIV in fe c t ion . This is  cu rren t ly  being studied in our
haemophiliac population.
Investigations on other arms o f the immune response are needed 
to see what e f fe c t  e ithe r  fac to r consumption or HIV in fec t ion  with 
consequent depletion o f T^ ce l ls  has had on the immune status o f the 
haemophiliacs.
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C H A P T E R  F I V E
RESPONSE TO MITOGEN AND SOLUBLE ANTIGEN
5 .1 INTRODUCTION
One of the easiest and therefore usually one of the f i r s t  
laboratory investigations to be carried out when studying the immune 
response is to measure the a b i l i t y  o f the pa tien ts ' ce l ls  to respond 
to in v i t r o  s tim u la tion . There are many agents generally termed 
mitogens which can be used. As the name suggests these agents switch 
on m ito t ic  d iv is ions , s tim ula ting  lymphocytes in to  DNA synthesis, 
b last transformation, and u lt im a te ly  d iv is ion  of the lymphocytes. 
Lectins which are non-enzymatic, non-antibody sugar binding proteins 
are the most commonly used mitogens. I t  is now known tha t le c t in  
induced p ro l i fe ra t io n  re f le c ts  IL-2 dependent expansion o f IL-2 
reactive T c e l ls .  The mechanism involved, although not completely 
understood, is  more complex than the simple binding o f le c t in  to the 
ce ll surface. There are probably complex c e l lu la r  in te rac t ions  
invo lv ing presentation o f le c t in  and also the requirement o f IL-2. 
Many mitogens are spec if ic  fo r  e ith e r  T c e l ls ,  B ce l ls  or both and 
th is  study has used Phytohaemagglutinin (PHA) and Conconavalin A 
(Con A) both T ce ll mitogens and Pokeweed Mitogen (PWM) which is  known 
to be a T ce ll dependent B ce ll  a c t iva to r .
Another approach to study in v i t r o  p ro l i fe ra t io n  is  to use a 
soluble antigen. Whereas mitogen stimulates large numbers of 
lymphocytes, antigens stimulate fa r  fewer ce l ls  which are s p e c i f ic a l ly  
sensitised to the antigen in question. In th is  study the soluble 
reca ll antigen, Tuberculin PPD, which is  a p u r if ie d  preparation from 
Mycobacterium tuberculosis was used. Most people w i l l  have been 
vaccinated against T.B. and should recognise and respond to PPD.
The T helper ce ll  as mentioned previously is the central ce ll  type in 
the immune system. One o f i t s  primary unique immune functions among
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those of the T ce ll  reperto ire  is i t s  a b i l i t y  to recognise and 
p ro l i fe ra te  in response to soluble protein antigens, which must be
processed and presented to i t  by antigen presenting ce l ls  such as
blood monocytes. This recognition ca pab i l i ty  coupled with the a b i l i t y  
of the helper T ce ll to re c ru i t  other immune ce lls  in to  action is 
thought to be the essence of the s p e c i f ic i ty  of the immune system. 
One o f the most constantly reported immunologic abnormality in AIDS 
patients is decreased b las t transformation to mitogens and antigens
(G ott le ib  e t a l , 1981) (Lane e t a l , 1983). Lane and colleagues (1985)
have shown a decrease in the response to soluble antigen by 
lymphocytes from AIDS patients. Their study suggests tha t the defect 
is caused by an in t r in s ic  defect in the a b i l i t y  of the lymphocytes to 
recognise and respond to soluble antigen. Reduced responses to 
mitogens have also been described in various studies on the 
haemophiliac population (Moffat, Bloom, Jones e t a l , 1985) (Stein et 
a l,  1985).
This study has looked a t the p a t ie n t 's  response and t r ie d  to 
corre la te  any abnormality with the usage o f concentrate or exposure 
to HIV.
5 .2 MATERIALS AND METHODS
5.2.1 Patients
A cohort o f 50 patients were studied. Patients were grouped 
according to th e ir  HIV antibody status and th e ir  mean annual 
concentrate consumption.
5.2.2 Cell Preparation
Cells were separated as.described in Chapter 4. For assay ce l ls  
were cultured in RPMI supplemented with 10% pooled human serum (RPMI/  
10% PUHS).
5.2.3 Mitogens and Soluble Antigen
The mitogens PHA, Con A and PWM were a l l  purchased from Sigma
(Poole, U.K.). PPD was obtained from The State Serum In s t i tu te ,
Copenhagen, Denmark.
The mitogens have been used fo r  many years in th is  laboratory
and have been standardised many times. A representative dose response 
curve is  shown in the resu lts  section fo r  each. The f in a l
concentrations used were PHA (5pg/ml), Con A (50pg/ml) and PWM (O.lpg/ 
ml). The optimum ce ll  concentrations had previously been determined 
to be 5 x 105/ml fo r  PHA and Con A and 106/ml fo r  PWM. I t  was 
necessary to optimise the concentration o f both c e l ls  and PPD to be 
used in the antigen stimulation assay, the resu lts  o f which are given 
in the resu lts  section. For the assays c e l ls  were used a t 106/ml and 
PPD at 5 or 0.5pg/ml. A ll concentrations are f in a l  concentrations.
5.2.4 Assay
Cells were cultured in t r ip l i c a te  in 96 well ' U' shape micro-
t i t r e  plates (Gibco, Paisley, U.K.). To 100 pi of ce ll  suspension 
was added, 100 pi of mitogen or antigen to give f in a l  concentration 
as stated above. Cells were cultured fo r  3 days fo r  mitogen and 5 days 
fo r  PPD at 37°C in a humidified atmosphere with 5% CO2 - Four hours 
to end of assay (19 hours fo r  PPD) each well was pulsed w ith lpCi of 
3H- Thymidine. The cultures were harvested on an automatic ce ll  
harvester (Skatron, Flow Labs, I rv in e , U.K.) by suction through discs 
of glass f ib re  paper, the paper was dried and the discs were 
transferred to s c in t i l l a t io n  v ia ls .  Following addition of 
s c in t i l l a t io n  f l u id ,  samples were counted on a Beta counter (LKB 
Croydon, U.K.). and thus, an estimate of the m ito t ic  a c t iv i t y  in the 
cu ltures as determined by incorporation o f 3H-Thymidine in to  DNA was 
obtained.
5.2.5 Expression of Results
Results are expressed as a corrected count per minute. The 
mean o f t r ip l i c a te  of resu lts  obtained in the absence o f any mitogen 
(or antigen) ie . spontaneous incorporation o f 3H-Thymidine is 
subtracted from the mean o f t r i p l i c a te  from re su lt  in the presence of 
stimulus.
5 .3 RESULTS
Figures 5.1 to 5.5 show the resu lts  o f standardisation o f the 
various mitogens and antigen.
The patients are divided in to  groups as fo r  other tes ts . These 
groups are denoted by the fo llow ing
"Heavy users" - (H)
"L ight users" - (L)
Not treated - (N)
Controls - (Con)
HIV haemophiliacs - (+)
This nomenclature is used in a l l  subsequent sca tte r p lo ts .
A sca tte r p lo t  fo r  response to PHA is  shown in Figure 5.6. When
treated haemophiliacs are considered as one group, irrespective  of HIV
status, th e ir  response to PHA is not s ig n i f ic a n t ly  d i f fe re n t  from
contro ls . However, when patients are divided e ithe r  on grounds o f HIV
status or fac to r usage, then differences are seen.
HIV+ patients have a reduced response compared to treated 
negative haemophiliacs (p<0.005) and compared to contro ls (p<0.05). 
Treated HIV negative haemophiliacs do not d i f f e r  s ig n i f ic a n t ly  from 
contro ls. When looking at another T ce ll mitogen, Con A, no s ig n i f ic a n t  
differences are seen between any o f the groups o f patients or between 
patients and contro ls as shown in Figure 5.7. The T ce ll dependent 
B ce ll mitogen PWM was also studied and resu lts  are shown in Figure 5.8 
A ll treated haemophiliacs taken as a single group have a reduced 
response compared to the control population (p<0.005). HIV+ 
haemophiliacs also have a reduced response compared to treated HIV" 
haemophiliacs taken together (p<0.005) and also negatives when s p l i t  
in to  "heavy users" (p<0.001) and " l i g h t  users" (p<0.005). The HIV" 
treated haemophiliacs do not d i f f e r  from contro ls .
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The resu lts  obtained fo r  the PPD stim u la tion  at both 
concentrations are essentia lly  the same, as shown in Figures 5.9 and 
5.10. A ll treated haemophiliacs as a group had a reduced response 
compared to con tro ls , p<0.02 at 5 pg/ml and p<0.01 at 0.5 pg/ml. 
Comparing HIV+ with treated HIV" the former had a reduced response at 
both PPD concentrations, p<0.005 at 5 pg/ml and p<0.002 at 0.5 pg/ml. 
HIV+ haemophiliacs also had a s ig n i f ic a n t ly  reduced response to PPD at 
both concentrations when compared to contro ls , p<0.001 at both PPD 
concentrations. . HIV" treated haemophiliacs c o l le c t iv e ly  or s p l i t  
according to concentrate usage did not d i f fe r  from contro ls .
F in a lly  the pos it ive  haemophiliacs showed a reduced response 
compared to both "heavy" and " l ig h t "  seronegative users; p<0.005 and 
p<0.05 respective ly when 5 pg/ml PPD was used and p<0.01 and p<0.01 
respective ly at 0.5 pg/ml PPD concentration.
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Figure 5 . 10: Response to PPD (0.5pg/ml).
5 . 4 DISCUSSION
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The find ings of th is  study d i f fe r  somewhat from other studies 
in tha t s ig n i f ic a n t  differences in pa tien ts ' mitogen responses 
compared to those of controls were only seen in haemophiliacs who were
HIV+. No mitogen or PPD gave a s ig n i f ic a n t ly  decreased response when
HIV treated haemophiliacs were compared to a control population.
Therefore, the use of Factor V II I  concentrate, ir respective  of the 
amount, does not seem to cause an impairment of mitogenic response. 
Other groups (Lee e t a l , 1985) (Moffat et a l , 1985) correlated a
reduced response with severity  of haemophilia in those asymptomatic 
fo r  HIV in fe c t ion . This study, however, only showed impaired 
responses in those who are HIV+. Our HIV+ haemophiliacs had a
reduced response to PHA, PWM and PPD but not Con A. The reduced 
responses are most probably due to the observed drop in T^ numbers in 
th is  group. I t  is known that PWM is a T ce ll  dependent B ce ll
mitogen ( i . e .  requires T ce ll  help [from T^+ ce lls ]). Also, the PPD
response requires antigen recognition by T^+ ce lls  and therefore i f  
T^+ numbers are low i t  would be expected tha t the response w i l l  also 
be diminished. This is the cause here, and is  in agreement w ith 
other studies on AIDS patients and those who are HIV+ (Lane e t a l , 
1985).
PHA and Con A are both T ce ll  mitogens yet the response to only
PHA is  reduced in the HIV+ group. I t  is  possible tha t these two
mitogens stimulate d i f fe re n t  subpopulations of T ce lls  and th is  could 
account fo r  the difference i f ,  fo r  instance, the population which 
responds to Con A is normal in th is  group of patients while tha t 
population which responds to PHA is in some way affected or perhaps 
reduced in number.
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Most of the reported studies on haemophiliacs f ind  a reduced 
number o f ce l ls  as well as a decrease in p ro l i fe ra t iv e  response to 
mitogen, irrespective  of HIV status. In th is  study, however,
numbers were reduced only in the HIV+ patients. This could account 
fo r  the discrepancy between th is  and other studies, i . e .  no
abnormality was found in the absence of HIV in fec t ion .
In summary, therefore, as p ro l i fe ra t io n  to stimulus was normal 
in the HIV groups, fac to r consumption does not seem to impair the 
response. In the HIV+ group, there was a s ig n i f ic a n t  decrease in
response which correlates with a drop in numbers in th is  group. 
Continued monitoring using these tests may be useful in determining i f  
asymptomatic haemophiliacs continue to have a normal response and also 
to determine i f  the in v i t r o  response to mitogen or antigen 
declines in the HIV+ group as ce ll  numbers drop or as th e i r  
c l in ic a l  condition deteriorates.
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C H A P T E R  S I X
INTERLEUKIN-2
6 .1 INTRODUCTION
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In te r leuk in -2  ( IL -2 ) ,  o r ig in a l ly  termed T ce ll  growth fa c to r ,  
represents one element in a cascade of lymphokines released during an 
immune response as can be shown in Figure 6.1. The o r ig ina l reports 
of mitogenic factors  present in mixed leucocyte cultures came in 1965 
(Gordon and McLean, 1965). I t  was thought then that many of the 
factors present in cu ltu re  supernate were of T ce ll  o r ig in .  In 1976 
there was a major advance with the discovery tha t i t  was possible to 
select and maintain the continuous p ro l i fe ra t io n  of T ce l ls  (Morgan, 
Ruscetti and Gallo, 1976). This discovery meant tha t i t  was possible 
to construct a sp e c if ic ,  quan tita t ive  assay to measure the mitogenic 
fac to r responsible fo r  T ce ll  growth (G il l  is ,  Ferm, Ou, e t a l , 1978). 
Thus, fo r  the f i r s t  time, i t  was possible to demonstrate the existence 
of an a c t iv i t y  separate from Lymphocyte A c t iv i ty  Factor (LAF) tha t 
functioned in promoting continued T ce ll growth (Smith, G i l l  is  and 
Baker, 1979). As a re su lt  of these find ings, i t  was decided to use 
common terms fo r  putative macrophage-derived factors and lymphocyte 
derived fac to rs . In te r leuk in -1  was chosen fo r  macrophage-derived 
factors and In te r leuk in -2  was chosen was lymphocyte-derived fac to rs . 
In recent years much work has concentrated on the ro le  of IL-2 on the 
immune system.
Prim arily  associated with T ce ll p ro l i fe ra t io n ,  IL-2 also 
d ire c t ly  or in d i re c t ly  plays a ro le in the p ro l i fe ra t io n  and maturation 
o f other ce ll  types. Such responses depend q u a n t ita t ive ly  on a source 
of IL-2 and expression of receptors fo r  the fac to r (Smith, 1980). I t  
is  now known tha t IL-2 is  released by T ce l ls  in response to two 
signals supplied by antigen pulsed accessory ce lls  such as monocytes. 
The f i r s t  signal is  antigen, presented in the context o f proteins of
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Figure 6.1: Role of IL-2 on T Cell and B Cell Growth.
the Major H is tocom patib il i ty  Complex (MHC) and the second signal is 
In te r leuk in -1  (formerly LAF). Although a l l  subclasses of T ce l ls  have 
been shown to release IL-2 under the appropriate conditions, helper 
T ce l ls  appear to be the major source (Pfizenmaier, Scheurich, 
Daubener e t a l , 1984). This, therefore, could have important
consequences in AIDS where the T helper c e l l ,  the major producer of 
IL-2 is  the very ce ll  which HIV attacks and destroys. Much work has 
looked at IL-2 production in AIDS patients (Hauser e t a l , 1984) and 
those who are infected by HIV (Borzy, 1987).
Although some of the early  studies suggested tha t the 
production o f IL-2 by ce lls  from AIDS patients was normal (Lane e t a l , 
1985), i t  is  now generally accepted tha t there is a defic iency of IL-2 
production in response to mitogen when whole ce ll populations from 
AIDS patients are examined (Murray, Welte, Jacobs e t a l , 1985). This 
defic iency has been found to be proportionate to the extent o f T ce ll  
depletion in the ce ll preparations studied (Gluckman et a l , 1985).
However, surviv ing T ce lls  respond normally to the addition of 
exogenous IL-2 ( i . e .  p ro l i fe ra t io n ,  IL-2 receptor expression, 
enhancement o f c y to to x ic i ty  and NK ce ll  a c t iv i t y )  (Gluckman et a l , 
1985 3 Hauser e t a l , 1984 -s Reddy, Pinyarat and Grecco, 1984).
To examine the haemophiliac population an assay to measure IL-2 
production by patients lymphocytes in v i t r o  has been set up in th is  
laboratory. Most of the assay systems fo r  measuring IL-2 are 
b io log ica l assays which make use o f ce ll  l ines  or primed ce lls  which 
require the presence of IL-2 fo r  continued growth. Other systems 
have been devised to quantitate IL-2 in supernate samples by ELISA.
89
6 .2  MATERIALS AND METHODS
6.2.1 Technical Aspects of Assay
The assay made use of the IL-2 dependent ce ll  l in e  f-^A 
(Cetus Corp., C a li fo rn ia , USA). This ce ll l in e  was maintained in our 
laboratory by feeding with exogenous human recombinant IL-2 (BCL,Lewes, 
U.K.) every 48 hours and cu tt ing  back and re-seeding as necessary. 
To prepare fo r  an assay, ce l ls  were seeded at a density o f 4x l01+/ml 
and fed with 20 U/ml IL-2. They were incubated at 37°C/5% CO ,^ pulsed 
at 48 hours with more IL-2 and then used fo r  assay the next day. 
Cells had usually reached a density o f 106/ml on the day o f assay.
For the assay, enough ce lls  were removed from the f la sk ,  washed 
twice in complete RPMI/20% FCS and resuspended a t 1.5x105/m l. 100 p/1
a liquots were dispensed in to  f l a t  bottomed 96 well plates (Nunc. Gibco 
L td ., Paisley, Scotland, U.K) to which were also added 100 pi of 
d i lu t io n s  of supernate or standard being tested ( in  t r i p l i c a te ) .  A fte r 
approximately 24 hours incubation, the plates were pulsed with IpCi 
3H-Thymidine (20 pi of 50p Ci/ml per w ell)  and incubated fo r  a fu r th e r  
4 hours. Plates were then harvested on a ce ll  harvester (Skatron, 
Flow Labs., Irv ine , U.K.). Cells were washed onto f i l t e r  paper discs 
and incorporated 3H-Thymidine measured on a Beta counter.
6.2.2 IL-2
The IL-2 used fo r  maintaining the ce ll  l in e  and fo r  use as a 
standard in the IL-2 assay was human recombinant IL-2 purchased from 
BCL. Although i t  was recommended to grow ce lls  at 100 U/ml, we found 
that ce l ls  grew better at 20 U/ml and th is  concentration was used to 
maintain the ce ll l in e .
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6.2.3 Cell Preparations
Peripheral blood lymphocytes were obtained as described in 
Chapter 4 and cultured in complete RPMI/2% FCS. I t  was decided to use 
2% FCS as most published methods use low serum concentrations and i f
FCS was used then there could be no carry over of human IL-2 which
could occur i f  using human serum.
6.2 .4  IL-2 Supernate Production
I t  was f i r s t  of a l l  necessary to determine the optimum
conditions fo r  producing IL-2. Variables investigated were ce ll 
concentration and mitogen concentration. PHA obtained from Wellcome 
(London, U.K.) was used throughout.
Lymphocytes from normal controls were used to optimise IL-2
production. Cells were used at 5 x 106/ml, 2 x 106/ml, 1 x 106/ml and
0.5 x 106/ml in the presence of PHA varying in concentration from
5 pg/ml to 0.5 pg/ml. I t  was decided to incubate ce l ls  fo r  48 hours as 
most published methods on IL-2 production have found peak production 
at th is  time. A fte r incubating ce l ls  fo r  48 hours supernates were 
recovered by cen tr ifuga t ion  and stored at -20°C u n t i l  assayed.
Results fo r  ca l ib ra t ion  o f assay are shown in Results Section. 
For production fo r  supernates by patients i t  was decided to use ce lls  
at 106/ml. Most other published methods also used ce lls  at 105 /ml. 
Patients ' ce l ls  were cultured fo r  48 hours in the presence of PHA at 2 
or 1 pg/ml. As a control fo r  spontaneous production o f IL-2, ce lls  
were also cultured in RPMI/2% FCS without any PHA.
6.2.5 Expression of Results
Results are expressed as units/ml IL-2 (U/ml) calculated by 
p ro b it  analysis of mean net counts per minute of te s t  supernate
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d i lu t io n s .  Results were determined at the 50% of maximal 3H-Thymidine 
incoration end point of our laboratory standard. As a standard, human 
recombinant IL-2 purchased from BCL was used. A standard curve was 
obtained by seria l two-fold d ilu t io ns  of the laboratory standard, 
s ta r t in g  at 100 U/ml f in a l  concentration.
92
6 -3  RESULTS
Results fo r  standardisation o f the assay are shown in Figures
6.2 and 6.3. Results shown represent the mean ±SE fo r  8 normals at 
each po in t. As can be seen from the Figures there is l i t t l e  
d ifference between 0.5 x 106cel Is/ml and 1 x 106ce ll s/ml at e ith e r  2 
or 1 pg/ml. However, 2 x 106 or 5 x 106 ce lls /m l gave much reduced 
responses. Other concentrations were t r ie d ,  i .e .  5 pg and 0.5 pg/ml. 
At 0.5 pg/ml there was no good response at any ce ll concentration and 
at 5 pg/ml the response was very varied. I t  was decided, therefore, to 
use ce lls  at 106/ml and use the PHA at 2 pg/ml and 1 pg/ml.
Figures 6.4 and 6.5 show the response o f the d i f fe re n t  pa tien t 
groups at 1 and 2 pg/ml respective ly. I f  a l l  treated haemophiliacs 
were taken as one group, irrespective  o f HIV status and compared to 
normals, then there was no s ig n i f ic a n t  d ifference in IL-2 production 
when 1 pg/ml PHA was used, but patients produced less than normals at 
2 pg/ml (p <0.02). There was a s ig n i f ic a n t  decrease in IL-2 
production between HIV+ haemophiliacs and a l l  treated HIV” 
haemophiliacs at both PHA stimulation concentration. p<0.01 fo r  1 pg/ 
ml and p<0.05 at 2 pg/ml. HIV” treated haemophiliacs, as one group, 
did not d i f f e r  from controls at e ith e r  concentration. As the numbers 
in the "never treated group" were small and showed a large range o f 
leve ls , i t  was questionable whether or not to include them in the 
s ta t is t ic a l  analysis. At 1 pg/ml PHA the "never treated group" did 
not d i f f e r  from any other group combination. At 2 pg/ml PHA, 
however, the "never treated group" showed increased production 
compared to HIV+ (p<0.005),
" l ig h t  treated" HIV" (p<0.02), contro ls (p<0.05), a l l  HIV” treated 
haemophiliacs (p<0 .02) and a l l  treated haemophiliacs irrespective  o f
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Figure 6-2: IL-2 Production in Normals (PHA at Ipg/ml).
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HIV status (pcO.Ol).
When the treated haemophiliacs were s p l i t  according to HIV 
status and fac to r usage as shown in Figures 6.4 and 6.5 then the
resu lts  were more or less as expected. HIV+ haemophiliacs produced
s ig n i f ic a n t ly  less IL-2 in response to both 1 pg/ml and 2 pg/ml when 
compared to contro ls , p<0.01 and p<0.005 respective ly . They also 
produced less than the "heavy treated" group. p < 0.02 fo r  1 pg/ml
and p<0.05 fo r  2 pg/ml. Rather su rp r is ing ly , they did not produce 
s ig n i f ic a n t ly  less than the " l i g h t  treated" group at e ith e r  PHA 
concentration. The "heavy users" produced s im ila r  levels of IL-2 at 
both concentrations when compared to the l ig h t  users and contro ls . 
Another suprising f ind ing  was tha t at 2 pg/ml PHA, but not at 1 pg/ml, 
the " l ig h t  users" produced less IL-2 than contro ls p<0 .05 . No
pa tien t or control had detectable spontaneous production o f IL-2,
i .e .  when the ce l ls  were cultured in the absence of PHA. The 
p o s s ib i l i t y  o f residual PHA in the supernate being carr ied over in to  
the assay was also investigated and, when PHA was added at varying
concentrations in the absence o f IL-2, no s tim ula tion  o f the ce ll
l in e  occurred. Also, when PHA at varying concentrations were added 
to supernates containing a known amount o f IL-2, the response was
equivalent to tha t expected fo r  the IL-2 concentration alone, i .e .
PHA and IL-2 do not have a synerg is t ic  e f fe c t  on the response o f the 
ce ll  l in e .
6 .4 DISCUSSION
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Since the discovery of IL-2 much work has gone in to  studying 
i t s  ro le  in the immune response. I t  is  now well established that th is  
lymphokine is very important fo r  an in ta c t  immune system. T ce l ls  
have been shown to have an IL-2 requirement fo r  sustained growth, 
and they die very quickly in cu lture i f  medium is not supplemented 
with i t .  T helper ce lls  (T^) are known to be the main producers of 
IL-2 on stimulation with antigen and IL-1 and o f course the ce ll  
which is  the ce ll  infected by HIV.
Studies on the e f fe c t  of IL-2 on the p ro l i fe ra t iv e  a b i l i t y  of 
p u r if ie d  T ce l ls  of AIDS patients (Borzy, 1987) have shown a decreased 
response compared to contro ls. When T^+ c e l ls  were fu r th e r  p u r if ie d  
they too had a decreased response. Borzy also found tha t the 
production of IL-2 was reduced. This present study has shown tha t 
the HIV+ haemophiliacs have impaired production o f IL-2 when compared 
to HIV~ treated haemophiliacs and a control population. HIV "heavy 
users" did not d i f fe r  from controls which suggests tha t the use of 
large quan tit ies  of fac to r concentrate does not impair th e ir  ce l ls  
a b i l i t y  to produce the lymphokine. A strange re su lt  was that at 2 
pg/ml PHA, " l ig h t  users" produced s ig n i f ic a n t ly  less IL-2 than 
contro ls . This raises the p o s s ib i l i t y  tha t being a haemophiliac 
means impaired production of IL-2 but through the use of large 
quantit ies of concentrate the ce l ls  are stimulated by antigenic 
challenge from the concentrate to produce leve ls of IL-2 comparable 
to con tro ls . This would account fo r  the near normal leve ls in "heavy 
users" but reduced levels in " l ig h t  users". However, th is  p o s s ib i l i t y  
seems very un like ly  because at 2 pg/ml PHA, haemophiliacs who had 
never been treated showed increased levels compared to normals (p<0.05)
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Therefore, simply being a haemophiliac obviously does not in fe r  low
production of IL-2. Also, production of IL-2 in the " l i g h t  users" was
not impaired at 1 pg/ml s tim ula tion . "Heavy" and " l ig h t "  users are 
a rb it ra ry  terms and there is no concrete evidence tha t treated HIV- 
haemophiliacs d i f fe r  in IL-2 production in accordance with the amount 
o f concentrate they consume. When taken as one group, HIV- treated 
haemophiliacs do not d i f f e r  from contro ls. Therefore, the most 
probable conclusion is that HIV- treated haemophiliacs as a whole do 
not d i f f e r  from controls and when divided in to  groups, i.e ."heavy" and 
" l i g h t " ,  the unexpected re s u lt  seen with the " l ig h t  users" at 2 pg/ml 
PHA is  one of those unexplained anomalies.
Of much more in te re s t is  the re su lt  o f IL-2 production in the 
HIV+ haemophiliacs, i . e .  impaired production at both s timulation 
concentrations compared to controls and HIV- "heavy users". The HIV+ 
are a l l  "heavy users" yet they d i f f e r  s ig n i f ic a n t ly  from the HIV- 
"heavy users". Therefore, HIV is in ferred as the cause fo r  th is  
decreased production of IL-2.
The reason fo r  th is  reduced production remains to be explained.
There was no co rre la t ion  between absolute lymphocyte count, or 
absolute T^ count, and the level of IL-2 produced in the HIV+ 
haemophiliacs. In fa c t ,  some of the highest production levels 
occurred in those patients who had lowest numbers o f T^ ce l ls  on 
sta in ing with monoclonal antibodies. Other studies have shown (Borzy 
et a l , 1987) a lack of co rre la t ion  with absolute numbers of
lymphocytes and have suggested tha t varia t ions in T ce ll  subsets are 
not a major cause of the observed decreased IL-2 production. Several 
workers have found a decreased a b i l i t y  of T4 ce lls  from AIDS patients 
to p ro l i fe ra te  to exogenously added IL-2 and Borzy (1987) has 
suggested that there are both quan tita t ive  and q u a l i ta t iv e
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abnormalities in the IL-2 - T lymphocyte system.
Other p o s s ib i l i t ie s  fo r  the apparent decrease in production are 
decreased expression on the ce lls  surface of receptors fo r  IL-2, an 
abnormal function or ra t io  of the high to low a f f i n i t y  IL-2 receptors 
or even metabolic defects w ith in  the c e l l ,  d is ta l  to the receptor- 
ligand binding stage. Prince (1984) has shown decreased expression 
o f IL-2 receptors on ce l ls  from AIDS patients but Lane and colleagues
(1985) have shown that ce lls  from AIDS patients can be induced to 
express normal receptor numbers by mitogen s tim u la tion . Arya and
Gallo (1985) have shown that in cultured HIV infected ce l ls  the level 
o f transcr ip t ion  of the IL-2 gene is  unimpaired. Thus, as there is 
no evidence suggesting abnormal regulation o f the IL-2 gene, the 
functional defic iency o f the IL-2 producing ce l ls  is  most probably at 
a la te r  stage in IL-2 production or may be the re su lt  o f a more
generalised virus-induced metabolic derangement o f protein (IL -2) 
synthesis.
Another p o s s ib i l i ty  fo r  decreased production in the HIV+ 
population is the findings by Donnelly (1986) tha t there is a serum 
fac to r in AIDS patients which in h ib i ts  p ro l i fe ra t io n  to IL-2. Siegel 
and colleagues (1985) have also shown tha t th is  fac to r  in the serum of 
AIDS patients, which seems to be d i f f i c u l t  to wash o f f  once ce lls  are 
incubated in the serum, can also in h ib i t  the production by normal 
lymphocytes of IL-2. Preliminary experiments exploring th is  
p o s s ib i l i ty  did not f ind  s im ila r  resu lts  when studying haemophiliac 
sera (see Chapter 9).
D if fe re n t groups have c o n f l ic t in g  resu lts  on IL-2 production in 
AIDS patients. The differences between d i f fe re n t  groups could be
explained by a va r ie ty  of reasons. An important fac to r  must be the
c l in ic a l  condition of patients being studied and whether or not they
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are on d i f fe re n t  drug regimes. Also, technical aspects o f the assay 
may d i f f e r ;  such as choice of le c t in  fo r  s t im u la t ion , length of 
incubations, ta rge t ce l ls  used in assay and ce ll  concentrations etc.
In th is  study, 48 hours incubation was used as th is  time has 
been shown to be optimum fo r  production o f IL-2 in studies o f normal 
ce lls  ( G i l l i s ,  1983). Another important fac to r  could be the use of 
ta rget c e l l .  Some workers use 14 day old lec t in -s t im u la ted  b las t 
ce lls  from normal donors and others use IL-2 dependent ce ll  l in e .  In 
my opinion, there is  less l ik e ly  to be va r ia t io n  i f  you use a ce ll
l in e ,  which a f te r  a l l  is orig inated from a single c e l l ,  ra ther than 
having to produce b las t ce l ls  from normals which w i l l  be a mixture of 
d i f fe re n t  ce ll  types.
There are more in t r ic a te  experiments on the ro le  of IL-2 in the 
haemophiliac population, which could be done, i f  time permitted. The 
number of ce l ls  expressing the IL-2 receptor could be determined. 
Other experiments outwith the ca p a b i l i t ie s  of th is  current study, but 
which could be in te res t ing , would be ce ll separation experiments. I f  
the various T ce ll subsets could be separated then i t  would be
possible to be tte r investigate the mechanisms involved in IL-2
production. Such experiments could include ce ll  mixing with
autologous ce ll  populations to see i f ,  fo r  example, Tg+ suppressor 
ce lls  from haemophiliacs inh ib ited  p ro l i fe ra t io n  o f autologous T^+ 
ce lls  to exogenously supplied IL-2. The e ffec ts  of fac to r concentrate 
or HIV administration could also be studied in v i t r o  looking at i t s  
e f fe c t  or expression on IL-2 receptors and subsequent production of 
and response to IL-2. Preliminary studies along these l ines are 
presented la te r  in the Thesis (Chapter 9).
Another recently  available assay which would be in te res t ing  to 
do is  that fo r  the quan tita t ive  determination of IL-2 receptors in
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serum. Elevated serum levels of free IL-2 receptor have been reported 
in various lymphoproliterative disorders, including HTLV-1 associated 
adult T ce ll  leukaemia (Nelson, 1986). Organ transplant patients 
as well as those with AIDS have also demonstrated elevated serum IL-2 
receptor leve ls . The level of receptor in the serum or plasma may be 
important in ide n t i fy in g  or characterising disease processes and may 
serve an important ro le in the immunoregulation of ce ll  growth and 
d i f fe re n t ia t io n .  These free receptors must somehow be released from 
the ce l l  surface o f activated T c e l ls .  I t  would be in te res t ing  to 
measure levels of free receptors in the haemophiliacs to see i f  the 
levels correlated with disease sta te , severity  o f haemophilia or usage 
of fac to r  concentrate.
In summary, therefore, th is  current study has shown that HIV+ 
haemophiliacs produce s ig n i f ic a n t ly  less IL-2 than e ithe r  controls or 
HIV” treated haemophiliacs. No s ig n i f ic a n t  d ifference was seen 
between "heavy" and " l ig h t "  users suggesting tha t amount of fac to r  
consumption is  not c r i t i c a l  in the a b i l i t y  to produce IL-2 in response 
to mitogenic s tim ula tion .
F in a l ly ,  treated HIV" haemophiliacs produced less IL-2 at 
2 pg/ml PHA stim ula tion  than haemophiliacs never treated (p<0.02). 
This e f fe c t ,  apparently due to the " l i g h t  users", was not seen at 
1 pg/ml s tim u la tion .
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C H A P T E R  S E V E N
IMMUNOGLOBULINS AND B CELL FUNCTION
7 .1
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INTRODUCTION
The B lymphocyte is the white ce ll  responsible fo r  
immunoglobulin production. B ce lls  once mature are programmed to 
produce antibodies of one s p e c if ic i ty ,  i .e .  against one antigen. The 
huge reservo ir  o f B ce lls  in the body gives a huge reperto ire  of
possible antibodies to be produced. Once stimulated by antigen the 
B ce ll  w i l l  mature in to  the antibody secreting plasma c e l ls .  B ce l ls  
recognise antigen by means of the B ce ll receptor. This is  in fa c t  
antibody on the ce ll  surface, of the same s p e c i f ic i ty  as tha t which 
the ce ll  w i l l  go on to produce once stimulated. Cross l in k in g  of the
receptors by antigen tr iggers  the B c e l l .  Like most of the immune
functions, B ce l ls  can be contro lled by T c e l ls .  However, some of the 
B ce ll  responses to certa in mitogens or antigens, e.g. 
1ipopolysaccharide can occur independent of T ce ll  help. The 
immunoglobulins produced can be one of 5 classes. These are IgG, IgM, 
IgA, IgD and IgE. The f i r s t  three are the most common. IgG is the 
main c i rc u la t in g  antibody. IgM is the primary immunoglobulin usually 
produced f i r s t  in the humoral immune response. IgA is found
especia lly  in mucosal and gut re lated responses. IgE seems to be 
important in a l le rg ic  and hypersens it iv ity  responses such as hay 
fever. The exact b io log ica l function o f IgD is  unknown.
Before AIDS the B ce lls  had been l i t t l e  studied in haemophiliac 
populations. As already discussed the virus causing AIDS shows 
tropism fo r  T helper ce lls  and as a re su lt  most the immunological 
research on AIDS has centred on T ce ll responses. However, some 
workers have studied the B c e l l .  Hypergammaglobulinaemia is a 
cha ra c te r is t ic  f ind ing  in HIV+ infected subjects (Schroff e t a l , 1983) 
(Fauci, 1984).
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Despite the polyclonal immunoglobulin e levation, HIV infected subjects, 
and p a r t ic u la r ly  AIDS patients, mount a poor antigen-specific  antibody 
response a fte r  in vivo immunisation. Primary responses seem to be 
affected to a greater degree than secondary responses (Lane e t a l , 
1983). Patients mount and sustain an ongoing antibody response to HIV 
that can be of considerable t i t r e ,  waning only with end stage 
disease (Sarngadharan e t a l , 1984) (Biggar, Melbye, Ebbeson, e t a l , 
1985). The normal sequence of events that occur when B ce lls  become 
antibody secreting plasma ce lls  can be dissected in v i t r o  in to  
d iscrete stages of ac tiva tion , p ro l i fe ra t io n  and d i f fe re n t ia t io n .  
Largely as a re su lt  o f the work by Lane, Fauci, and co-workers, B ce ll  
responses in AIDS patients have been extremely well characterised. 
Lymphocytes from AIDS patients produce a poor immunoglobulin response 
in v i t r o  to PWM stimulation (Lane e t a l , 1983). This phenomenon is 
not due e n t i re ly  to abnormalities caused by defective T ce ll  help 
because p u r if ie d  B ce lls  from patients are poorly responsive when 
mixed with normal T ce lls  and the B ce lls  are not stimulated by T ce ll  
independent activa tors  such as formalin treated Staphylococci (Lane e t 
a l,  1983) (Pahwa et a l , 1984). Thus, a high degree of apparently 
spontaneous, polyclonal B ce ll s timulation occurs in HIV-infected 
subjects rendering them poorly responsive to normal early ac tiva tion  
signals. Diffuse elevations of a l l  three major immunoglobulin classes, 
though c h ie f ly  IgG and IgA seem to be raised in HIV infected patients. 
(S iega l, 1984). Serum IgD has also been shown to be raised as much
as tenfo ld  and some workers have considered i t  a good marker fo r  th is  
disease (Chess, Daniels, North e t a l , 1984) (Mizuma, Zol1a-Pazner,
Li twin e t a l , 1987).
The reason fo r  B ce ll ac tiva tion  has been a matter of 
speculation. HIV can in fec t B ce ll l ines which express the CD4
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molecule but i t  is  not clear what proportion o f B c e l ls  express CD4, 
and no one has shown spontaneous immunoglobulin production a fte r  
inoculation o f p u r if ie d  normal B ce lls  with HIV. I t  is possible that 
the phenomenon is a secondary rather than primary consequence of 
infecton with HIV, though recent work by Schmitten and colleagues
(1986) have shown that HIV can cause pu r if ied  B ce lls  to p ro l i fe ra te  
to as great a degree as that produced by T ce ll  independent B ce ll 
mitogens. Immunoregulatory abnormalities w ith in  the CD4 T cell 
compartment are compatible with the notion tha t re la t iv e  preservation 
of the more potent CD4 helper subset in concert w ith a p re ferentia l 
loss o f the CD4 subset tha t induces CD8 T ce ll suppressors, allows 
unrestrained B ce ll ac tiva tion . However, a recent publication 
(Gupta, 1986) has shown tha t in early HIV in fec tion  both the inducers 
of help and the inducers of suppression are equally depleted.
There is no evidence tha t loss of suppressor-inducers necessarily
resu lts  in spontaneous B ce ll ac tiva tion , nor has i t  been demonstrated 
tha t CD4 suppressor-inducer function is abnormal in HIV infected 
subjects. Another explanation, may be that the abnormalities in 
T ce ll  regulation allow in fec tion  or reactiva tion  of other v ira l  
in fec tions  such as EBV or CMV that, in turn, are B ce ll  activa tors . 
In support o f th is  idea is  a nearly universal f ind ing  o f exposure to
EBV and CMV in AIDS patients (Quinnan, Masur, Rook e t a l , 1984). No
one has reported a d e f in i t iv e  corre la tion  between th is  exposure and 
immunoglobulin or B ce ll abnormalities in HIV infected subjects.
F in a l ly ,  i t  has been proposed that HIV infected T ce lls  
elaborate B ce ll  stimulating factors. This followed the find ing that 
ce ll  l ines transformed by HTLV-1 show elaboration of lymphokines 
(Salahuddin, Marham, Lindner et a l , 1984). However, i t  has not been 
found w ith  the predominantly cytopathic HIV.
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In th is  study, we have measured the c ircu la t in g  immunoglobulin 
levels and also investigated the a b i l i t y  of HIV pos it ive  and negative 
haemophiliac pa t ien ts ' ce l ls  to produce immunoglobulin in response to 
stimulus.
7 .2 MATERIALS AND METHODS
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7.2.1 Serum Collection
Serum was collected from c lo tted  blood by cen tr ifuga t ion  and 
stored at -20°C u n t i l  assayed. Serum immunoglobulins were measured by 
radia l immunodiffusion and laser nephelometry.
7.2.2 Immunoglobulin Production In Vitro
For immunoglobulin production, peripheral blood mononuclear 
ce lls  were co llected as described in Chapter 4. A fte r counting ce l ls  
were adjusted to 106/ml in RPMI supplemented with 20% FCS. 1 ml of 
ce lls  were dispensed in wells of a 24 well plate (Flow Labs., Irv in e , 
U.K.). To th is  was added 1 ml of RPMI (as a negative contro l) or 1 ml 
of PWM (Gibco) or 1 ml o f formalin treated Staphylococcus A. (Staph.A).
Cells were incubated in RPMI/10% FCS fo r  7 days at 37°C/5% CC .^ 
Thereafter, supernate was removed and stored at -70°C u n t i l  assayed 
fo r  presence of IgM and IgG by ELISA. Optimum concentrations of 
mitogen and antigen were determined on normal subjects p r io r  to study 
on patients - see Results.
7.2.3 ELISA for Determination of IgG and IgM
IgG and IgM produced spontaneously or as a re su lt  of s tim u la tion  
were measured by an ELISA technique. The basis o f an ELISA is tha t 
the substance being measured, in th is  case immunoglobulin, is trapped
on a m ic ro t i t re  plate which has been previously coated with antibody
against that p a r t icu la r  substance. Then a secondary antibody to the 
substance is added and th is  w i l l  in turn bind. The second antibody 
is conjugated with the enzyme a lka line phosphatase and by addition of 
the substrate OPD there is a development of colour which is
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proportional to the amount of a lka l ine  phosphatase present which, of 
course, depends on the amount of immunoglobulin which bound from 
the sample. The reaction is then stopped by the add it ion  o f 3M 
sodium hydroxide and the op tica l density (0D) at 405 nm read on a 
Skatron spectraphotometer (Flow Labs.). The 0D obtained is  the end 
product of the assay and is d i r e c t ly  re la ted to the amount of
immunoglobulin which was present in the i n i t i a l  sample.
By incorporating samples of p u r i f ie d  immunoglobulin o f known 
concentration i t  is  possible to construct a standard curve o f 0D vs 
Immunoglobulin concentration from which the unknown concentration of 
immunoglobulin in the samples can be determined.
The buffers used in the assay are described in the Appendix.
Both the goat anti-human IgG (orlgM) and the second antibody, 
the a lka l ine  phosphatase conjugated goat anti-human IgG (or IgM) were 
obtained from Sigma. Both these antibodies were used a t 1:1000 
d i lu t io n  as recommended by the supplier.
P u r if ied  IgG and IgM were obtained from Sigma and stored in
a liquots  at -70°C u n t i l  use.
The 0PD substrate was obtained from Sigma and used as 
recommended.
7.2 .4  Problems Associated With Assay
I t  was necessary to f i r s t  of a l l  optimise the concentrations o f 
mitogen or antigen used fo r  production o f immunoglobulins. I t  was 
decided to use 106 ce l ls  per cu ltu re  ( f in a l  concentration o f 0.5 x 106/  
ml) on lo g is t ic  grounds. Most published methods use 7 day cu ltures 
fo r  optimum production of immunoglobulin and th is  time was used fo r
production o f supernate. I t  was also necessary to grow c e l ls  in
fe ta l  c a l f  serum as human serum contains immunoglobulins which would
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in te r fe re  w ith and be detected by the assay. The assay i t s e l f  is 
very stra ightforward and uses commercially ava ilab le  immuno-reagents 
as per manufacturer's spe c if ica t io ns .
Staph. A. was prepared fo r  use as an antigen by growing up 
the bacteria in Meullar Hinton broth and then tre a t in g  fo r  18 hours 
with 10% buffered formalin at 37°C. Bacteria were then washed and 
stored in saline a t 4°C u n t i l  use. Concentration o f Staph. A. were 
were determined by p late pouring analysis. B r ie f ly ,  ten fo ld  
d i lu t io n s  of Staphylococci preparations were plated on blood -agar 
and incubated overnight. The colonies were then counted and i t  was
possible to ca lcu la te  what 0D of bacter ia l suspension was equivalent 
to what number of Colony Forming Units (CFU). I t  is  assumed tha t one 
colony orig inates from one bacterium, the re fo re , 106 CFU = 106 
bacteria /m l. When d i f fe re n t  concentrations of PWM were used there 
was no s ig n i f ic a n t  d ifferences in amount o f IgG or IgM produced over
a wide concentration range using normals. From a 1:10 d i lu t io n  o f
PWM r ig h t  down to a 1:1000 d i lu t io n  IgM and IgG, production did not
drop. I t  was decided, there fore , tha t a working concentration of 
PWM a tl:250  (1:500 f in a l )  would be used in the production of
immunoglobulin containing supernates.
S im ila r ly  w ith  Staph. A. as stimulus, no noticeable d if fe rence 
was seen in a range from 109/ml down to 106/m l. Only from 105/ml down 
did the leve ls  o f IgM s ta r t  to drop. I t  was decided, therefore, to 
use Staph.A at 107/ml (working concentrations).
There seemed to be a problem with IgG production when using
Staph A. I t  is known tha t soluble prote in  A (SPA) which can be
released by Staph. A. w i l l  bind IgG and form immune complexes. This
would therefore take out the IgG and none would be detected by ELISA.
Formalin treatment should prevent leakage o f SPA, but i t  was decided 
only to assay IgM when using the T ce ll  independent Staph. A.
7 .3 RESULTS
7.3 .1  Serum Levels
Serum levels are shown in Table 7.1. IgA was raised in a l l  
groups (p<0.001) compared to control group. IgM was raised in the HIV+ 
group (p<0.02) and HIV but treated group (p<0.05) when compared to 
con tro ls . IgG was raised in both the HIV+ group and HIV but treated 
group when compared to contro ls (p<0.001). Patients who had received 
treatment w ith in  the la s t  year had increased IgG leve ls compared -to 
those who were untreated (p<0.001). In HIV patients current raised 
IgG leve ls  correlated with amount of treatment (r=0.36 p<0.02).
Serum samples were available fo r  87 patients from whom we knew 
IgG leve ls  in 1981. Results of th is  are shown in Table 7.2. As can 
be seen, there is  a s ig n i f ic a n t  increase in the HIV+ patients in 1986 
compared to 1981 (p<0.005) but no increase in the HIV" pa tien ts .
Serum IgD was not raised in any pa tien t group.
7.3 .2  Supernate Immunoglobulin Production by PWM and Staph. A. 
Stimulation
The leve ls  of IgM and IgG produced in response to 7 day stimulus 
is  shown in Tables 7.3 and 7.4. Results are shown as ng/ml produced 
and also as a s tim ula tion  index (S I) . The SI is  worked out as:
P i. . . .  T . Stimulated - Unstimulated w inn
Stimulation Index =  UnstimUlated------------ x 100
W* /
A high SI w i l l  mean tha t ce l ls  were stimulated in presence o f mitogen 
and a low SI w i l l  mean ce lls  could not be stimulated so much above the 
unstimulated leve l,  i .e .  could not be stimulated to produce more 
immunoglobulin than they already spontaneously produce.
CONTROLS 3IV+ HIV" f 113 AT ED 
n=55
q r y— NO 
ttlv TREATMENT 
n=33n=33 n= 1 2
IgA
I .4*t 
(0.8 - 3.0)
2.7 
(1.2 - 5.7)
2. 1 
(0.4 - 5.7
2.2 
(0.9 -6.1)
IgM
1.5
(0.3 - 2.8)
1.7
(0.6 - 12.6)
1.9
(0.2 - 4.9)
1.5
(0.8 - 5.0)
IgG
10.2 
(4.1- 18.5)
20
(15.2 - 39)
14
(9. 1 - 21.8)
11.8 
(7.6 - 17.9)
IgD
1.2
(0.6 - 9.6)
2. 1
(0.6 - 7.9)
1.5
(0.6 - 1.3)
* g/L Table 7.1: Serum Immunoglobulin Levels 1985-86.
"^Median
(range)
HIV HIV"
n= 12
14.914.7
1981
(8.4 - 22)(7.8 - 21)
2 2 . 2
1986 ( 12. 1 - 39)
* g/L Table 7.2: IgG Levels in Patients with Paired Samples.
^Median
(range)
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IgM
For IgM production in response to PWM stim u la t ion  a l l  treated 
haemophiliacs when taken as one group had a s ig n i f ic a n t ly  reduced SI 
(p<0.05) compared to con tro ls . When the groups were taken separately 
only the HIV+ had a reduced SI compared to control (p<0.001). This 
group also had a reduced SI (p<0.001) compared to both HIV" "heavy" 
" l ig h t "  users.
By looking at e ith e r  the simulated or unstimulated leve ls , i t  
should be possible to detect whether the patients have a high 
spontaneous production or an i n a b i l i t y  to be stimulated to produce 
more immunoglobulin.
The HIV+ group has higher unstimulated leve ls  o f IgM compared 
to the "heavy users" (p<0.005) and " l i g h t  users" (p<0.01) and those 
never treated (p<0.005). No other group has increased unstimulated 
leve ls . On s t im u la t ion , treated haemophiliacs as a group have a 
s ig n i f ic a n t ly  lower level o f s tim u la t ion  ( p<0 .001) as compared to 
con tro ls . Taken as separate groups the HIV+ patients  produce 
s ig n i f ic a n t ly  less on s t im u la tion  compared to the others: p<0.005
compared to "heavy users", p<0.05 compared to " l i g h t " ,  and p<0.001 
compared to con tro ls . Both "heavy" and " l i g h t "  users also produce 
less than contro ls  (p<0 .01) although they do not d i f f e r  from each 
other in leve ls  o f IgM fo r  spontaneous or s t im i la te d  samples. 
Paired Wilcoxons comparing stimulated (w ith PWM) and unstimulated 
w ith in  a group show s ign if icance in a l l  groups (p<0 . 01) except the 
HIV+ group. Therefore a l l  o f the pa t ien t groups except the HIV+ can be 
stimulated to produce more IgM.
IgG
The resu lts  fo r  IgG are e s s e n t ia l ly  s im ila r .  When taking a l l
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treated haemophiliacs as a s ing le  group they have a reduced SI 
compared to both contro ls (p<0 . 01) and haemophiliacs who had not 
received treatment (p<0.05). Again on d iv id ing  patien ts  in to  th e ir  
respective groups i t  is  only the HIV+ patients which d i f f e r  from 
contro ls (p<0.001). They also d i f f e r  s ig n i f ic a n t ly  from HIV" "heavy
users" (p<0.002), " l i g h t  users" (p<0.05) and those never treated
(p<0 . 001).
Looking at the stimulated leve ls  produced there is  no
difference between any group. There are, however, d if fe rences i f
unstimulated leve ls are examined. HIV+ patients seem to spontaneously 
produce more IgG than contro ls (p<0.001), HIV "heavy users" (p<0.005) 
and those never treated (p<0.02). HIV+ also spontaneously produce more 
than treated HIV” haemophiliacs as one group (p<0.01) and a l l  treated 
treated haemophiliacs, i r respe c t ive  of th e i r  HIV status or fa c to r  
consumption, have a higher spontaneous production than normals (p<0 .02) 
"Heavy users" do not spontaneously produce more immunoglobulin
than contro ls but ra ther s u rp r is in g ly  " l i g h t  users" margina lly  do
(p<0.05). Paired Wilcoxons show no d iffe rence between spontaneous and 
stimulated leve ls fo r  HIV” "heavy" and " l ig h t "  users or those never 
treated. As expected contro ls  show a d iffe rence in stimulated g iv ing  
higher leve ls than contro ls  (p<0.01). Unexpectedly, however, HIV+ 
patients seem to produce more spontaneously than they do when 
stimulated (p<0 . 02).
IgM Production to Staph. A. Stimulation
The resu lts  o f IgM production are shown in Table 7.5.
Treated haemophiliacs have a smaller SI than contro ls  (p<0.01). 
HIV+ patients are lower than contro ls  (p<0.005) as are HIV” "heavy 
users" (p<0.02). Treated HIV haemophiliacs, i r resp e c t ive  o f amount,
UNSTIM.
STIMULATED
S.I.
^ Median Table 7.5: Supernate Levels of IgM
(range) (Staph.A Stimulation).
* Stim. - Unstim. x jqq 
Unstim.
# n g / m l .
HIV+
HIGH 
HIV USER
LOW 
HIV USER CONTROL
n= 12 n= 13 n=8 n= 10
76 34 4 1 50
(11 - 355) (10 - 178) ( 10 - 400) (10 - 190)
89 51 117 166
(16 - 275) (12 - 188) (32 - 400) (25 - 400)
-5 * 15 77 156
(-4 1 - 132) (-41 - 452) (-52 - 556) (-17 - 2700)
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also had a lower SI than contro ls (p<0.05). "Heavy users" appear to 
produce less IgM than contro ls (p<0.05), whereas " l i g h t  users" do 
not, when leve ls in the stimulated supernates are analysed. This 
suggests tha t heavy treatment impairs the a b i l i t y  to respond to 
antigen in v i t r o  and produce IgM in amounts comparable to con tro ls .
Paired Wilcoxons were again looked at to determine i f  w ith in  
ind iv idua l groups there were d ifferences between stimulated and 
spontaneous production. As expected the HIV+ group showed no 
d ifferences but the control population produced more IgM on 
s tim u la tion  (p<0.01) as did the HIV- treated pa tien ts  taken as a 
s ingle group (p<0.05). "Heavy users" produced more on s t im u la t ion  
than they did spontaneously (p<0 .02) but su rp ris ing  " l i g h t  users" did 
not. This la t t e r  group was small (n=8) and s ix  patients  produced more 
on s tim u la t ion  while two did not.
At the same time as T ce ll  subsets were being performed the 
numbers o f c i rc u la t in g  B ce l ls  were determined. These did not d i f f e r  
fo r  the pa t ien t groups: HIV+ (median 0.1 [range 0.04-0.42] x 109/L ) ,
HIV- "heavy" (median 0.1 [range 0.03-0.46] x 109/L ) ,  and HIV- " l i g h t  
user" (median 0.12 [range 0.05-0.33] x 109/L ) ,  nor did they d i f f e r  
s ig n i f ic a n t ly  from the normal range (0.07-0.53 x 109/ L ) .
In summary, a l l  treated haemophiliacs had increased serum
levels o f IgA, IgG and IgM compared to con tro ls , i r resp ec t ive  o f th e i r  
HIV status. This would suggest an in t r in s ic  B ce ll  defect in some way 
caused by the use o f concentrate. In HIV+ patients  there is  a
progressive polyclonal r ise  in IgG leve ls re la ted to HIV in fe c t io n .  
IgD was not raised in any pa tien t group. From the in v i t r o  work, i t  
can be seen tha t HIV+ patients have a higher spontaneous production o f
IgM and IgG compared to the others and they cannot be stimulated to
produce more. Treated HIV haemophiliacs, although not producing more
IgM or IgG spontaneously compared to con tro ls , cannot be 
produce immunoglobulins to the same degree as contro ls  
the use o f Factor V I I I  concentrate in  some way seems to 
the a b i l i t y  to produce immunoglobulin in v i t r o .
stimulated to 
Therefore, 
e in h ib i t in g
7 .4 DISCUSSION
AIDS has generally been regarded as a disease a ffe c t ing  
the T ce ll  arm of the immune response. Hypergammaglobulinaemia and 
elevated levels of immune complexes are near universal f ind ings in 
HIV infected ind iv idu a ls . Despite the polyclonal immunoglobulin 
e levation, HIV infected subjects, p a r t ic u la r ly  AIDS pa tien ts , mount a 
poor an t igen-spec if ic  antibody response a f te r  in vivo immunisation. 
Largely through the work of Lane, Fauci and colleagues, B ce ll  
responses in AIDS patients have been extremely well 
characterised. . In v i t r o  studies have shown tha t these patients 
produce a poor immunoglobulin response to PWM s tim u la t ion .
Co-culture experiments have shown tha t i t  is  not simply a T ce l l  
defect as normal T ce l ls  cannot restore the response. S im ila r work
by Brieva (1985) looking at the abnormal B ce l l  function in
haemophiliacs found comparable re su lts .  His study showed tha t
spontaneous production o f IgM, IgG and IgA in cu ltu re  was three times
higher than contro ls but on s tim u la t ion  w ith  PWM, the leve ls  produced 
were s ig n i f ic a n t ly  lower than normals. The amount o f c lo t t in g  fa c to r  
used correlated with increased spontaneous imumnoglobulin production, 
decreased PWM-driven production o f immunoglobulins and increased 
serum IgG leve ls .
As yet the cause fo r  the polyclonal B c e l l  a c t iva t ion  is
unknown but could be caused by a va r ie ty  of reasons inc lud ing :
( i )  T ce l l  independent a c t iva t ion  and transformation o f B c e l ls  by EBV 
or CMV in the absence of regula tory T c e l ls ;  (2) production of B ce l l  
a c t iva t ing  factors from HIV infected T c e l ls ,  and (3) d ire c t  
ac tiva tion  of B ce l ls  by HIV. Recent work by Schmittman and colleagues 
(1986) has t r ie d  to address the problem of polyclonal B ce ll
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ac t iva t io n . They have found tha t d i f fe re n t  HIV iso la tes  can cause as 
great a degree o f p ro l i fe ra t io n  o f B ce l ls  as any o f the known T ce ll  
independent B ce l l  mitogens used. This ac t iva t io n  is  due to d ire c t  
B c e l l - v i r u s  contact and the magnitude of response in th e i r  studies 
suggests that th is  type o f ac t iva t ion  may be the major mechanism 
responsible fo r  the hypergammaglobulinaemia in AIDS pa tien ts . I f  th is  
is  so, then there may be an a lte rn a t ive  receptor s i te  fo r  the v irus  on
B c e l ls ,  as most B c e l ls  do not express the CD4 molecule thought to be
part o f the HIV receptor on T helper c e l ls .
This study has looked at B ce ll  function and immunoglobulin 
leve ls fo r  any abnormality. As described in Chapter 5 , the 
p ro l i fe ra t iv e  response to PWM, a T ce ll dependent B c e ll  mitogen, was 
reduced when treated haemophiliacs were compared to con tro ls . On 
d iv id ing  the patients according to HIV status and amount o f 
concentrate used in therapy, only HIV+ patients  d if fe re d  from
con tro ls . Serum leve ls  o f IgG and IgM were raised in both the HIV+
and HIV" treated group and IgA was raised in a l l  groups studied 
compared to con tro ls . These resu lts  agree w ith other studies on both 
HIV+ patients and haemophiliacs. I t  is  in te res t in g  tha t the study on 
paired samples shows th a t although in 1981 HIV+ and HIV” patients had 
s im ila r  IgG leve ls , in 1986 they d if fe red  from each other and more 
s t r ik in g ,  the HIV+ patients  had increased leve ls  compared to th e i r  
1981 leve ls  (p<0.005). This is  probably a consequence of in fe c t io n  
w ith  HIV. No association was found w ith current transaminase leve ls  
or other v i ra l  in fe c t io n  and IgG leve ls . I t  would seem from these 
find ings tha t concentrate usage resu lts  in B ce l l  a c t iva t io n . This 
causes an increase o f ce rta in  immunoglobulin isotypes which does not 
s ig n i f ic a n t ly  change over time unless HIV in fe c t io n  supervenes, which 
resu lts  in sustained and progressive r is e .  I t  is  unclear but a
p o s s ib i l i t y  tha t the defect in HIV patients is due to concentrate 
re lated immunoregulatory defects such as s p e c if ic  antigenic stimulus 
with fore ign antigens in the Factor V I I I  and fu tu re  in v i t r o  studies 
may help e lucidate the reason fo r  the observed hypergammaglobulinaemia 
in asymptomatic HIV haemophiliacs. E a r l ie r  studies (Chess e t a l , 
1984) and more recently  one by Mizuma and colleagues (1987) suggested 
tha t IgD could be a useful marker fo r  AIDS or HIV re la ted  disorders. 
The la te r  study found up to n inefo ld  increase in serum IgD leve ls  in 
AIDS-related complex patients compared to con tro ls . This elevated 
level started to decrease in AIDS but was s t i l l  higher than control 
leve ls . They found tha t increased IgD corre la ted w ith  increased IgG 
or IgA, increased percentage of B c e l ls  and decreased percentage of T 
helper c e l ls .  This current study has not been able to show a 
s ig n i f ic a n t  increase in IgD levels in the HIV+ haemophiliacs but i t  
is  in te res t in g  to note tha t the highest level o f a l l  pa tien ts was 
from a serum sample taken from the only haemophiliac to die from AIDS 
in our centre.
The resu lts  from the in v i t r o  s t im u la t ion  are in keeping with 
those o f others (Lane e t a l , 1983). HIV+ patien ts  spontaneously 
produce more IgG and IgM than the other groups te s ts . Also, on 
s t im u la t ion , the HIV+ patients could not be stimulated to the same 
degree as other patients or contro ls to produce IgG or IgG. However, 
the other patients (a l l  HIV” ) produced less IgM on s tim u la t ion  w ith 
PWM than con tro ls . This suggests tha t while HIV+ patients have 
polyclonal a c t iva t ion  of B ce l ls  re su lt ing  in spontaneous production 
of IgG or IgM and an in a b i l i t y  to be stimulated fu r th e r  to produce 
more there is  also some in t r in s ic  defect in the HIV” pa tien ts . There 
was no d iffe rence between HIV” "heavy" and " l i g h t "  users e ith e r  in 
spontaneous or stimulated production of IgM or IgG suggesting tha t
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amount of usage is  not c ru c ia l .  The fa c t ,  however, tha t HIV 
asymptomatic patients were incapable of producing comparable levels to 
contro ls on s t im u la t ion  suggests tha t there is ,  indeed, some defect in 
the B ce l ls  from treated haemophiliacs. The cause o f th is  defect is 
most l i k e ly  due to the use of c lo t t in g  fa c to rs , but the mechanism by 
which the c lo t t in g  fac to r  usage induces these B ce ll  a l te ra t io n s  is 
s t i l l  unknown. Allogeneic co-cu lture  experiments (Brieva e t a l , 1985) 
have shown tha t the fa i lu re  of haemophiliacs' B c e l ls  to produce 
immunoglobulin in response to PWM is not due to a lte red  T ce ll  
function . This suggests tha t e ith e r  a defect of the PWM responsive 
B ce ll  subset or an excessive suppressor a c t iva t io n  o f monocytes could 
be invoked as the cause o f th is  observed a l te ra t io n .
Future work could look at the s p e c i f ic i t y  o f the immunoglobulin 
produced in v iv o . I t  would also be in te re s t in g  to determine i f  a 
large percentage o f B ce l ls  are producing antibody causing the 
observed hypergammaglobulinaemia. Lane (1983) has shown tha t around 
'0.1-1% of B c e l ls  from AIDS patients are responsible fo r  the 
hypergammaglobulinaemia. A high proportion o f the to ta l immunoglobulin 
is  anti-H IV, but in in v i t r o  cu ltu re  c e l ls  cannot be induced to 
produce higher leve ls  o f anti-HIV antibody.
Co-culture experiments, espec ia lly  in the HIV" patients may 
help determine what is  causing th is  abnormal production of 
immunoglobulin in  vivo coupled w ith  a decreased a b i l i t y  to produce 
immunoglobulin in v i t r o  a f te r  s t im u la t ion .
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C H A P T E R  E I G H T
B2-MICROGLOBULIN LEVELS
8.1 INTRODUCTION
82- M icroglobulin  (32M) is a small s ing le  chain polypeptide 
(Mr=ll,600) tha t is  found on the surface of most nucleated c e l ls .  I t  
may play an important ro le  in the immune system of the body as i t  is 
found on the c e l ls  surface as the constant subunit, noncovalently 
linked to the c lass ic  transp lan ta tion  antigens encoded by the major 
h is tocom patab il i ty  complex (MHC) (Poulik, Ferrone, Pe llegrino e t a l , 
1974). I t  may also normally be present in trace amounts in both serum 
and urine (Woo, Floyd, Longley e t a l , 1980). Measurements on the 
concentration o f 82M have been used as a re l ia b le  in d ica to r  of 
glomerular and tubu lar functions (Ervin and W ibe ll, 1973). Abnormally 
high serum concentrations have been reported in many disease states 
includ ing rheumatoid a r t h r i t i s  (Ta la l,  Grey, Z v a i f le r  e t  a l , 1975),
malignant tumours (K ith e r , Cejka, Belamaric e t a l , 1974) and more
s t r ik in g  increases were shown in lym phopro lite ra tive  disorders (Pou lik , 
Farrah and Smithies, 1972) and acute v i ra l  in fe c t ions  (Forman, 1982). 
F ranc io l i  (1982) f i r s t  showed increased 32M leve ls  in an immunodeficient 
homosexual man. More recently  there have been reports o f increased 
serum leve ls  o f 82M in AIDS cases (Bhalla, Safa i, Mertelsmann e t a l , 
1983). Serum 82M is  thought to o r ig ina te  mainly as a re s u l t  o f being
released from the surface o f ce l ls  and increases there fore , w ith  ce ll
turnover. Therefore, increased values in AIDS patien ts  are most 
probably in d ica t ive  o f increased ce ll  turnover or ce l l  death.
Zolla-Pazner (1984) has suggested tha t in conjunction w ith
other laboratory te s ts , is  a useful marker fo r  the ea r ly  stages o f
8.2 MATERIALS AND METHODS
8.2.1 Serum Collection and Patients
Serum samples were obtained by ce n tr i fuga t io n  of c lo t te d  blood 
samples and were stored at -20°C u n t i l  assayed. A ll  samples were 
assayed w ithout knowledge of HIV antibody sta tus. Two hundred and 
fo r ty  three samples were assayed. These included 46 age and sex 
matched healthy normals, 112 samples from HIV negative pa tien ts , 60 
HIV pos it ive  samples and 25 samples from Factor IX d e f ic ie n t  pa tien ts .
8.2 .2  32~Microglobulin Assay
B2M was measured using the commercially ava ilab le  Micro RIA 
from Pharmacia (Pharmacia, M ilton Keynes, U .K.). B r ie f ly ,  th is  is  a 
double antibody radioimmunoassay method. B2M in the sample competes 
w ith a f ixed  amount o f 1251- 1abe1 led B2M fo r  the binding s i te s  o f the 
sp e c if ic  antibody to B2M. Bound and free B2M are separated by 
addit ion  o f a second antibody immunoadsorbant (a Sepharose-anti-sheep 
IgG raised in horse) followed by centr igua tion  and decanting. The 
ra d io a c t iv i ty  in the resu lt ing  p e l le t  was then measured on a gamma 
counter. The amount of ra d io a c t iv i ty  is  inverse ly  proportional to the 
quan tity  o f B2M in the sample.
By using known concentrations o f B2M i t  is  possible to 
construct a standard curve o f ra d io a c t iv i ty  measured versus 32M 
concentration enabling the determination o f the leve ls  in p a t ien ts '
8 .3 RESULTS
Results are expressed as a percentage o f the mean o f t r i p l i c a te  
counts o f the "0-Standard", i . e .  when no 32M is  present.
Therefore : % a c t i v i t y  bound
_ mean count (o f standard or unknown) ^qq 
count of 0-Standard
Figure 8.1 shows a standard curve fo r  the % a c t i v i t y  bound
versus 82M concentration. From th is ,  i t  was possible to ca lcu la te  the
concentration o f 82M in unknown samples once % a c t iv i t y  bound was 
determined. The concentration was simply calculated by reading the 
po in t on the x-axis corresponding to the po in t where the % a c t i v i t y
bound cut the standard curve.
Figure 8.2 shows a sca tte r  p lo t  o f concentration fo r  the 
d i f fe re n t  groups studied. The HIV+ haemophiliacs had a median level 
o f 2.2 [range 0.49-4.55] mg/L. This was s ig n i f ic a n t ly  more (p<0.001) 
than the leve ls  obtained fo r  both the HIV” haemophiliacs (median 1.79 
[range 0 .72-3.3] mg/L and also in the contro ls (median 1.4 [range 0.98 
- 5 .4 ]) . All Factor V I I I  pa tien ts taken together also had s ig n i f ic a n t ly  
greater leve ls  than contro ls  (p<0.001). Some F.IX samples were also 
ava ilab le  and they gave a median level o f 1.7 mg/L w ith  a range of 
1.2-3.45. This was s ig n i f ic a n t ly  greater than contro ls  (p<0.02).
In a l l  pa tients  there was a s ig n i f ic a n t  co rre la t io n  between 82M
leve ls  and hepatic dysfunction, as suggested by elevated ALT, (r=0.35,
p<0 .02) but no association was evident w ith 82M leve ls  and the amount
o f concentrate used in the preceeding year.
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8 .4  DISCUSSION
There have been many attempts to f in d  a surrogate marker 
ind ica t ive  of AIDS. Zolla-Pazner and colleagues (1984) state tha t the 
use o f the 3zM te s t ,  while not spe c if ic  fo r  AIDS, appears to be a 
h ighly useful marker of the disease. The s e n s i t iv i t y  o f the disease, 
i .e .  the p ro b a b i l i ty  tha t concentrations above a ce rta in  level w i l l  
c o rre c t ly  c la s s i fy  persons with AIDS was 100% fo r  both patients in 
th e ir  study w ith  confirmed AIDS and also patients  w ith  suspected AIDS. 
They conclude tha t $2^ q u an t ita t ion , used in conjunction w ith other 
laboratory tes ts ,  is  a useful marker fo r  ea r ly  stages o f AIDS.
This study is in keeping with other reports (Stein e t a l , 1985) 
tha t increased B2M leve ls  are observed in haemophilia A pa tien ts . 
However, i t  d i f fe r s  from the find ings of Lee and colleagues (1985) who 
did not f in d  s ig n i f ic a n t  d ifferences between haemophilia A and B 
patients and con tro ls . There is  a p o s s ib i l i t y  th a t the increased 
leve ls  observed in the haemophiliacs are as a consequence o f carry 
over o f 62M in the concentrate. However, on checking batches o f Factor 
V I I I ,  no detectable 32M levels were found. Elevated leve ls  o f B2M are 
most probably due to c e l l  turnover w ith  32M being shed from the ce l ls  
surface. Increased leve ls are also thought to be associated w ith 
v i ra l  and other antigen ic exposures through the use o f blood products.
In our group o f patients there was no c lea r d if fe rence in 
leve ls  associated w ith  any c l in ic a l  signs o f disease. However, i t  is 
o f in te re s t  tha t the highest 32M level recorded in the HIV+ group came 
from a pa t ien t who sh o rt ly  afterwards died, the diagnosis being AIDS.
In summary, there fore , in th is  study haemophiliacs have been 
shown to have increased 32M levels when compared to con tro ls . This 
was not due to a carry over of 32M in th e i r  treatment. Also, HIV+
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patients have s ig n i f ic a n t ly  higher leve ls  than HIV ones. However, 
the leve ls  in haemophilia appear to be a re f le c t io n  o f biochemical 
hepatic dysfunction as well as HIV re la ted disease. I t  is  unclear 
whether or not leve ls w i l l  be useful in ind ica t ing  those who w i l l  
develop symptomatic HIV disease but perhaps i f  the resu lts  are used 
in conjunction w ith other laboratory f ind ings they w i l l  be o f use in 
backing up c l in ic a l  f ind ings  while try in g  to diagnose disease sta tes.
SECTION I I
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C H A P T E R  N I N E  
M I S C E L L A N E O U S  S T U D I E S
9.1 INTRODUCTION
This section is  a co l le c t io n  of various in  v i t r o  experiments 
which seem best put together as one. The in v i t r o  e f fe c t  of
Factor V I I I  concentrate and i t s  bu ffe r, as well as disrupted HIV on
various in v i t r o  immunological tests already described in th is  
Thesis, namely, mitogenesis, IL-2 production and immunoglobulin 
production has been studied.
This study has also looked at the e f fe c t  o f pa t ien ts ' serum on 
the in h ib i t io n  o f mitogenesis and IL-2 production.
Various workers including ourselves have t r ie d  to examine what 
ro le  d ire c t  c e l l  to Factor V I I I  concentrate contact has in various 
immunological tes ts . McDonald and colleagues (1985) have described 
experiments in which they found tha t a d if fusab le  fa c to r  in Scottish 
Factor concentrate could in h ib i t  lymphocyte transformation in v i t r o . 
Our previously unreported f ind ings on s im ila r  work are presented here.
At the time o f doing th is  work there had been few reports on 
the e f fe c t  o f Factor V I I I  concentrates on in v i t r o  assays but recent 
publications (Lederman, Saunders, Toossi e t a l , 1986) (Wang, Beck, 
Furl an e t a l , 1985) have reported th e i r  f ind ings on s im ila r
experiments. Also, very l i t t l e  had appeared in the l i t e ra tu re  on the
e f fe c t  o f disrupted HIV on various in v i t r o  assays. However, a recent 
paper by Pahwa et al (1985) has reported f ind ings on s im ila r  work.
F in a l ly ,  w ith  the report by Siegal and colleagues (1985) tha t 
IL-2 production by normal lymphocytes could be in h ib ite d  by sera from 
AIDS pa tien ts , i t  was decided to look at the e f fe c t  o f haemophiliac 
sera on IL-2 production.
The work on these top ics, therefore: ( i )  Factor V I I I  concentrate
( i i )  HIV and, ( i i i ) Haemophiliac sera - w i l l  be dea lt w ith separately.
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9 .2  FACTOR V I I I  CONCENTRATE
9.2.1 Introduction
Published reports have shown the a b i l i t y  o f Factor V I I I  
concentrate to in h ib i t  mitogenesis and IL-2 production. In the 
experiments described here, the e f fe c t  of concentrate on IL-2 
production and mitogenesis by normal lymphocytes has been studied. 
The assays fo r  IL-2 production and mitogenesis have been described 
previously and only modifications w i l l  be mentioned here.
9.2 .2  Methods and Results
Factor V I I I  concentrate was obtained from the Protein 
Fractionation Unit, Edinburgh. For mitogenesis 50 pi o f both ce l ls  
and mitogen or PPD were added to the w e lls . To th is  was added 100 pi 
o f e ith e r  neat Factor V I I I  (6 U/ml) or twofold d i lu t io n s  o f the 
concentrate which were made up in RPMI. Factor V I I I  was 
reconstitu ted  in RPMI ra ther than d is t i l l e d  water so tha t in cu ltu re  
the ce l ls  s t i l l  had th e ir  normal medium, other than the sa lts  which 
are in the lysoph il ised  concentrate. The bu ffe r  fo r  Factor V I I I  is  
0.02M Tris/0.02M Trisodium C itra te  adjusted to pH 7.3. This was made 
up in RPMI and used in the same way as the concentrate. Factor V I I I  
was also d ilu te d  in RPMI containing the same concentration o f T ris  
and Trisodium C itra te  as bu ffe r.  This would allow d i lu t io n  of the 
Factor V I I I  while keeping the bu ffe r concentration the same. These 
three preparations were tested in mitogenesis and p ro l i fe ra t iv e  
response to PPD.
The resu lts  are shown in Figures 9.1 to 9.4.
Results are mean of e igh t normals and are expressed as a percentage 
response of maximum response in the absence of any concentrate and
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bu ffe r . As can be seen from the graphs there is a dose dependent 
in h ib i t io n  fo r  a l l  three mitogens and PPD. The response when bu ffe r 
only is  present recovers most by se r ia l d i lu t io n .  When Factor V I I I  is 
d ilu ted  in medium containing bu ffe r ,  there is near constant in h ib i t io n  
a t a l l  three concentrations. Therefore, the bu ffe r is  probably 
causing th is  e f fe c t  as i t  is kept constant while the concentrate is 
d ilu te d . In h ib i t io n  caused by Factor V I I I  reduces as se r ia l d i lu t io n s  
are used but does not reach the level of "bu ffe r  alone" suggesting 
tha t the concentrate i t s e l f  plays a major ro le  in th is  observed 
in h ib i t i  ion.
In summary, addition  of concentrate causes in h ib i t io n  of 
mitogenesis which is dose dependent. The addition  o f bu ffe r  alone can 
also cause in h ib i t io n  but on d i lu t io n  i t  is  less marked than tha t 
caused by the concentrate i t s e l f ,  and response tends towards normal as 
bu ffe r concentrate is  reduced.
McDonald (1985) suggested tha t th is  in h ib i t in g  fac to r  was a low 
molecular weight substance which could be removed by p r io r  d ia ly s is  of 
the concentrate. However, on several occasions I was unable to remove 
the in h ib i t io n  observed on mitogenesis i f  concentrate was dialysed 
overnight against 500 vo ls. of medium p r io r  to addition in to  assay. 
C itra te  is  a known constituen t o f the concentrate bu ffe r  and added to 
mitogenesis over a concentration range 5-40 mM i t  t o ta l l y  in h ib ite d  
the response.
One f in a l  small experiment carr ied  out on the e f fe c t  of 
concentrate on mitogenesis was to look at the e f fe c t  of pre-incubating 
ce l ls  in concentrate or bu ffe r.  I f  c e l ls  were incubated overnight at 
37°C/5% CO^  and then they were washed and resuspended at appropriate 
concentration, the responses to PHA, Con A and PWM were s t i l l  t o ta l l y  
in h ib ite d .  However, i f  ce l ls  were incubated in medium containing
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b u ffe r, washed and added to mitogens, then there was a d i f fe re n t ia l  
return of response depending on the mitogen. PHA returned to 71%, 
Con A to 80% and PWM to 86% of th e ir  respective normal mitogenic 
responses. This would suggest tha t the main cause of in h ib i t io n  was 
not the c e l ls  being in bu ffe r ,  although th is  did have some e f fe c t ,  but 
rather the concentrate i t s e l f .  Perhaps concentrate adheres to the 
ce l ls  duing th is  pre-incubation and cannot be washed o f f .  Then on 
addition to mitogenic assay, ce l ls  are e ith e r  incapable of binding the 
mitogen due to concentrate coating the ce l l  or concentrate in some 
other way in h ib i ts  the ce l ls  response, perhaps by binding to the 
mitogen.
The e f fe c t  o f concentrate on the ce l ls  a b i l i t y  to produce IL-2 
was also studied. Eight normals were used and th e i r  c e l ls  were set up 
to produce IL-2 as described in Chapter 6. To the cu ltu res , however, 
were added Factor V I I I  at varying concentration or bu ffe r equivalent 
which was made up in medium. A fte r  incubation the supernates were 
removed as normal and assayed in a standard IL-2 assay as described 
previously. For each normal, a supernate was produced using PHA at 
2 pg/ml. The response of the IL-2 dependent ce l l  l in e  to th is  
supernate, (as determined by incorporation o f 3H-Thymidine) was taken 
as 100% and the response produced by other supernates were expressed 
as a percentage o f the maximum.
The responses obtained are shown in Table 9.1.
Results are mean±S.E. o f e igh t normals and are expressed as % response.
Supernate % Response
Medium only 
Buffer only 
FV I I I
PHA + Buffer 
PHA + FV III 6 U/ml 
3 U/ml 
1.5 U/ml
Mean± S.E.
(n=8)
10.1± 0.8 
8.5 t  0.8
5.3 t o . 5
7 . 4 t  0 .8
3.9± 0.5 
37.7 t  4.4 
53.8 t  8.3
Table 9 .1 : Effect of Concentrate and Buffer on IL -2 Production
by Normals.
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The resu lts  show tha t the addition of Factor V I I I  can in h ib i t  the 
production of IL-2 in response to PHA. This e f fe c t  is  dependent on 
the concentration o f Factor V I I I  used and at high concentrations (6U/ml) 
the response obtained is even less than tha t obtained fo r  the
spontaneous production o f IL-2 in the absence o f PHA. Lederman (1985) 
has shown tha t the in h ib i t io n  observed is not caused by the Factor V I I I  
in h ib i t in g  the IL-2 ce l l  l in e  from p ro l i fe ra t in g  to IL-2 because on 
addition of concentrate to a supernate containing IL-2 the response of 
the IL-2 ce l l  l in e  was s im ila r  to response obtained when supernate
without concentrate was added.
The e f fe c t  of incubation o f c e l ls  in concentrate in the
production of immunoglobulin could not be studied by the method 
previously described because the concentrates themselves contain 
large amounts o f human immunoglobulin which carr ied  over in to  the
ELISA assay.
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9 .2 .3  DISCUSSION
The resu lts  described here represent some pre lim inary  work on 
the e f fe c t  o f concentrate on various in v i t r o  assays. They are by no 
means complete. Those experiments, however, were not the main theme 
of the p ro jec t and were done as some add it iona l work. The question of 
the e f fe c t  of concentrate on lymphcyte responses could e as ily  produce 
enough work fo r  at least one complete thes is .
These studies, however, have demonstrated tha t Factor V I I I  
concentrate can profoundly suppress lymphocyte p ro l i fe ra t io n  to
mitogen and antigen. The response was in h ib ite d  by concentrate in a 
dose dependent fashion. Lymphocyte p ro l i te ra t io n  is  dependent on the 
production by T ce l ls  of IL-2 and th is  work has shown tha t IL-2 
production can also be inh ib ite d  by IL-2 in a dose dependent fashion. 
The reason fo r  the observed find ings is  unknown. I t  could be simple 
lec tin -concentra te  binding thus preventing c e l l  s t im u la t ion . However, 
when c e l ls  were pre-incubated in concentrate, w ithou t any obvious 
tox ic  e f fe c t  (confirmed by trypan blue exclusion which was comparable 
to tha t fo r  ce l ls  incubated in medium), then washed, the in h ib i to ry  
e f fe c t  remained. I t  is  possible, however, tha t concentrate coated 
the ce l ls  which could not eas ily  be washed o f f .  Another p o s s ib i l i t y  
is  the c i t r a te  content in the concentrate b u ffe r .  The work has shown 
that bu ffe r can produce a s im ila r  dose dependent in h ib i t io n .  C itra te  
could be reducing the a v a i la b i l i t y  o f calcium and possib ly other 
cations required fo r  lymphocyte a c t iva t ion . Whatever the reason, the 
fa c t  remains tha t concentrate has in h ib i to ry  e ffe c ts  on mitogenesis 
and IL-2 production. Future experiments could look at the k ine t ics  of 
th is  in h ib i t io n  and perhaps separation techniques could be used, e.g. 
column gel f i l t r a t i o n  in order to separate the concentrate in to  i t s  
various components which could be analysed separately.
The c l in ic a l  s ign if icance  of the in v i t r o  immunosuppressive 
e ffec ts  of the concentrate is uncertain. Several workers have 
reported an observed subc lin ica l immunodeficiency in haemophiliacs in 
the absence of HIV in fe c t ion  (Lederman, Ratnoff, Evatt e t a l ,  1985). 
I t  is  always possible tha t these cases r e f le c t  in fe c t io n  o f HIV in the 
absence of serological evidence of in fe c t ion  but th is  is  u n l ik e ly .  
Administration of preparations containing Factor V I I I  may re s u lt  in a 
subc lin ica l immunosuppressed state tha t may serve as a co -fac to r fo r  
the development of c l in ic a l  immunodeficiency or AIDS a f te r  exposure to 
HIV. Ludlam and colleagues (1985) have shown tha t the r is k  o f sero­
conversion a f te r  exposure to a presumed batch o f HIV infected 
concentrate was corre la ted w ith the annual consumption o f concentrate 
and also pre-exposure T helper/T suppressor subset ra t io s .
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9.3 EFFECT of HIV on IN VITRO ASSAYS
9.3.1 Introduction
HIV is known to be the causative agent o f AIDS. I t  is 
se lec t ive ly  t ro p ic  fo r  the T^+ lymphocytes (helper T c e l l ) .  The CD4 
molecule on T^ c e l ls  serves as the receptor fo r  HIV, binding the g p l10 
envelope g lycoprotein of the v irus .
Most in v i t r o  work on AIDS has involved looking a t the 
responses of patients own ce l ls  in various assays. This study, however, 
has examined the e f fe c t  o f HIV on the response o f normal lymphocytes 
in some of the assays previously described fo r  the pa t ien t study.
9.3.2 Methods and Results
Again, most of the methods have been described e a r l ie r  and only 
a lte ra t io ns  to methodology w i l l  be described here. This study has 
used a disrupted HIV v i ra l  preparation (a kind g i f t  from Dr. E. 
F o l le t t ) .  The crude ex trac t was at 9 mg/ml and was fu r th e r  
d ilu ted  in medium to 1 mg/ml to serve as a reference stock so lu t ion . 
The preparation was examined fo r  i t s  a b i l i t y  to in h ib i t  p ro l i fe ra t iv e  
response to mitogens and antigen. IL-2 production was also examined 
in the presence of HIV. D ilu t ions  o f the stock so lu t ion  (1 mg/ml) were 
made in medium to give varying f in a l  concentrations in the assays. 
The HIV was used at 1/50, 1/100, 1/250, 1/500 and 1/1000 d i lu t io n  of 
the stock. For mitogenesis 100 pi of appropriate d i lu t io n  was added 
to 50 pi o f ce l ls  and 50 pi of mitogen. Cell and mitogen 
concentrations were as before. For IL-2 production, 0.5 ml o f HIV 
was added to wells w ith 1 ml o f c e l ls  and 0.5 mis o f PHA. Once again 
a l l  the other conditions were as before w ith PHA at 2 pg/ml and ce lls  
at 106/m l. The tox ic  e f fe c t  o f HIV was determined by looking
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at v ia b i l i t y  of ce l ls  a f te r  48 hour cu ltu re  fo r  IL-2 production. The 
v ia b i l i t i e s  were s im ila r  fo r  the wells w ith  PHA and those w ith HIV 
added as well as PHA (95±3%). The resu lts  o f the response to various 
mitogens or antigen are shown in Figure 9.5 Each po in t represents 
mean o f e igh t normals ±S.E. Results are expressed as a percentage 
response of tha t obtained fo r  each normal in the presence o f mitogen 
but absence of HIV.
The resu lts  show tha t p ro l i fe ra t iv e  response to mitogen or 
antigen is inh ib ite d  in a dose dependent fashion by HIV. HIV on i t s  
own ( in  absence of mitogen) gave s t im u la t ion  values equal or less than 
those obtained fo r  negative con tro ls , i . e .  when medium was used 
instead o f mitogen. Therefore, on i t s  own i t  is  not s tim u la tory .
The production of IL-2 in the presence of HIV is  shown in 
Figure 9.6. Each po in t represents mean ±S.E. o f seven normals. 
Results are expressed as a % response of tha t obtained fo r  each normal 
in the absence of HIV. Again, IL-2 production is  in h ib ite d  in 
a dose dependent fashion by HIV. HIV alone did not induce normal 
lymphocytes to produce detectable leve ls  o f IL-2.
9.3.3 Discussion
The small study agrees w ith  and expands on the f ind ings o f a
recent publication  (Pahwa et a l,  1985) which looked at the influence
of HIV on polyclonal B ce ll  a c t iva t io n . Disrupted HIV v i ra l  
preparations had in h ib i to ry  b io log ic  e ffe c ts  on normal lymphoid c e l ls .  
HIV was capable o f in h ib i t in g  p ro l i fe ra t iv e  response to mitogen and 
antigen in a dose dependent fashion. This in h ib i to ry  e f fe c t  was 
extended to the a b i l i t y  o f normal c e l ls  to produce IL-2 in response to
s tim ula tion  with PHA. At the present time i t  is  not c lear how the
influences of k i l le d  v irus  are to be explained, but fu r th e r  studies
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examining the influences o f d i f fe re n t  concentrations of v i ru s ,  or 
d i f fe re n t  ind iv idua l v i ra l  components in various in v i t r o  assays, 
could help to explain the e ffec ts  seen here. Pawha also found tha t 
p ro l i fe ra t iv e  responses to T and B ce ll  mitogens could be in h ib ite d .  
They also studied s tim u la t ion  o f immunoglobulin production by HIV 
preparations and these preparations could also in fluence the 
expression of certa in  membrane antigens on normal peripheral blood 
lymphocytes.
I t  is  known tha t only a very small number o f lymphocytes, 
perhaps as few as 1:1,000, or even 1:100,000 c e l ls ,  appear to be 
in fected by v irus ,  in amounts detectable, ye t AIDS patients  show 
profound immunodeficiency. I t  is  not only T ce l ls  which are a ffected 
but also other ce l ls  of the immune response as seen by the hypergamma- 
globulinaemia nearly always seen associated w ith  HIV in fe c t io n .
I t  is  possible tha t fu r th e r  in v i t r o  experiments using 
ind iv idua l components o f the v irus may contr ibu te  towards a be tte r  
understanding o f the mechanisms o f HIV in fe c t io n  w ith  subsequent 
development o f an immunocompromised sta te .
9.4
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EFFECT OF HAEMOPHILIAC SERA ON IN VITRO ASSAY
9.4.1 Introduction
Siegel and colleagues (1985) have shown th a t sera from patients 
w ith AIDS can in h ib i t  the production of IL-2 by normal lymphocytes. 
This small study has looked at the e f fe c t  o f haemophiliac sera on 
both IL-2 production and also the p ro l i fe ra t iv e  response to mitogens 
o f normal peripheral blood lymphocytes.
9.4.2 Methods and Results
The mitogen assays were carr ied  out as described before but 
instead o f adding pooled human serum at 10% f in a l  concentration, th is  
was substitu ted with haemophilic sera. In the IL-2 production assay 
d i f fe re n t  haemophilic sera were added at a f in a l  concentration o f 10% 
instead of the FCS which is usually used when producing IL-2. Cells 
were cultured at 106/ml w ith  2 pg/ml PHA. A ll  responses were 
compared and expressed as a percentage of tha t obtained when a 
standard pooled human serum was used. The three mitogens used before 
were tested with over t h i r t y  sera from haemophiliacs who were e ith e r  
HIV+ or HIV” "heavy" or " l ig h t "  users or haemophiliacs who had 
received no treatment in the previous year. No s ig n i f ic a n t  
d ifferences were obtained w ith  any mitogen tested when the d i f fe re n t  
pa tien t groups were compared w ith a group o f ind iv idua l con tro ls . A 
s im ila r  re s u lt  was obtained when the a b i l i t y  o f sera to i n h ib i t  IL-2 
production was tested as shown in Figure 9.7.
9.4 .3  Discussion
These resu lts  suggest tha t whatever is  causing the in h ib i t io n  
as seen by Siegel is  not present in haemophiliac sera, even those who
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were HIV+. Of course, th is  was only a p re lim inary  experiment and as 
w ith the question o f the e f fe c t  o f fa c to r  concentration on in v i t r o  
assays there is  s t i l l  scope fo r  fu r th e r  research in th is  area.
9 .5 SUMMARY
This section o f the Thesis was made up o f various pre lim inary 
experiments which alone could form the basis fo r  a complete thes is . 
Results, however, have shown tha t enough questions could be raised fo r  
a more complete study.
In summary, Factor V I I I  concentrate can in h ib i t  various in v i t r o  
assays including mitogenesis and production o f IL-2. The exact nature 
of th is  in h ib i t io n  is unknown but involvement of various constituents 
of the concentrate bu ffe r  as well as some o f the ind iv idua l components 
of the concentrate themselves are suspected. Disrupted preparations of 
HIV can also in h ib i t  mitogenesis and IL-2 production in a dose 
dependent fashion. The mechanism fo r  th is  is as yet unknown.
F in a l ly ,  sera from haemophiliacs, inc lud ing those who are HIV+ 
do not seem to in h ib i t  mitogenesis or IL-2 production by normal 
peripheral blood lymphocytes.
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C H A P T E R  T E N
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A FINAL DISCUSSION
Since early  in the AIDS epidemic i t  has been recognised tha t 
haemophiliacs through the use o f c lo t t in g  fa c to r  concentrates, 
produced from blood donations, are a high r is k  group fo r  contracting 
AIDS. Most countries in the world have now reported cases o f AIDS or 
at leas t signs of HIV in fe c t ion  in th e ir  haemophiliac populations. 
Cases o f AIDS have been highest amongst haemophiliacs in countries 
which re ly  heavily on the commercially produced concentrate, la rg e ly  
from the United States.
Within the la s t  few years concentrate has a l l  been heat treated 
in an attempt to inac t iva te  HIV, but un fortunate ly  many thousands of 
patients have most probably been infected w ith  contaminated products 
used before the in troduction  of heat t re a t in g . Hopefully, however, 
the numbers o f new HIV seroconversions should slow down and eventually  
stop as a l l  patients receive the new generation of concentrates. The 
incubation time o f AIDS, however, w i l l  mean th a t new cases o f f u l l  
blown AIDS or re la ted c l in ic a l  conditions w i l l  continue to be reported 
fo r  perhaps many years to come. The problem is  s t i l l  great and much 
work s t i l l  has to be done.
P rior to AIDS, there had been reports in  the medical l i t e ra tu re  
to suggest tha t the use of c lo t t in g  fa c to r  concentrates, even in
the absence o f HIV in fe c t io n ,  could, in some way, produce an
immunocompromised state fo r  treated haemophiliacs. With th is ,  as well 
as the desire to know more about the extent o f ,  and e f fe c t  o f ,  HIV 
in fec t ion  w ith in  the haemophiliac population, th is  study set out to 
examine the immune status o f a cohort o f the haemophiliacs who attend 
the Haemophilia Centre at Glasgow Royal In firm ary .
The fa c t  th a t there were many regular c l in ic s  in the Royal
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In firmary fo r  haemophiliacs, meant tha t i t  was possible to obtain 
samples as required fo r  the various studies carr ied  out.
The f i r s t  inves t iga t ion  which we thought ought to be done was 
to determine the extent o f HIV in fe c t io n  in our population. With the 
a v a i la b i l i t y  of commercially produced screening k i t s  i t  was possible 
to te s t the patients fo r  the presence of antibodies to HIV. . Most of 
the patients have now been screened and 21 have proven to be p os it ive .  
I f  the to ta l number of patients is  taken to be around 250, then the 
incidence of in fe c t io n  is  around 8%. This f ig u re  is  re la t iv e ly  low 
and is  in contrast to many other reports on the incidence o f in fe c t io n  
in d i f fe re n t  haemophiliac populations. The most probable cause fo r  
th is  is that around the same time tha t the i n i t i a l  cases of AIDS were 
being reported in the United States, here in Scotland we were becoming 
s e l f - s u f f i c ie n t  in home produced concentrates. Therefore, the patients 
were no longer having to be treated w ith the commercial 
concentrate which has la rg e ly  been blamed fo r  spreading AIDS in the 
haemophiliacs. A ll our HIV antibody pos it ive  pa tien ts  have a t some 
time received commercially ava ilab le  concentrates or batches known to 
be contaminated w ith HIV. The one pa t ien t who has died, from our 
centre, received large q uan t it ie s  o f imported concentrate while being 
treated when he l ived  in England. Scottish Factor V I I I  has not been 
e n t i re ly  free from HIV contamination. Ludlam and colleagues (1985) 
have reported tha t 15 o f th e i r  pa tien ts  seroconverted a f te r  they a l l  
received concentrate from a s ing le  batch o f home produced concentrate. 
An in te res t ing  observation from th e i r  study was tha t at leas t another 
18 patients received th is  same implicated batch ye t they did not 
seroconvert. There are several possible explanations fo r  th is  as they 
discuss. I t  is possible tha t the ex is t ing  immunological status of a 
pa tien t, which may be influenced by the use o f large quan t it ies  of
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concentrate, may determine whether or not he w i l l  become infected with 
HIV a f te r  exposure to i t ,  i .e .  perhaps only those patients who are 
already immunocompromised in some way through the use o f infusion of 
concentrates can read ily  be infected with HIV. Previous studies have 
shown tha t various parameters of the patients  immune response can be 
influenced by fac to r consumption, e.g. inverted T ce l l  ra t ios  and 
diminished in v i t r o  response to mitogens. (Stein e t  a l , 1985).
I t  was decided to t r y  to assess both in vivo and in v i t r o  
responses to our patients . Twenty-nine patients  were tested fo r  th e ir  
response to skin tes ting  with DNCB. This in vivo te s t  is  considered 
one o f the best ways of examining both the a f fe re n t and e ffe re n t arms 
o f the ce ll  mediated immune response. I t  is ,  the re fo re , a re la t iv e ly  
accurate measure of th e ir  current ce ll  mediated immunological status. 
Results from th is  study showed tha t a l l  haemophiliacs tested, 
irrespective  of th e ir  HIV status, had a reduced response compared to a 
control population. This impaired response was present both in the 
HIV+ patients and more in te re s t in g ly  also the seronegative patients. 
This is  the f i r s t  such report o f depressed c e ll  mediated immune 
response in the absence o f in fe c t ion  w ith  HIV. The impairment
was re lated to the amount of concentrate used in therapy, lending
more support to the suggestion tha t concentrate usage resu lts  in 
impaired immune function.
In v i t r o  tests performed, included Tcell subset analysis and 
p ro l i fe ra t iv e  responses to mitogen and soluble antigen. T ce ll  subset 
ra t ios  were abnormal only in those patients who were HIV+. In most 
cases the inverted ra t io  was due to a decrease in absolute numbers of 
T^ c e l ls .  Some reports have suggested increased Tg numbers in 
haemophiliacs (Stein et a l,  1985) but l ik e  Carr and colleagues (1985)
we found normal numbers of Tg c e l ls .  Lymphopenia is  a ch a rac te r is t ic
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f ind ing  in AIDS pa tien ts . We did not f in d  th is  in any o f our patient 
groups. However, we did f in d  a drop in numbers in the HIV+ group. 
This is in keeping w ith  others and is  probably as a re s u lt  of 
depletion by HIV, which is  known to be t ro p ic  fo r  the T helper ce ll 
subset.
The in v i t r o  response to mitogens amongst the HIV” patients was 
comparable to con tro ls . Amongst the HIV+ pa tien ts , however, there was 
a s ig n i f ic a n t  decrease in response to PHA, a T ce ll  mitogen, and PWM, 
a T c e l l  dependent B c e l l  mitogen. Both these f ind ings  are consistent 
w ith reports by others on HIV infected ind iv idu a ls .  The in v i t r o  
response to the reca ll  antigen PPD was normal in HIV” patients but 
reduced in HIV+ pa tien ts . Again, probably as a consequence of 
decreased numbers and/or a defective response o f the T^ c e l l .
Although AIDS produces an immunodeficient s ta te , hypergamma- 
globulinaemia is  another c h a ra c te r is t ic  f in d in g  amongst HIV infected 
persons. This study has found increased serum levels o f IgA, IgM and 
IgG in our population. These increased leve ls  were highest in the HIV+ 
patients but s t i l l  s ig n i f ic a n t ly  raised in the HIV” ones. Raised IgG 
leve ls in  the HIV” patients corre la ted w ith  the amount o f concentrate 
therapy they received. Paired samples from 1981 and 1986 were 
available  fo r  87 o f the pa tien ts . Levels o f IgG in 1986 were raised 
compared to 1981 only in the HIV+ pa tien ts . This r ise  is  assumed to 
be caused by ongoing HIV in fe c t io n . Raised IgD leve ls  have been 
suggested as a marker fo r  AIDS or HIV re la ted disease (Mizuma e t a l , 
1987). This study, however, has not been able to detect raised IgD 
leve ls in any o f our pa tien t groups.
An assay was set up to measure the in v i t r o  production o f IgM 
and IgG in response to s tim ula tion  w ith mitogen. A ll  patients seem to 
have an impaired a b i l i t y  to produce immunoglobulin on stimulation
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compared to con tro ls . Spontaneous production o f immunoglobulins M 
and G, in the absence o f mitogen, was raised in the HIV+ group. The 
conclusions from th is  part o f the study were th a t,  in v i t r o , HIV+ 
patients are switched on to produce immunoglobulin spontaneously, 
probably as a re s u lt  of HIV in fe c t ion  but also possib ly due to the use 
of concentrate. Also, a l l  patients seem to have an in t r in s ic  defect 
in th e i r  B ce l ls  as they cannot be stimulated to produce leve ls  of 
immunoglobulin comparable w ith con tro ls . As th is  occurs in the 
apparent absence o f HIV in fe c t io n ,  and the response o f haemophiliacs 
who were not treated was normal, i t  is  probably due in some way to the 
use o f concentrate. Further stud ies, such as co -cu ltu r ing  various 
lymphocyte subsets with normal a llogeneic c e l ls  may help e lucidate 
th is  apparent defect in the pa t ien ts ' c e l ls .
Many workers have t r ie d  to f in d  surrogate markers which could 
ind icate AIDS or progression towards AIDS, e.g. raised IgD leve ls . 
Another such marker suggested has been serum leve ls  o f BzMicroglobulin 
(Zo l1a-Pazner e t a l , 1984). In conjunction w ith  other laboratory 
f ind ings , leve ls of B2M were successful in diagnosing AIDS cases.
This present study has found increased leve ls  in  a l l  pa t ien t groups 
but espec ia lly  in the HIV+ pa tien ts . This e f fe c t  was not caused by 
carry over o f 82M in the concentrate as these preparations contained 
no detectable levels o f the p ro te in . Increased serum leve ls  are 
thought to occur as a re s u lt  of increased ce ll  turnover and probably 
in our pa tien ts , increased leve ls  are caused by the antigenic 
stim u la tion  provided by the use of concentrate and also the HIV ( in  
the HIV+ group).
The T^ ce ll  is  considered the central ce l l  in the immune
response. This ce ll  also happens to be the one which HIV in fec ts  and
depletes. These T helper c e l ls  have many functions as shown in
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Figure 1.3. Amongst these is the production o f IL -2 , a lymphokine, 
required fo r  T ce ll  growth. The resu lts  on IL-2 production by AIDS 
patients have provided c o n f l ic t in g  reports but i t  is  now generally 
thought tha t IL-2 production is impaired in these patients  (Murray 
e t a l , 1985). To study the production o f IL-2 by the haemophiliacs, 
an IL-2 assay has been developed in our laboratory. The assay makes 
use o f the IL-2 dependent ce l l  l in e  HT^A. The assay had to be
standardised as described in Chapter 6. The resu lts  from th is  study 
show tha t the c e l ls  from HIV+ patients produce s ig n i f ic a n t ly  less 
IL-2 than both other haemophiliacs and contro ls . In general, the 
HIV treated patients produced leve ls  comparable to con tro ls . Future 
work on IL-2 could look at p u r i f ie d  T ce ll  subsets to see i f  the 
abnormality in the HIV+ patients was simply due to a decrease in T^ 
numbers in th is  group or i f  there are other more complex functional 
defects in th is  group, such as over suppression.
Summarising the studies on the pa tien ts , th is  work has shown 
several defects in the p a t ie n t 's  immune response. Some o f these 
defects, e.g. reduced T^ numbers, reduced IL-2 production, and reduced
response to mitogen and antigen seem to be due la rge ly  to HIV
in fe c t io n . Other abnormalities such as increased serum immunoglobulin 
leve ls , increased 32M leve ls , an a b i l i t y  to produce high leve ls  of 
immunoglobulin in  v i t r o  a f te r  s t im u la t ion , and a reduced in vivo 
response to DNCB, although occurring in the HIV+ pa t ien ts , were also 
observed in the apparent absence o f HIV in fe c t io n . Therefore, although 
HIV can be blamed fo r  some of the observed abnormalities, the in fusion 
o f concentrate, in the absence o f HIV, seems capable o f producing 
several abnormalities in the haemophiliacs.
In an attempt to look at the e f fe c t  o f concentrate on various
responses, some pre lim inary experiments were carr ied  out in v i t r o
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using normal c e l ls .  These experiments involved looking at the e f fe c t  
of concentrate or i t s  bu ffe r on the response o f normal ce l ls  in 
various assays such as IL-2 production and mitogenesis. The take home 
message from these experiments is tha t concentrate can in h ib i t  
mitogenesis and IL-2 production by normal lymphocytes in a dose 
dependent manner. Buffer used in the preparation o f the concentrates 
can also cause a degree o f in h ib i t io n  but i t s  e f fe c t  is  not as marked 
as the concentrate. Therefore, in some way, concentrate and perhaps 
i t s  bu ffe r in h ib i t s  responses o f normal lymphocytes. This is  an area 
which could be fu r th e r  investigated, as mentioned in Chapter 9.
The e f fe c t  o f HIV was also looked a t in a s im ila r  way to the 
e f fe c t  of concentrate. Again, the responses o f normal c e l ls  were 
in h ib ite d  in a dose dependent fashion and th is  is  another area o f 
research which could be fu r th e r  expanded in the fu tu re .
The f in a l  top ic  examined was the e f fe c t  o f p a t ien ts ' sera on 
mitogenesis and IL-2 production o f normals. Siegal e t al (1985) have 
shown tha t sera from AIDS patients can i n h ib i t  the production o f IL-2 
by normal lymphocytes. This study, however, did not f in d  in h ib i t io n  
o f mitogenesis or IL-2 production by normals when the serum source in 
the assay was substitu ted fo r  haemophiliac sera.
What work could be done in the future?
We are cu rren t ly  carrying out a study in co llabora t ion  w ith 
Professor Swanson Beck a t Ninewells, Dundee. Mantoux reactions are 
being done on the patients and reaction s ites  are being biopsied. 
Then, by sectioning the biopsies, i t  w i l l  be possible to s ta in  them 
using monoclonal antibodies and standard immunocytochemical techniques. 
I t  is  hoped to quantita te  the i n f i l t r a t i n g  c e l ls .
Another study which is planned and is  cu rre n t ly  being developed 
is  to assay IL-1 production by pa t ien ts ' monocytes to look fo r
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abnormalities which could be associated w ith HIV in fec t ion  or 
concentrate usage.
Some fu r th e r  experiments, such as co -cu ltu re  experiments and an 
expansion o f the in v i t r o  work which concentrate and HIV preparations, 
have already been discussed. There are others though tha t would 
probably be worth fo l low ing . Amongst the HIV" patients fu r th e r  
monitoring should be carr ied  out to examine the e f fe c t  o f continued 
exposure to concentrates. I t  is  also important to detect any new sero- 
conversions which may occur, although hopefully the incidence o f new 
cases should now be very low.
The HIV+ patients must also be c lose ly  followed looking fo r  any 
de te r io ra tion  in responses which may herald the progression o f disease 
especia lly  now tha t HIV antigen has been detected in the serum o f 
several o f the HIV+ pa tien ts .
The haemophiliac population are a good group to study in an 
attempt to be tte r  understand the mechanisms and functions o f HIV. 
Most l i k e ly ,  these patients have been in fected w ith  re la t iv e ly  low 
numbers o f genetic variants  o f HIV. As v i r a l  antigens have now been 
isola ted from some of our pa tien ts , i t  is  an ideal opportun ity  to 
study the v irus .  Patients ' ce l ls  could be cu ltured in an attempt to 
make iso la tes  o f the v iru s .  Some basic molecular bio logy could then 
be done on iso la ted  v iru s . I t  is  important to determine whether or 
not iso la tes from d i f fe re n t  people are id e n t ic a l,  s im ila r ,  or even 
whether they show marked d iffe rences. Within ind iv idua ls  i t  would be 
very in te res t ing  to determine i f  only one iso la te  is  found or i f  
ind iv idua ls  show iso la tes  which d i f f e r  g e n e t ica l ly .  By studying 
ind iv idua ls  over a period o f time, i t  should be possible to detect 
whether or not there are genetic va r ia t ions  in the sequential 
iso la tes of HIV obtained from an ind iv idua l ind ica ting  genetic d r i f t
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of the v irus . The answer to th is  question could have important 
im plications in try ing  to develop both a successful vaccine against 
AIDS and also treatment regimes which w i l l  be e f fe c t iv e  in the 
treatment of those already in fected.
F in a l ly ,  th is  thesis has set out to make a study on the 
immunological status of the haemophiliac population. Hopefully, from 
both the f ind in gs , and from the discussions and points ra ised, i t  w i l l  
be possible to continue with th is  l in e  o f research in an attempt to 
be tte r understand the e f fe c t  o f both HIV in fe c t io n  and Factor V I I I  
concentrate usage on the immune system o f the haemophiliac pa t ien t.
APPENDIX
Mediums Used:
For Mitogens and B Cell Assay 
RPMI (1640)
+
2mM L-Glutamine 
+
P en ic illin  (50 U/ml) /Streptomycin (50 pg/ml)
+
Sodium Bicarbonate (13.5 mis of 7.5X/500 mis medium)
RPMI (Complete)
For IL-2 Work 
RPMI (1640)
+
2 mM L-Glutamine 
+
P en ic illin  (50 U/ml) /Streptomycin (50 pg/ml)
+
Indomethacin (1 mg/ml)
+
3-Mercaptoethanol (5xl0”sM)
+
Hepes ( 20mM)
+
Sodium Bicarbonate (5.67 mis of 7%/500 mis medium)
All Tissue Culture Mediums and Additives 
from Gibco (Paisley, Scotland, U .K .).
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Buffers used in ELISA 
Solutions
(1) 0.2 M Na2C0
(2) 0.2 M NaHCO
(3) 0.01M MgCl2
Coating Buffer:
1.1 ml of (1) + 1.4 ml of (2) + 7.5 mis d is t ille d  water.
Substrate Buffer:
1.1 ml of (1) + 1.4 ml of (2) + 1 ml of (3) + 6.5 mis
d is t ille d  water.
D iluting Buffer:
PBS/0.5% BSA/0.05% Sodium Azide.
Washing Buffer:
PBS/0.5% BSA/0.05% Sodium Azide/0.05% Tween 20.
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